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Abstract 
Thesis title: Novel strategies for targeting botulinum neurotoxin-based therapeutics to 
neuronal populations involved in pain sensation 
Author: Marc Nugent  
Botulinum neurotoxin serotype A (BoNT/A) is a bacterial di-chain protein containing a 
protease light-chain which cleaves synaptosomal-associated protein of Mr = 25 k (SNAP-
25), a protein essential for neuronal exocytosis; this produces prolonged, but ultimately 
reversible, abolishment of neurotransmitter release. The retargeting of a BoNT/A-
derivative to sensory neurons involved in heightened pain sensation is a potential 
therapeutic strategy for the treatment chronic pain. The development of such a therapeutic 
is, however, a complex multi-step process dependent on the identification of suitable cell-
surface target receptors, functional expression of appropriate targeting ligands, and the 
employment of an effective means of conjugating the latter to a binding domain-deficient 
BoNT/A core-therapeutic. 
An extensive literature research was conducted which identified both transient receptor 
potential vallinoid 1 (TRPV1) and tyrosine kinase A (TrkA) as promising target 
candidates and, furthermore, a spider-venom peptide (double-knot toxin) and nerve-
growth factor (NGF) as respective means by which to target them. Two published 
approaches for the conjugation of targeting ligands to the core-therapeutic were initially 
assessed: conventional protein fusion and “protein stapling” technology. Comprehensive 
investigation of these strategies highlighted relative advantages and deficiencies; hence, 
an additional novel method was developed, based on the binding of S. aureus protein A 
to immunoglobulin G (IgG) antibodies. 
This latter strategy was optimized to provide a means to couple the core-therapeutic to 
either antibodies raised against TrkA, or a recombinantly expressed fusion of NGF and 
fragment crystallizable (Fc) of rabbit IgG. These approaches both culminated in 
detectable delivery of the protease into target cells, demonstrating the versatility of this 
innovative technology. However, NGF produced considerably more efficient protease 
delivery than its IgG counterpart, thereby, highlighting that for effective toxin retargeting 
the biological activity of the employed ligand is paramount.  Consequently, NGF-
mediated targeting via TrkA represents a potentially viable strategy for the intracellular 
delivery of engineered BoNT/A-based pain therapeutics.  
 1 
 
 
 
Chapter 1. General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 
1.1 Botulinum neurotoxin as a potential therapeutic for chronic pain 
1.1.1 Nociception, pain and chronic pain 
Pain has been defined as a “complex constellation of unpleasant sensory, emotional and 
cognitive experiences provoked by real or perceived tissue damage and manifested by 
certain autonomic, psychological, and behavioural reactions” (Terman, 2003). The 
complexity of this definition mirrors the actual intricacy of pain sensation; it is highly 
subjective, involving interplay and communication between the peripheral nervous 
system (PNS) and central nervous system (CNS).  
Physiological pain sensation is instigated by a process termed nociception that involves 
specialized high-threshold sensory neurons within the PNS known as nociceptors. These 
are primarily non-myelinated C-fibre neurons or thinly myelinated Aδ-fibres expressing 
a plethora of surface receptors and channels that sense noxious stimuli which signal actual 
or potential tissue damage. Noxious heat, cold or the release of inflammatory mediators 
such as cytokines, growth factors or proteases following tissue insult, activate specific 
receptors on the nociceptors, which participate in the generation of an action potential 
(transduction); the latter is transmitted along the nerve fibre by voltage-gated ion channels 
(conduction). This signal is relayed from the peripheral neurons to second order neurons 
in the spinal cord (transmission) which processes and propagates the signal to the 
appropriate regions of the brain, where the message is interpreted (modulation) and may 
lead to the sensation of pain (Dubin and Patapoutian, 2010).  
The system described above affords an extraordinary evolutionary advantage, enabling 
rapid response to damaging or dangerous stimuli and, thus, supports the preservation of 
homeostasis. However, advantages conferred by sensation of acute pain are nullified if 
the sensation of pain no longer signals information regarding preventable tissue damage. 
Chronic pain is defined as pain lasting longer than 6 months, which extends far beyond 
the benefit of acute pain sensation associated with the initial injury (Treede et al., 2015). 
This definition can be further sub-divided into chronic inflammatory and neuropathic pain 
(Xu and Yaksh, 2011). The inflammatory variety occurs as a result of the aberrant release 
of inflammatory mediators, resulting in long-lasting and increased pain sensation (Huang 
et al., 2006). Neuropathic pain involves the sensitization of sensory neurons, due to an 
injury-induced increase in the surface expression of channels involved in nociceptive 
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transduction, conduction and transmission; resulting in lower thresholds to noxious 
stimuli (hyperalgesia) or painful interpretation of innocuous stimuli (allodynia) (Bridges 
et al., 2001). 
Chronic pain represents a major challenge for both patients and healthcare providers. 
Estimates of its prevalence vary wildly, but it is generally accepted that as many as 20% 
of European adults suffer from the condition (Breivik et al., 2006). In the Irish context, 
its incidence has been estimated as high as a staggering 35.5% of the population (Raftery 
et al., 2011). It has been estimated that in 2008 its overall cost to the Irish exchequer was 
€5.34 billion or 2.86% of GDP, with the average cost in Ireland per patient standing at 
€5,665 per annum (Raftery et al., 2012). Current treatments for the disorder rely heavily 
on short-acting non-steroidal anti-inflammatory drugs, which often have serious side 
effects. This restricts most patients to on-going pain management with often inadequate 
analgesics or highly addictive opioid drugs (Rosenblatt and Catlin, 2012). There is, 
therefore, a severe unmet need for effective, long-acting and non-addictive therapeutics 
for chronic pain. 
1.1.2 SNARE complex-mediated Ca2+-dependent exocytosis  
Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins 
are essential constituents of the membrane fusion apparatus, responsible for regulated 
fusion of intracellular vesicles with the cell membrane. In neurons, the respective 
SNAREs are: synaptosomal-associated protein of relative molecular mass (Mr) of 25 k 
(SNAP-25), tethered to the plasma membrane via several cysteine-linked palmitoyl 
chains, and, syntaxin 1 and vesicle-associated membrane protein (VAMP) which are 
anchored on the plasma and vesicle membranes, respectively. Formation of a neuronal 
SNARE complex involves the assembly of a parallel four-α-helical bundle. The nascent 
complex initially links the vesicle and cell membranes prior to a Ca2+-dependent fusion 
event, resulting in the exocytosis of the vesicle contents (Südhof and Rizo, 2011). The 
core SNARE complex consists of one α-helix respectively from syntaxin-1 and VAMP, 
with an additional two helices contributed by SNAP-25 (Sutton et al., 1998). Assembly 
of SNARE complexes requires exquisite regulation to prevent spontaneous membrane 
fusion. To this end, vesicle-bound synaptotagmin serves as a Ca2+ sensor, with an 
additional role in early docking of synaptic vesicles to the presynaptic membrane via 
interaction with SNAP-25. Upon binding Ca2+, synaptotagmin instigates the  fusion of 
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vesicles with the presynaptic membrane, resulting in exocytosis (Fig. 1.1) [reviewed by 
(Chapman, 2008)]. 
The stimulated exocytosis of pain signalling neurotransmitters from nociceptors is 
mediated by such Ca2+ dependent SNARE complex formation (Meng et al., 2007). 
Moreover, the insertion of nociceptive transducers into the membrane of nociceptors has 
been demonstrated to utilize these same SNAREs (Meng et al., 2016). Consequently, 
inhibition of such mechanisms has considerable potential in a novel therapeutic approach 
for chronic pain. To this end, neuronal proteolytic toxins known as botulinum neurotoxins 
(BoNTs) are of particular significance, due to their ability to specifically, but reversibly, 
cleave SNARE proteins, perturbing the formation of the SNARE complex and, 
consequently, inhibiting exocytosis. 
  
Figure 1. 1 SNARE complex-mediated Ca2+-dependent exocytosis 
The core SNARE complex is formed by four α-helices, to which VAMP (dark-blue) and syntaxin (red) 
contribute one each to the exocytotic vesicle and the cell membrane, respectively, with the additional two 
provided by cell membrane localized SNAP-25 (green). Vesicle-bound synaptotagmin (light-blue) 
functions as a Ca2+ sensor, and upon binding the latter instigates SNARE zipping, resulting in vesicle-
membrane fusion and the consequent exocytosis of vesicle cargo. Schematic adapted from (Carr and 
Munson, 2007). 
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1.1.3 Structure and mechanism of action of botulinum neurotoxins (BoNTs) 
BoNTs are a group of homologous 150 k di-chain proteins consisting of 7 confirmed 
serotypes (A-G), with a controversial 8th serotype (H) recently reported (Dover et al., 
2013). BoNTs contain 4 structural domains (individually colored in Fig. 1.2), which 
mediate distinct steps in the multi-step intoxication of neurons (Fig. 1.3). This process 
culminates in the cytosolic delivery of a zinc dependent proteolytic light-chain (LC = ~50 
k), that selectively cleaves at least one of the aforementioned SNARE proteins involved 
in Ca2+-dependent exocytosis of neurotransmitters. The LC from each BoNT serotype 
uses binding sites remote from its active protease site to recognize distinct regions on 
SNAREs; these exosites dictate both which SNARE is cleaved by each serotype and the 
position of the scissile bond (Breidenbach and Brunger, 2004) (Table 1.1). 
The LC is linked by a disulphide bond to a heavy chain (HC = ~100 k). The C terminus 
of the HC (HC) consists of two binding sub-domains: HCN and HCC (both ~25 k each). The 
HCC binds the toxin to acceptors composed of Gt1b and Gd1a ganglioslides, and ectopic 
domains of synaptic vesicle proteins (Table 1.1). Binding of both together is necessary 
for effective endocytosis of the toxin with the binding to ganglioslides serving as an initial 
step, anchoring the toxin at the cell membrane. The exposure of the luminal domains of 
synaptic vesicle proteins, following neuronal exocytosis, facilitates the high-affinity 
binding of the toxin to these acceptors; the toxin is then internalized into the cell during 
endocytic recycling (Dong et al., 2006). The exact functional role of the HCN subdomain 
has not yet been fully elucidated, despite it being highly-conserved between all BoNT 
serotypes (Lacy and Stevens, 1999). It has, however, been shown to interact with 
phosphatidylinositol phosphates in the mammalian cell membrane, and on this basis has 
been predicted to contribute to toxin binding. It has also been suggested that this binding 
may assist in the correct orientation of the toxin within endosomes, a prerequisite for 
effective translocation (Muraro et al., 2009).  
The N terminus of the HC is referred to as the translocation domain (HN = ~50 k), because 
it is thought to be responsible for the translocation of the LC across the limiting membrane 
of the endocytic vesicle into the neuronal cytosol, following binding and internalization  
of the toxin (Fischer et al., 2012). The precise mechanism by which the HN orchestrates 
translocation of the LC remains somewhat enigmatic, although the acidification of the 
endosome is an essential pre-requisite (Fischer et al., 2008), as translocation is prevented 
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by inhibitors of the vesicular proton pump or other chemicals that attenuate endosome 
acidification (Azarnia Tehran et al., 2015). A decrease in endosomal pH below pH 5.5 
causes the alpha helices of the HN to undergo conformational change and penetrate the 
endosomal membrane; creating a channel through which a partially unfolded LC can 
travel. The disulfide bond linking the LC, is then cleaved by vesicle bound thioredoxin 
reductase, releasing the protease into the cytoplasm (Pirazzini et al., 2016). There is no 
inherent pH sensor on BoNT, it has instead been suggested that protonation of carboxylate 
residues in the HC precedes HN channel formation and this, potentially, serves a role in 
coordinating efficient translocation in response to endosomal acidification (Pirazzini et 
al., 2013). 
 
Figure 1. 2 BoNT structure 
(A) Schematic representation and (B) crystal structure of BoNT/A (PDBcode; 3BTA). The same color 
scheme applies to both (A) and (B). The LC protease, HN translocation, the enigmatic HCN and the HCC 
receptor binding domains are colored red, yellow, purple and green, respectively. Crystal structure in (B) 
taken from (Rossetto et al., 2014).  
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Figure 1. 3 Inhibitory action of BoNTs on transmitter release 
(A) Four steps are involved in the neuronal intoxication by BoNTs: (i) the BoNT heavy chain (HC, black) 
orchestrate dual-binding on the cell-surface through an initial interaction with gangliosides (orange), 
followed by binding to glycoprotein receptors (orange); (ii) acceptors-mediated internalization by 
endocytosis; (iii) translocation of light chain LC (grey) to the cytosol mediated by the HN translocation 
domain following acidification of the endosome and (iv) Proteolytic LCs cleave their respective SNARE 
substrates; VAMP (blue), syntaxin (red) and SNAP-25 (green). (B) The SNARE substrate cleavage sites of 
each BoNT serotype. Schematic adapted from (Breidenbach and Brunger, 2005). 
 
Table 1. 1 BoNTs and their respective cleavage substrates 
BoNT serotype Intracellular 
target protein 
Cleavage sites in 
human 
Protein acceptor 
/A SNAP-25 EANQ197RATK Synaptic vesicle 2 & 
fibroblast growth 
factor receptor 3 
/B VAMP 1/2 GASQ76FETS Synaptotagmin II & 
I 
/C SNAP-25 
Syntaxin I 
ANQR198ATKM 
DTKK254AVKY 
Unknown 
/D VAMP 1/2 RDQK61LSELD Synaptic vesicle 2 
/E SNAP-25 QIDR180IMEK Synaptic vesicle 2 
/F VAMP 1/2 ERDQ60KLSE for I 
ERDQ58KLSE for 
II 
Synaptic vesicle 2 
/G VAMP 1/2 ETSA83AKLK for I 
ETSA81AKLK for 
II 
Synaptotagmin II & 
III 
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1.1.4 Potential of BoNT/A as a novel pain therapeutic 
BoNT/A preferentially targets cholinergic neurons of the neuromuscular junction through 
binding of a ganglioside (GT1b) plus synaptic vesicle 2 (SV2) (Stenmark et al., 2008), 
with another co-acceptor, fibroblast growth factor receptor 3 (FGFR3) recently reported 
(Jacky et al., 2013). BoNT/A then acts through cleavage of SNAP-25, a SNARE 
indispensable in the stimulated exocytosis of acetylcholine, the neurotransmitter which 
stimulates muscle contraction (Lebeda et al., 2008). BoNTs have long been exploited 
therapeutically to treat a broad range of disorders by inhibiting over-active muscles and 
glands (Bigalke et al., 1985). There are several BoNT-based therapeutics available, 
probably the most well-known of which is BOTOX® (Allergan Inc., California), which 
contains BoNT/A as its active component in a complex with accessory proteins.  
BOTOX® or BoNT/A have shown potential in the treatment of >100 human conditions 
(Münchau and Bhatia, 2000, Mahajan and Brubaker, 2007, Luvisetto et al., 2015), and 
the therapeutic use of botulinum neurotoxins (BoNTs) represents an emerging treatment 
for chronic pain as, significantly, BoNT activity is not restricted to cholinergic neurons. 
The internalization of toxin into other nerve cell types, albeit requiring higher 
concentrations, also results in SNARE cleavage and inhibition of transmitter release 
(Meng et al., 2014). It was observed that following administration of BOTOX® for 
cosmetic purposes, patients reported a reduction in the incidence, duration and severity 
of migraine (Silberstein et al., 2000). Furthermore, after a number of supportive clinical 
trials, the FDA approved BOTOX® for the treatment of chronic migraines in 2010. 
Although it has yet to be fully deciphered how BOTOX® or its active component BoNT/A 
acts to alleviate migraine, experimental evidence from in-vitro experiments suggests it 
could result from a dual effect upon nociceptors. Firstly, BoNT/A inhibits release of 
neurotransmitters and peptides involved in pain transmission (Durham et al., 2004, Meng 
et al., 2009) and, secondly, cleavage of SNAREs reduces the surface expression of 
channels and receptors which function as nociceptive transducers (Morenilla-Palao et al., 
2004, Meng et al., 2016). These suggested applications are supported by pain studies in 
animal models (Cui et al., 2004, Aoki, 2005).  
The above-noted dual action has potential as a proficient means by which to attenuate 
sensation of pain. Furthermore, BoNT/A has a long duration of action, with a single-
treatment capable of inhibiting neurotransmitter release for up to 6 months in the human 
 9 
 
facial area (Flynn, 2010). As a well-tolerated protein-based therapeutic, BoNT/A could 
conceivably confer significant personal and economic benefits as a non-addictive, 
efficient, long-lasting and sorely needed alternative treatment for chronic pain. 
Despite the therapeutic value of BoNT/A, its inhibition of acetylcholine release remains 
a concern for many applications due to the risk of neuromuscular weakness (Pappert and 
Germanson, 2008). The exceptional potency of BoNTs limits dosage and, thus, the 
therapeutic window. In order to capitalize upon the effectiveness of BoNTs, the toxins 
must be redesigned in such a way as to retain the desirable high efficiency ablation of 
SNARE complex formation, while preferentially retargeting of BoNT/A away from 
cholinergic neurons, and towards the pain-sensing peripheral nociceptive neurons. It is 
fortuitous, therefore, that BoNTs and BoNT/A in particular, are well characterized 
proteins which have been the subject of intense investigation since 1822, when Justinus 
Kerner first alluded to potential therapeutic uses of this “sausage poison” (Erbguth, 2004). 
Since then, the depth of research and continued interest in BoNTs is demonstrated by 
“botulinum toxin” producing 17,448 unique results on PubMed (as of November 2016).  
The extensive research into BoNTs has involved attempts to fully characterize the 
functional role of each domain which has, consequently, highlighted the modular nature 
of the toxin. Each domain is for the most part structurally-and functionally-distinct; this 
characteristic allows engineering at the genetic level to manipulate the protein domains 
for defined functional outcomes and, most interestingly, the creation of BoNT chimeras 
(Wang et al., 2008). The development of novel chimeras, which substitute the receptor 
binding domain of BoNT/A with an appropriate targeting peptide could, in theory, target 
BoNT/A away from the cholinergic neurons and, instead, redirect its SNARE protease 
into nociceptors. The principle of BoNT retargeting to normally refractory cells has been 
previously established (Chaddock et al., 2000a), demonstrating the feasibility of such an 
approach. A novel nociceptor-targeted BoNT/A chimera could afford significant potential 
as an innovative treatment of chronic pain, by greatly reducing the prospect for motor 
deficits and, thus, increasing the therapeutic window.  
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1.2 Nociceptor selective cell-surface proteins  
1.2.1 Literature review to identify putative nociceptor targets 
For identifying putative novel targets for a novel nociceptor selective BoNT/A-based 
therapeutic, an exhaustive literature research was conducted to categorize protein 
receptors or channels which are expressed on the surface of peripheral nociceptors. The 
criteria were then refined to isolate candidates which are unique to such nociceptive 
neurons, and absent from peripheral motor neurons or sensory neurons responsible for 
non-noxious sensation. The nociceptive roles of the resultant candidates were then 
assessed to ensure they represent viable targets for a chronic pain therapeutic, based on 
the criteria that they (i) function in the transduction or conduction of painful stimulus and 
(ii) their surface expression is up-regulated during incidences of chronic pain. 
It had to be determined that the refined list of putative targets were also compatible with 
the requirements of a BoNT therapeutic, namely that they undergo ligand-induced 
endocytosis, to elicit internalization of the toxin, and then enter endocytic acidifying 
vesicles. Acidification of the endocytic vesicle is paramount, as once the toxin is 
successfully internalized, the LC must be translocated across the limiting membrane into 
the cytoplasm in order to cleave its SNARE substrate, for which vesicle acidification is a 
critical step (Fischer et al., 2008). The summary of findings from the described literature 
review are outlined in Table 1.2. 
The literature review identified 28 proteins which fulfilled aspects of the prescribed 
criteria; however, only 9 satisfied the aforementioned requisites: Acid Sensing Ion 
Channel 3 (ASIC3), Voltage-gated Sodium Channels 1.7 and 1.8 (Nav 1.7 and 1.8), MAS-
related G-protein coupled receptor D (MrgD), Purinergic receptors 2 and 3 (P2X2 and 
P2X3), Tropomyosin kinase A (TrkA), Transient receptor potential ankyrin 1 (TRPA1) 
and Transient receptor potential vallinoid 1 (TRPV1). The targeting of a BoNT/A based 
therapeutic to the above channels/receptors, would require conjugation of a toxin-based 
core-therapeutic to a pertinent ligand, capable of binding and inducing internalization of 
its defined target. To this end, the 9 potential target candidates were subjected to a final 
screening, which involved further appraisal of the available literature, to determine if 
suitable targeting ligands could be identified for each respective candidate. This resulted 
in the ultimate refinement of the list to 2 targets: TRPV1 and TrkA. 
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Table 1. 2 Candidate nociceptor selective cell-surface targets  
Nociceptor expressed 
receptor 
 
Nociceptor 
selective 
 
Function in 
nociception 
 
Expression 
upregulated 
 
Ligand induced 
endocytosis 
 
References 
 
ASIC3 √ √ √ √ (Deval et al., 2008) 
TRESK 
 
X √ √ ? (Wood, 2010) 
TREK-1 
 
X √ ? √ (Noël et al., 2009) 
TRAAK X √ ? ? (Hur et al., 2009) 
KNCQ X √ √ √ (Passmore et al., 
2003) 
mGluRs 
 
X √ √ √ (Yogeeswari et al., 
2009, Blackshaw et 
al., 2011) 
MrgD 
 
√ √ √ √ (Rau et al., 2009, 
Honda et al., 2012) 
MrgX1 
 
√ √ √ X (Solinski et al., 
2010, Sikand et al., 
2011) 
MrgX2 
 
√ √ √ X (Yang et al., 2005) 
MrgX3 
 
√ √ ? ? (Kaisho et al., 
2005) 
Nav 1.7 and 1.8 
 
√ √ √ √ (Fang et al., 2005, 
Chahine and 
O’Leary, 2014) 
Neuropeptide Y 
receptors 
 
X √ √ √ (Walker et al., 
1988) 
N-type Ca2+ 
Channels 
 
X √ √ √ (Saegusa et al., 
2001) 
P2X2 
 
√ √ √ √ (Staikopoulos et 
al., 2007) 
P2X3 
 
√ √ √ √ (Staikopoulos et 
al., 2007, Stanchev 
et al., 2009) 
P75 
 
X √ √ √ (Bronfman et al., 
2003) 
PAR2 
 
X √ √ √ (Noorbakhsh et al., 
2003) 
TrkA 
 
√ √ √ √ (Fang et al., 2005, 
Kumar and Mahal, 
2012) 
TRPA-1 
 
√ √ √ √ (Eid et al., 2008, 
Schmidt et al., 
2009) 
TRPC1 
 
X √ ? √ (Remillard and 
Yuan, 2006) 
TRPC3 
 
X √ ? √ (Kunert-Keil et al., 
2006) 
TRPC5 
 
X √ √ √ (Zimmermann et 
al., 2011) 
TRPC6 
 
X √ √ √ (Guilbert et al., 
2008) 
TRPM8 
 
X √ √ √ (de la Peña et al., 
2005, Bautista et 
al., 2007) 
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TRPV1 
 
√ √ √ √ (Michael et al., 
1997, Bohlen et al., 
2010, Julius, 2013) 
TRPV2 
 
X √ √ √ (Tamura et al., 
2005) 
TRPV4 
 
X √ √ √ (Wegierski et al., 
2006) 
T-Type Ca2+ 
Channels 
 
X √ √ √ (Jagodic et al., 
2008) 
√ = Confirmed; X = negative; ? = not known or disputed 
1.2.2 TRPV1 as a nociceptor target for a BoNT/A-based pain therapeutic 
TRPV1 is tetrameric, non-selective cation channel, with each subunit consisting of 6 
transmembrane α-helices (Fig. 1.4). It is a key component in the transduction and 
modulation of nociceptive signaling, and in the PNS is almost exclusively expressed in 
sub-populations of non-myelinated C-fibre and thinly-myelinated Aδ-fibre nociceptors 
(Mitchell et al., 2010). TRPV1 has been shown in several studies to be up-regulated 
during chronic pain (Kim et al., 2014) and a contributor to the pathophysiology of 
migraine (Meents et al., 2010). TRPV1 was originally known as the “capsaicin receptor” 
(Schumacher, 2010). Capsaicin, the main pungent ingredient in 'hot' chilli peppers, has 
long been known to elicit a sensation of burning pain; however, since the cloning of 
TRPV1 (Michael et al., 1997) a multi-faceted and integral role of TRPV1 in nociceptive 
transduction has been deciphered. 
TRPV1 acts as a molecular sensor of noxious heat and a polymodal integrator of painful 
stimuli, placing it in a central role in the pathophysiology of pain (Wang and Woolf, 
2005). TRPV1 responds directly to huge variety of exogenous and endogenous physical 
and chemical stimuli, including capsaicin, heat >42°C, H+, ATP, and certain spider 
venoms (Winter et al., 2013). In response to such stimulus, the TRPV1 channel pore 
opens, with the resultant influx of Ca2+ producing localized depolarization, leading to the 
generation of an action potential (Takayama et al., 2015). The gating of TRPV1 is, 
however, far from simplistic. There is an enormous degree of molecular interplay; for 
example, a certain stimulus might lower the overall threshold of TRPV1 for activation by 
a secondary stimulus that may, previously, have been innocuous (Julius, 2013). In terms 
of the pain response of a patient, this manifests as a heightened pain response to noxious 
stimulus (hyperalgesia) or a painful response to what is normally an innocuous stimulus 
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(allodynia). Allodynia and hyperalgesia have been described as the cornerstones of 
neuropathic pain (Bridges et al., 2001). 
TRPV1 is expressed on the surface of peptidergic nociceptors which release, SNARE-
dependently, pain-eliciting inflammatory neuropeptides calcitonin gene-related product 
(CGRP) and substance P (SP) (Meng et al., 2009). In addition to the transduction of 
nociceptive signals, the influx of Ca2+ following TRPV1 activation induces the exocytosis 
of CGRP and SP, which subsequently interact with adjacent immune cells such as 
basophils and mast cells, stimulating them to release an “inflammatory soup”. The latter 
contains a plethora of noxious compounds which further activates the already sensitized 
TRPV1 channel, resulting in additional amplification of the nociceptive signal (Julius, 
2013) (Fig. 1.5).  
 
Figure 1. 4 Structure of TRPV1 
(A) Individual TRPV1 subunit showing the 6 transmembrane α-helices depicted in purple. The pore-
forming region occurs between the 5th and 6th α-helix. (B) Tetrameric structure of TRPV1 consisting of 4 
identical subunits, which functions as a non-selective cation channel, depicted by the arrow indicating Na+ 
and Ca2+ travelling through the channel. Figure adapted from (Conway, 2008). 
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Figure 1. 5 Amplification of nociceptive signalling in the PNS 
The nociceptor is depicted in purple; TRPV1 is expressed at the nerve terminal and along the fiber (not 
shown). Tissue injury activates TRPV1 stimulating the release of SP and CGRP, which interact with 
immune cells to stimulate the release of “inflammatory soup” containing histamines, proteases etc. These 
then further act upon TRPV1 causing an amplification cycle. The noxious stimulus is transmitted down the 
nerve fiber to the spinal cord, where it is relayed to the CNS, inducing a pain response.  Diagram taken 
from (Julius, 2013). 
Although TRPV1 has a primary role in pain transduction, somewhat paradoxically, 
agonists of the channel have long been appreciated for their analgesic properties. As early 
as 4000 BC, the therapeutic benefit of chili peppers was realized by the ancient Aztecs; it 
was used as a treatment for toothache and other such inflammatory conditions 
(Schumacher, 2010). Separated geographically and temporally, the ancient Romans used 
the resin from the cactus Euphorbia resinifera to treat arthritic pain; this resin is now 
known to contain resinferatoxin, an ultra-potent analogue of capsaicin (Schumacher, 
2010). One way in which these ancient analgesics functioned was by exploiting one of 
the inherent characteristics of TRPV1: it undergoes agonist-induced internalization. The 
result of which is a reduction in the levels of TRPV1 on the cell surface, rendering the 
nociceptors less-responsive to noxious stimulus. Significantly, TRPV1 endocytic vesicles 
undergo acidification (Sanz-Salvador et al., 2012). Thus, in principle, a novel BoNT-
based derivative which contains an agonistic TRPV1 targeting moiety could serve as an 
effective means by which to productively deliver the SNARE-cleaving protease into 
peripheral nociceptors.  
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1.2.3 TrkA as a nociceptor target for a BoNT/A-derived pain therapeutic 
TrkA is the high-affinity receptor for nerve-growth factor (NGF) (Wiesmann et al., 1999). 
It is a canonical receptor tyrosine kinase, which exists as a monomer on the cell surface 
of certain sensory neurons and some sympathetic neurons in both the PNS and CNS (Fig. 
1.6 A). Biologically active NGF occurs as a homodimer (βNGF), with each of its subunits 
capable of binding to the immunoglobulin like domain of TrkA monomers and, thus, 
induce dimerization of adjacent receptors and transphosphorylation of their intracellular 
tyrosine kinase sites (Grimes et al., 1996) (Fig. 1.6 B); stimulating internalization of the 
complex into endosomes which undergo subsequent acidification (Diering et al., 2013). 
βNGF-TrkA signalling mediates neurotrophic effects during development by initiating 
multiple intracellular signalling cascades involving mitogen-activated protein kinases, 
protein kinase B and protein kinase C. The activations of these proteins initially promote 
neuronal survival and differentiation, which are indispensable for the maturation of 
sensory neurons (Lindsay, 1996). However, upon reaching adulthood, peripheral 
expression of TrkA is restricted to TRPV1 expressing small-diameter peptidergic C-fibre 
nociceptors (Averill et al., 1995), where TrkA signalling transitions from a role in 
neuronal survival to also promoting whole organism survival through mediation of 
nociceptive function (Kumar and Mahal, 2012). As such, either sequestering NGF (Kan 
et al., 2016), or antagonizing TrkA with small molecules (Watson et al., 2008) has 
emerged as a therapeutic strategy for pain management.  
TrkA activation recruits numerous downstream effectors, including phosphatidylinositol 
3-kinase (PI3K), which subsequently phosphorylates TRPV1; this sensitizes the channel 
(Bonnington and McNaughton, 2003) and increases its trafficking and membrane 
insertion (Huang et al., 2006). Significantly, the up-regulation of TRPV1 surface 
expression occurs via SNARE-mediated exocytosis (Morenilla-Palao et al., 2004), which 
can be reduced by BoNT/A truncation of SNAP-25 (Meng et al., 2016). TrkA activation 
also upregulates the expression of both CGRP and SP (Lindsay and Harmar, 1989), the 
SNARE-dependent exocytosis of which serves to incite further release of NGF from 
adjacent immune cells (Aloe et al., 1992, Ye et al., 2011); this rapidly elevates the surface 
expression of TrkA (McKelvey et al., 2013), thereby, producing a self-perpetuating 
nociceptive positive-feedback loop (Kumar and Mahal, 2012). A TrkA targeted BoNT/A-
derived therapeutic could, therefore, serve as an additional approach by which to 
productively target peripheral nociceptors for analgesic benefit. 
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Figure 1. 6 TrkA structure and activation 
(A) Schematic of the TrkA monomer indicating the intracellular tyrosine kinase, the extracellular 
immunoglobulin like domain which serves as the binding site for βNGF and the leucine rich motif which 
stabilizes the association with βNGF. (B) The binding of the βNGF homodimer to two adjacent TrkA 
receptors induces their dimerization, resulting in phosphorylation of the intracellular tyrosine kinases, 
which subsequently phosphorylates downstream effectors such as mitogen-activated protein kinases, 
protein kinase B and protein kinase C. 
1.3 Previous approaches to retargeting the BoNT protease 
The retargeting of BoNT to specific cell types had been previously achieved by a variety 
of methods. The first published accounts of which involved preparation of BoNT/A 
derivatives lacking the HC following digestion of full-length toxin with trypsin protease. 
These binding domain deficient toxins were then purified and subsequently chemically 
conjugated to NGF (Chaddock et al., 2000a), wheat germ agglutinin (Chaddock et al., 
2000b) and a lectin from Erythrina cristagalli (Duggan et al., 2002). Although a degree 
of protease delivery into cultured cells was achieved for each of these ligands, trypsin 
removal of the HCC from BoNT confers an inherent risk of both off-target proteolytic 
degradation, or incomplete digestion leading to a heterogeneous product (Shone et al., 
1985). Furthermore, chemical conjugation can lead to inactivation of either the BoNT or 
ligand components due to over-derivatization, and was reported to produce conjugation 
efficiency of only 12-16% (Chaddock et al., 2000b, Duggan et al., 2002). 
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The recombinant expression of BoNT derivatives which had been manipulated 
genetically to substitute the HC with targeting ligands, provided an advance on the 
chemical conjugation of ligands to trypsin treated BoNT toxins. Genetic fusion was 
employed for targeting moieties such as epidermal-growth factor (EGF) (Foster et al., 
2006, Fonfria et al., 2016), growth-hormone releasing hormone (Somm et al., 2012) and 
single-chain antibodies (Ma et al., 2014). These fused ligands successfully delivered the 
SNARE protease into cultured cells in vitro, and in the case of growth-hormone releasing 
hormone, the rat pituitary gland in vivo. In addition to BoNT retargeting, genetic 
manipulation has been utilized to make composite BoNT toxins such as a LC/E-BoNT/A 
tri-chain, in which the SNARE protease of BoNT/E was fused to full-length BoNT/A to 
confer two SNAP-25 cleaving enzymes (Wang et al., 2017a). Also a functional hybrid of 
LC/A and full-length tetanus toxin has been published, capable of delivering the LC/A 
protease into neurons susceptible to tetanus, but refractory to BoNT (Wang et al., 2012). 
However, genetic fusion presents its own limitations due to an inherent difficulty in 
expressing the resultant chimeras in soluble form (Wang et al., 2011, Wang et al., 2012), 
as well as issues regarding the functionality of both the BoNT and targeting ligand 
components (Arsenault et al., 2013). 
To address the above-mentioned concerns with both chemical and genetic linkage of 
BoNT to ligands, a protein-mediated coupling strategy termed protein stapling has been 
developed (Ferrari et al., 2012) (detailed in Chapter 4). This approach was successful in 
the high-efficiency conjugation of a BoNT/A derivative devoid of the HC to a panel of 9 
targeting ligands, with each capable of mediating detectable delivery of the SNAP-25 
protease into neuroendocrine tumour cells (Arsenault et al., 2013). Although the above 
approaches demonstrated the feasibility of developing a nociceptor-specific BoNT/A-
based therapeutic, the diversity in targeting moieties employed, as well as the 
multifariousness of the conjugation protocols utilized, meant that there was no defined 
effective strategy for the conjugation of BoNT to targeting ligands. 
1.4 Project aims and objectives 
The principle project objective was the development of a novel means by which to 
productively deliver the LC/A protease into either TRPV1 or TrkA expressing cells, 
through specific targeting of the latter proteins. Achievement of this could, potentially, 
contribute to the future development of a novel targeted BoNT/A-based pain therapeutic. 
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TRPV1 and TrkA were selected due to their PNS expression being constrained to 
peptidergic nociceptors which utilize SNAP-25, their respective endocytosis in response 
to ligand binding, and the subsequent acidification of the resultant endosomes, 
characteristics considered indispensable for the delivery of the SNARE protease.  
The contribution of the HCN sub-domain to BoNT neuronal binding being 
unsubstantiated, consequently, presented an additional facet of the toxins functionality 
which merited investigation. The inclusion of the HCN in a nociceptor-targeted BoNT 
chimera would permit elucidation of its contribution to neuronal intoxication (see Chapter 
3). Furthermore, although the published examples of BoNT retargeting demonstrated the 
feasibility of the endeavor, there existed an innate divergence in the ligand conjugation 
approaches. A secondary aim of the project was, therefore, an appraisal of the previously-
employed fusion and protein stapling conjugation strategies, to identify their respective 
advantages and shortcomings (see Chapter 3 and 4). The independent evaluation of these 
approaches, supported the design and development of an optimized and innovative 
technology, applicable to the conjugation of BoNT to diverse ligands. This novel strategy 
facilitated the specific targeting of a nociceptive transducing receptor by two distinct 
approaches, both of which culminated in the delivery of the SNARE-cleaving LC/A 
protease into pertinent cells (see Chapter 5). 
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2.1 Materials 
2.1.1 Plasmid vectors 
The bacterial expression vectors pET32b and pGEX-KG were, respectively, purchased 
from Merck Millipore or kindly provided by Dr. Gopal of the Adyar Cancer Institute, 
India. The Staphylococcus aureus Protein A immunoglobulin G antibody binding domain 
B (SpA-B) in the pGEX-KG vector was provided by Prof. Joan Geoghegan of Trinity 
College, Dublin. The pACYC duet vector for co-expression of seventeen kilodalton 
protein (Skp) and trigger-factor (TF) protein chaperones (Lamppa et al., 2013), was 
generously provided by Prof. Karl Griswold of Dartmouth College, USA. 
pIRES2-EGFP and pIRES2-DsRed2 mammalian expression vectors were provided by 
my co-supervisor, Dr. Jiafu Wang, Dublin City University (DCU), and the TRPV1 gene 
in the pcDNA3.1 vector gifted by Prof. David Julius of the University of California, USA.  
2.1.2 Synthetic deoxyribonucleic acid 
Synthetic deoxyribonucleic acid (DNA) with codon optimization for the bacterial 
expression of double-knot toxin (DkTx), and the insect cell expression of human NGF 
and rabbit immunoglobulin gamma chain C (rFc), was supplied by Life Technologies. 
2.1.3 Molecular biology reagents 
Polymerase chain reaction (PCR) reagents, benzonase® nuclease and thrombin were 
purchased from Merck Millipore. TOP10™ and Origami B™ E. coli, TOPO™ gateway 
cloning vectors and the Baculodirect™ insect cell expression system were purchased 
from Biosciences, a distributor for Life Technologies. Kits for DNA isolation and 
purification were purchased from Qiagen. Oligonucleotides for the PCR manipulation of 
DNA were from Eurofins Genomics. Restriction endonucleases, DNA ligase, DNA 
kilobase pair (kbp) size standards, DNA sample buffer and SHuffle® E. coli were 
purchased from Brennan & Company, a distributor of New England Biolabs. Glutathione 
agarose, Talon® resin and HisTrap Excel™ columns were purchased from Sigma Aldrich, 
a supplier for GE Healthcare. 
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2.1.4 Synthetic syntaxin peptide 
A synthetic peptide encompassing residues 201-245 of rat syntaxin, labelled on the C-
terminus with N-terminal carboxytetramethylrhodamine (TAMRA) fluorophore was 
purchased from either Biomatik (USA) or Peptide Synthetics (UK). 
2.1.5 Mammalian cell lines 
HEK-293, SH-SY5Y, F11 and PC-12 cells were purchased from ATCC. 
2.1.6 Animals 
Sprague Dawley rats were purchased from Envigo (formerly Harlan), and bred in an 
approved Bio-resources Unit in DCU. The experiments, maintenance and care of the 
rodents complied with the European Communities (Amendment of Cruelty to Animals 
Act 1876) Regulations 2002 and 2005. Experimental procedures had been approved by 
the Research Ethics Committee of DCU, and licenced by the Irish Health Products 
Regulatory Authority. 
2.1.7 Cell culture and related reagents 
Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute 1640 
medium (RPMI-1640), fetal bovine serum (FBS), horse serum, trypan blue, Dulbecco’s 
phosphate buffered saline (PBS), penicillin/streptomycin antibiotics, L-glutamine, 
Cytosine-β-D-arabinofuranoside, dispase II, collagenase I, poly-L-lysine and laminin 
were purchased from Sigma. TransIT®-LT1 Transfection Reagent was bought from Mirus 
Bio. Mouse nerve growth factor (NGF-2.5S) and capsaicin were supplied by Alomone. I-
PER® lysis reagent, Sf-900™ and Sf-900II™ insect cell media, AlamarBLUE™ and 
Fluo-4 AM were provided by Biosciences, a distributor for Life Technologies. Tissue 
culture flasks and plates were from Sarstedt. 
2.1.8 Western-blotting and immuno-cytochemical reagents 
Polyvinylidene fluoride (PVDF) membrane, nitrocellulose membrane, Precision Plus 
protein™ molecular mass standards and Bio-Rad protein assay reagents were purchased 
from Fannin, a distributor of Bio-Rad. Immobilon™ enhanced chemiluminescent luminol 
(ECL) substrate and Hoescht stain were obtained from Merck Millipore. NuPAGE™ and 
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BOLT™ polyacrylamide gels were purchased from Biosciences, a distributor of Life 
Technologies. Vector Laboratories provided VECTASHIELD Mounting medium. 
2.1.9 Antibodies used 
Table 2. 1 List of primary antibodies 
Antibody target 
(catalogue 
number) 
Raised in species 
(immunogen 
epitope) 
Vendor Dilution / 
concentration used 
Western 
blotting 
Immuno-
fluorescence 
α-Tubulin 
(T9026) 
Mouse (purified α-
Tubulin) 
Sigma Aldrich 1 : 1000 Not tested 
ß-Tubulin III 
(T8578) 
Mouse (residues 
436-450) 
Sigma Aldrich 1 µg/ml Not tested 
TrkA 
(ANT-018) 
Rabbit (TrkA, 
residues 342-356) 
Alomone 1 : 500 1 : 50 
Erk 1/2 
(ab17942) 
Rabbit, (ERK 
residues 317-339) 
Abcam 1 : 1,000 Not-tested 
BoNT LC/A Rabbit (residues 
not defined) 
Allergan. Inc. 1 : 1,000 Not-tested 
Nerve-growth 
factor 
(AN-240) 
Rabbit (purified 
NGF-2.5 S)  
Alomone 1 : 200 Not-tested 
Poly-histidine 
[(His)6]  
(OB05) 
Mouse, (His)6 Merck Millipore 1 µg/ml 4 µg/ml 
p-Erk 1/2  
(ab4819) 
Rabbit, [ERK 
1(pT202/pY204) 
and ERK 2 
(pT185/pY187)] 
Abcam 1 : 1,000 Not-tested 
SNAP-25 
(SMI-81) 
Mouse (N-
terminus of SNAP-
25) 
Abcam 1 : 3,000 Not-tested 
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SNAP-25/A Rabbit (SNAP-25 
residues 190-197) 
Allergan. Inc. 1: 1,000 Not-tested 
TRPV1 Rabbit (human 
TRPV1, residues 
606-621) 
Produced in-
house 
1 µg/ml 5 µg/ml 
VAMP 1/2/3 
(104 011) 
Mouse (purified 
VAMP 1) 
Synaptic 
systems 
1 : 1,000 Not-tested 
Rabbit non-immune immunoglobulin G (IgG) was purchased from Sigma; anti-species secondary 
antibodies conjugated to horseradish peroxidase (used at 1:5,000) or to either Alexa-Fluor® 488 
or Alexa-Fluor® 590 fluorescent probes (used at 1:3,000) were obtained from Jackson Immuno-
Research or Life technologies, respectively. 
 
2.1.10 Other reagents 
Sodium 125-I-iodine (Specific activity: ~17 Ci/mg, radioactive concentration: 103.23 
mCi/ml, quantity: 3 mCi) was purchased from Perkin Elmer.  All other reagents and 
chemicals were purchased from Sigma Aldrich. 
2.1.11 Suppliers 
Suppliers’ addresses are listed in the Appendix. 
2.2 Generation of constructs for expression of recombinant proteins  
2.2.1 DNA isolation and purification 
Plasmid DNA was isolated using either QIAprep® Mini, Midi or Maxi Kits according to 
the manufacturer’s instructions, typically producing purified DNA with yields of 1 µg/µl 
in a final volume of 50, 500 and 1,000 µl, respectively. 
2.2.2 Polymerase chain reaction 
PCR amplification was performed in a DNA thermal cycler (Applied Biosystems). 
Reactions were typically carried out in 50 μl volumes using KOD Hot Start DNA 
polymerase. Plasmid DNA (10 ng) was used as template for PCR, with DNA primers, 
deoxynucleotide triphosphates and MgSO4 added to final concentrations of 0.3 µM, 0.2 
mM and 1.5 mM, respectively. 
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Initial denaturation was performed at 95°C (2 min) followed by 30-35 cycles of 
denaturation (20 s) at 95°C, 10 s annealing (temperature dependent on primer used) and 
extension at 70°C for 20 s/kb. PCR products were purified using QIAquick® PCR 
purification kit and the final DNA yields quantified by absorbance at 260/280 nm using 
a spectrophotometer (Nanodrop™ 1000).  
Site-directed mutagenesis was carried out using the Quikchange™ method, with the PCR 
performed as above. Purified PCR produces were subsequently incubated with 1 U Dpn1 
restriction endonuclease at 37°C for 60 min to digest methylated parental template DNA. 
2.2.3 Restriction endonuclease digest of DNA and agarose electrophoresis 
Isolated plasmid DNA or purified PCR products were subjected to either single or double 
restriction endonuclease digest, according to the protocol prescribed by New England 
Biolabs. Agarose gels were prepared by dissolving 1-2% agarose in boiling Tris-acetate- 
ethylenediaminetetraacetic acid (EDTA) buffer (40 mM Tris, 20 mM acetic acid and 1 
mM EDTA), with ethidium bromide added to a final concentration of 0.5 μg/mL. The 
gels were subsequently cooled to 65°C and cast in mini trays, with combs inserted to 
produce wells for sample loading.  
Digested DNA was combined with DNA sample loading buffer, added to wells, subjected 
to electrophoresis at 90 V in Tris-acetate-EDTA buffer and imaged by exposure to 
transilluminator ultra-violet (Trans-UV) light using G: BOX Chemi-16 gel 
documentation system (Syngene). In instances where the digested DNA was to be utilized 
for cloning, the DNA was isolated from the gel and subsequently purified using the 
QIAquick® gel extraction kit, according to the manufacturer’s instructions. 
2.2.4 DNA ligation and bacterial transformation 
DNA fragments (plasmid vector DNA or PCR products) restriction digested to generate 
compatible 5’ and 3’ ends and gel purified (see 2.2.3) were ligated using T4 DNA ligase. 
Typically, digested plasmid vector and PCR products were combined in a 1:3 respective 
molar ratio overnight at 22°C with 1 U T4 DNA ligase, in a final volume of 20 µl.  
E. coli strains (TOP10™, BL21, Origami B™ or SHuffle®) were made chemically 
competent as described (Hanahan et al., 1991) and subsequently transformed with the 
ligated vectors by the heat-shock method (Froger and Hall, 2007). The bacteria were then 
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spread on Luria broth (LB) agar containing an appropriate antibiotic to select for positive 
transformants, and incubated overnight at 37°C. The DNA inserts in plasmid vectors 
isolated from individual clones was assessed by size analysis of the base pairs (bp) 
excised following restriction digest, prior to confirmation of sequence fidelity by DNA 
sequencing. 
2.2.5 Constructs generated for bacterial expression of recombinant proteins 
Table 2. 2 List of constructs for recombinant bacterial expression 
Construct 
No. 
Expression 
vector 
DNA insert 
encoding 
(amino acid 
residues) 
Restriction 
endonuclease 
sites 
Vector notes 
5’ 3’ 
1 pET32b  BoNT/A(1-1092) SacI XhoI The vector encodes 
an in-frame 5’ 
fusion with folding 
chaperones, 
purification tags 
and protease 
susceptible sites. 
See Figure 2.1.  
2 pET32b  BoNT/A(1-1092)-
linker1-DkTx(1-
79) 
SacI XhoI “ “ 
3 pET32b  DkTx(1-79) SacI XhoI “ “ 
4 pET32b  BoNT/A(1-878)- 
SNAP-25(1-206) 
MscI XhoI “ “ 
5 pET32b  VAMP 2(25-84)–
linker2-DkTx(1-
79) 
MscI XhoI “ “ 
6 pET32b  BoNT/A(1-1092)- 
HCC/B(1081-1291) 
MscI XhoI As above + HCC/B 
contains mutations 
(K1192E, Q1200K) 
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7 pET32b  BoNT/A(1-1092)- 
HCC/B(1081-1291)-
linker1-DkTx(1-
79) 
MscI XhoI As above + HCC/B 
contains mutations 
(K1192E, Q1200K) 
8 pGEX-KG  BoNT/A(1-878)-
SNAP-25(1-206) 
XmaI XhoI The vector encodes 
an in-frame 5’ 
fusion with 
glutathione-S-
transferase 
purification tag and 
a thrombin protease 
susceptible site. 
See Figure 2.2. 
9 pGEX-KG  VAMP 2(25-84)–
linker1-DkTx(1-
79) 
XmaI XhoI “ “ 
10 pGEX-KG  VAMP 2(25-84)–
linker1-
epidermal 
growth factor(1-
53) 
XmaI XhoI “ “ 
11 pGEX-KG  BoNT/A(1-878)- 
linker1-SpA-B(1-
58) 
XmaI XhoI As above + 
SpA-B contains 
mutations (D36A, 
D37A) 
Linker1 = 10 alternating glycine-serine amino acid residues 
Linker2 = 27 alternating glycine-serine amino acid residues 
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Figure 2. 1 Schematic of pET32b bacterial expression vector 
Adapted from (Liu and Yang, 2012), prepared using SnapGene software. 
 
Figure 2. 2 Schematic of pGEX-KG bacterial expression vector 
Adapted from (Hakes and Dixon, 1992), prepared using SnapGene software. 
 28 
 
2.2.6 Generation of recombinant baculovirus stocks for protein expression in insect 
cells 
Recombinant DNA encoding the full-length of human NGF was designed with a direct 
3’ fusion of nucleotides encoding residues 102-324 of rFc, with a subsequent 3’ sequence 
encoding a thrombin protease cleavage site and a polyhistidine [(His)6] purification tag. 
The resultant gene (NGF-rFc-thrombin-His6) was synthesised with codon optimization 
for insect cell expression. The full-length gene, or a fragment encoding only NGF was 
inserted into pENTR-D/TOPO™ Gateway vectors by the prescribed method. These 
Gateway cloning vectors were subsequently recombined with Baculodirect™ DNA; 
recombinant baculovirus stocks were generated according to the manufacturer protocol. 
The titre of each baculovirus was determined by a standard plaque assay. Briefly, 10-fold 
dilutions of the viral stocks were prepared in 1 ml of Sf900II™ medium before applying 
to Sf9 insect cells seeded at 8 x 105 cells/well in 6-well plates. The cells were incubated 
for 1 hour at 27.5°C, the medium was then removed and the cells were overlaid with 
agarose diluted to a final concentration of 4% in Sf900™ medium. The cells were then 
incubated for 6 days at 27.5°C until plaques were well formed. The viral titre was 
calculated as plaque forming units per ml (pfu/ml), determined by the formula: pfu/ml = 
pfu / dilution factor × ml of inoculum. 
2.3 Expression and purification of recombinant proteins 
2.3.1 Bacterial expression of recombinant proteins by auto-induction, and 
preparation of culture lysate 
This was performed in ZYP-500 auto-induction medium, as previously defined (Studier, 
2005), supplemented with appropriate antibiotics to select for the relevant expression 
construct. The medium was inoculated 1:500 with an overnight starter culture of 
transformed bacteria, grown at 37°C with shaking at 220 rotations per minute (RPM) for 
8 hours, then at 22°C overnight, following which the cells were collected by 
centrifugation at 5,000 x g for 30 minutes at 4°C. The resultant cell pellet was lysed by 
resuspension in 1 ml of “bacteria lysis buffer” (150 mM NaCl, 20 mM HEPES, pH 8.0) 
per g of cell pellet, followed by benzonase® at 500 U/L of culture, with lysozyme added 
to a final concentration of 2 mg/ml. The mixture was shaken at room temperature (RT) 
for 40 minutes followed by freezing at -20°C and thawing at 22°C, repeated three times. 
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The soluble fraction of the lysate was subsequently isolated by centrifugation at 14,000 x 
g for 30 minutes at 4°C, and stored at -20°C until purification (see 2.3.3 and 2.3.4). 
2.3.2 Induction of bacterial expression of recombinant proteins by isopropyl β-D-1-
thiogalactopyranoside 
Luria broth medium was supplemented with selective antibiotics, inoculated 1:500 with 
an overnight starter culture of transformed bacteria and grown at 37°C with shaking at 
220 RPM until an absorbance of 0.6 - 0.8 at a wavelength of 600 nm (OD600) was reached. 
Expression was induced by addition of 0.1 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG), lowering the temperature to 22°C and incubation overnight. The subsequent cell 
harvesting, lysis and clarification was performed as described (see 2.3.1). 
2.3.3 Immobilized metal affinity chromatography of recombinant proteins 
expressed in bacteria 
Recombinant proteins fused with a (His)6 tag were purified from the soluble fraction of 
prepared cell lysates (see 2.3.1) by immobilized metal affinity chromatography (IMAC), 
after incubation with 1 ml bed volume of Talon® resin per 100 ml of lysate, initially by 
batch binding with agitation for 1 hour at 4°C, this was followed by binding in a 25 ml 
column at RT, with the flow-rate determined by gravity. The resin was washed with 2 
column volumes of “IMAC wash buffer” (150 mM NaCl, 20 mM HEPES, 5 mM 
imidazole, pH 8.0), following which the protein was eluted in 1 ml fractions with “IMAC 
elution buffer” (500 mM imidazole, 150 mM NaCl, 20 mM HEPES, pH 8.0). The total 
protein of each eluted fraction was measured by the Bio-Rad protein assay, and the three 
with the highest content were buffer exchanged into “protein storage buffer” (150 mM 
NaCl, 20 mM HEPES, pH 7.4) using PD-10 gel filtration columns. The protein yield 
following buffer exchange was determined by bicinchoninic acid (BCA) protein assay 
against standards of bovine serum albumin (BSA). 
2.3.4 Affinity chromatography of recombinant proteins expressed in bacteria 
Recombinant proteins fused with a glutathione-S-transferase (GST) tag were purified 
from the soluble fraction of prepared cell lysates (see 2.3.1) by affinity chromatography 
following incubation with 1 ml bed volume of glutathione agarose per 100 ml of lysate, 
initially by batch binding overnight with agitation at 4°C, followed by binding in a 25 ml 
column at RT. The agarose was initially washed with 2 column volumes of protein storage 
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buffer (150 mM NaCl, 20 mM HEPES, pH 7.4), following which it was resuspended in 
a volume of the latter buffer equal to its bed volume. The bound recombinant proteins 
were released from the agarose immobilized GST by incubation with thrombin protease 
(2 U/per ml of agarose) for 40 minutes at 22°C. Activity of thrombin was then quenched 
by adding of phenylmethane sulfonyl fluoride (PMSF) to a final concentration of 1 mM. 
Eluates containing the purified proteins were then separated from the agarose by 
centrifugation using SigmaPrep™ filtration spin columns, and the protein yield was 
determined by BCA protein assay against BSA standards. 
2.3.5 Baculovirus-mediated expression of recombinant proteins in Sf9 insect cells 
Sf9 insect cells were cultured in Sf900II™ medium at 27.5°C either adherent in T-75 
flasks or in shake flasks with rotation at 130 RPM. Recombinant expression in Sf9 insect 
was induced by the inoculation of the culture with medium containing baculovirus. The 
volume of inoculum was determined by the desired multiplicity of infection (MOI), as 
indicated in the figure legends, and was calculated according to the formula: Inoculum 
required = MOI (pfu/cell) × number of cells / viral titre (pfu/ml). The cells were then 
incubated for up to 96 hours at 27.5°C prior to harvesting of the supernatant. 
The optimal protocol for baculovirus-mediated recombinant expression of NGF 
containing fusion proteins involved seeding Sf9 cells in log-phase growth at 2.5x106 
cells/ml in Sf900II™ medium, in a total volume of 500 ml. Cells were infected with low-
passage recombinant baculovirus at a MOI of 0.05 and incubated for 96 hours at 27.5°C, 
with shaking at 130 RPM. Intact cells and cellular debris were subsequently cleared from 
the cell supernatant by centrifugation at 5,000 x g for 30 minutes at 4°C, followed directly 
by IMAC purification (see 2.3.6). 
2.3.6 Fast protein liquid chromatography of (His)6-tagged proteins from insect cell 
supernatant by IMAC 
The clarified Sf9 supernatant containing recombinant homo-dimerized NGF (ßNGF) 
fused to rFc and a (His)6 tag (see 2.3.5) was purified by IMAC on a ÄKTA explorer (GE 
Healthcare) fast protein liquid chromatography (FPLC) system using a 1 ml HisTrap 
Excel™ column. The supernatant was applied to the column at a flow-rate of 1 ml/min 
overnight at RT, in a recirculating loop. The column was then washed with 20 column 
volumes (100 mM sodium phosphate, pH 7.4) and the protein eluted in 1 ml fractions 
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(500 mM imidazole, 100 mM sodium phosphate, pH 7.4). The protein contents of the 
eluted fractions were subsequently precipitated by the addition of ammonium sulfate to 
80% saturation, following which the protein pellets were isolated and reconstituted into 
200 µl of protein storage buffer (150 mM NaCl, 20 mM HEPES, pH 7.4). 
2.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis, protein 
staining and Western-blotting  
2.4.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Protein samples were mixed with “SDS sample buffer” (final concentration: 62.5 mM 
Tris-HCl pH 6.8, 2.5 % SDS, 10% glycerol, 0.002% bromophenol blue) and heated at 
95°C for 5 minutes. In instances where it was necessary to reduce disulfide bonds, beta-
mercaptoethanol (ßME) was freshly added to a final concentration of 2.5%. Prepared 
samples were loaded onto self-cast or precast NuPAGE™ sodium dodecyl sulfate 
polyacrylamide gels (SDS-PAGE) between 8 and 15%. Electrophoresis was run at 180 
volts at 4°C using MOPs running buffer (250 mM MOPS, 250 mM Tris, 5 mM EDTA, 
0.1% SDS) until proteins were separated according to their molecular masses, indicated 
by pre-stained protein markers.  
2.4.2 Protein staining 
Protein staining was performed by incubation of SDS-PAGE gels for 10 minutes in 
“Coomassie stain” (40% methanol, 10% acetic acid, 0.1% Coomassie) heated to ~60°C. 
The gel was then removed, rinsed and incubated with deionized H2O with gentle agitation 
at RT. The H2O was replenished continuously until the background staining on the gel 
was sufficiently diminished and protein bands became distinct; digitised gel images were 
recorded using G: BOX Chemi-16 gel documentation system (Syngene). 
2.4.3 Western-blotting 
Proteins to be subjected to Western-blotting were resolved by SDS-PAGE, then 
electrophoretically transferred to PVDF membrane by the semi-dry method, using a 
Pierce™ power blotter (Thermofisher) according to the prescribed protocol. Non-specific 
binding to membranes was inhibited by incubation for 30 minutes in “TBS” (10 mM Tris-
HCl, 100 mM NaCl, pH 7.4) containing 5% (w/v) BSA. The membrane was then probed 
with pertinent primary antibodies diluted in the same buffer for either 1 hour at RT or 
 32 
 
overnight at 4°C, washed three times with gentle agitation for 10 min in TBS buffer; 
bound antibody was detected by incubation with anti-species specific antibody 
conjugated to horseradish peroxidase (HRP). Following additional wash steps, the 
membrane was exposed to ECL, which reacts with HRP to release a fluorescent signal; 
this was recorded as a digitised image using G: BOX Chemi-16 gel documentation system 
(Syngene). 
2.4.4 Densitometric quantification and statistical analysis 
Densitometric analysis of digitised images following either Coomassie staining or 
Western-blotting was performed using ImageJ software, with the resultant data 
normalized as indicated in figure legends. Data collated from several independent 
experiments were processed using Excel and graphs generated by GraphPad Prism 6.0; 
each point represents the means ± S.E.M.; student’s unpaired t-test was used to evaluate 
significance of changes observed. 
2.5 Conversion of purified single-chain BoNT/A derivatives to di-chain 
isoform, and confirmation of proteolytic activity towards a 
recombinant SNAP-25 substrate 
2.5.1 Thrombin-mediated creation of di-chain forms of purified BoNT/A derivatives 
The recombinant BoNT/A derivatives outlined in Table 2.2, were expressed, purified as 
detailed in section 2.3 and isolated as single-chain proteins. These each contained an inter-
chain thrombin protease cleavage site engineered between the LC and HC, as previously 
described (Wang et al., 2011), facilitating conversion to disulfide bonded di-chain. 
Typically, thrombin protease was added directly to the sample of purified protein (1 U/mg 
of protein), and incubated for 1 hour at 22°C, with the thrombin subsequently inactivated 
by addition of PMSF to a final concentration of 1 mM. To visualize the conversion of the 
proteins to active di-chain form and the presence of an inter-chain disulfide bond, an 
aliquot of the sample was subjected to SDS-PAGE in both the presence and absence of 
reductant, followed by Coomassie staining. 
2.5.2 In vitro protease cleavage of recombinant SNARE fragment substrate 
The proteolytic activities of di-chain BoNT/A derivatives were assessed using an 
established in vitro SNAP-25 cleavage assay (Wang et al., 2012). Briefly, toxin samples 
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were diluted appropriately into the assay buffer (20 mM HEPES, 100 mM NaCl, 10 µM 
ZnCl2, 5 mM dithiothreitol, 10 µg/ml BSA, pH 7.4) and a recombinant SNAP-25 
fragment substrate (residues 134-206) C-terminally fused to green fluorescent protein 
(GFP), was added to a final concentration of 0.5 mg/ml and incubated at 37°C for 30 
minutes. To determine the % of SNAP-25 cleavage, the samples were resolved on SDS-
PAGE, Coomassie stained, imaged and subjected to densitometric analysis using ImageJ 
software.  
2.6 Culture of mammalian cells and transient transfection 
2.6.1 Storage and maintenance of mammalian cell lines 
Low passage aliquots of the cell lines listed in Table 2.3 were stored in the defined 
medium, supplemented with 10% dimethyl sulfoxide and submerged in liquid nitrogen. 
Once thawed, the cells were maintained in T-75 tissue culture flasks at 37°C, 5% CO2 in 
15 ml of culture medium. When the cells reached ~90% confluency, typically every 4 
days, the medium was decanted, the cells were washed with PBS and detached from the 
flasks by the addition of 3 ml of trpysin-EDTA and incubation for 3 minutes at RT, 
subsequently quenched by the addition of 12 ml of medium pre-warmed to 37°C. The cell 
suspension was collected, subjected to centrifugation for 3 minutes at 170 x g, and the 
resultant cell pellet resuspended in 10 ml of fresh medium. For maintenance of cells, a 
1:5 dilution was then made into a fresh T-75 flask, and the cell passage number increased 
by 1. Cells were never maintained in excess of 20 such passages. For cell-based assays, 
the resuspended cells were counted using a haemocytometer (Sigma-Aldrich), with 
trypan blue exclusion used to determine cell viability (Strober, 2001). The cells were then 
seeded into tissue culture plates or dishes, as indicated in the figure legends. 
Table 2. 3 Mammalian cell lines cultured  
Cell line 
name 
Species Origin Tissue 
derived 
Culture medium 
HEK-293 Human Embryonic Kidney DMEM supplemented 
with 10% FBS, 20 mM 
glutamine and 1% 
penicillin/streptomycin 
antibiotics 
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SH-SY5Y Human Neuroblastoma Bone marrow “ “ 
F11 Rat/mouse 
hybrid 
fusion 
Neuroblastoma / 
embryonic 
Dorsal root 
ganglion 
“ “ 
PC-12 Rat Neuroblastoma / 
embryonic 
Adrenal 
medulla 
RPMI-1640 supplemented 
with 10% horse serum, 5% 
FBS, 20 mM glutamine 
and 1% 
penicillin/streptomycin 
antibiotics 
 
2.6.2 Constructs generated for exogenous protein over-expression in mammalian 
cell-lines 
The constructs listed in Table 2.4 were generated as outlined in section 2.2 
Table 2. 4 List of constructs for recombinant mammalian protein expression 
Construct 
no. 
Vector DNA insert 
encoding residues 
Restriction 
endonuclease 
sites 
Vector notes 
5’ 3’ 
1 pIRES2-
EGFP 
SNAP-25(1-206) XhoI SacI Vector encodes 
GFP reporter 
which is 
independently 
co-expressed 
with inserted 
genes 
2 pIRES2-
EGFP 
Human TRPV1(1-839) NheI EcoRI “ “ 
3 pIRES2-
DsRed 
Human TRPV1(1-839) NheI EcoRI Vector encodes 
Discosoma sp. 
red fluorescent 
protein 
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(DsRed) 
reporter which 
is 
independently 
co-expressed 
with inserted 
genes 
4 pcDNA3.1 Human TRPV1(1-839) NheI EcoRI N/A 
 
2.6.3 Transient transfection of mammalian cell lines 
Unless otherwise stated, HEK-293, SH-SY5Y or F11 cells were seeded at 1x105 
cells/well in a 12-well plate (3.8 cm2/well), and transient transfection with the constructs 
listed in Table 2.3 was performed using TransIT®-LT1 Transfection Reagent, according 
to the manufacturer protocol. All assays were performed 48 hours post-transfection. 
2.6.4 Culturing of rat trigeminal ganglion neurons 
Trigeminal ganglion neurons (TGNs) were dissected from 1-5 day old neonatal rat pups; 
dissociated and cultured as previously described (Malin et al., 2007). Briefly, the TGNs 
were dissected and stored temporarily in ice-cold DMEM, following which they were 
pelleted by configuration at 170 x g for 5 minutes, and the tissue was chopped into small 
pieces and incubated at 37°C for 25 minutes in Hanks Balanced Salt Solution [HBSS (137 
mM NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.1 g glucose, 0.44 mM KH2PO4, 1.3 mM 
CaCl2, 1 mM MgSO4, 4.2 mM NaHCO3, pH 7.0)] with dispase II and colleganse I diluted 
to final concentrations of 2.4 U/ml and 1 mg/ml, respectively. The suspension was gently 
triturated through a 10 ml serological pipette, before the addition of DNase I to a final 
concentration of 1 mg/ml and incubation at 37°C for 15 minutes. The cells were subjected 
to centrifugation at 170 x g for 5 minutes, the resultant pellet was resuspended and washed 
three times in DMEM containing 10% FBS (v/v). Cells were seeded at ~3x106 cells/well 
onto poly-L-lysine (0.1 mg/ml) and laminin (20 µg/ml) coated 24-well plates (1.9 
cm2/well) in DMEM supplemented with 10% FBS and 50 ng/ml 2.5S NGF. After 24 
hours incubation at 37°C, 5% CO2, and every other day thereafter, the culture supernatant 
was replaced with medium containing an antimitotic agent, Ara-C, diluted to a final 
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concentration of 10µM. The cultures were maintained as described for a minimum of 7 
days in vitro prior to cell treatment. 
2.7 Immuno-cytochemical staining, microscopy and recording of 
images 
Immuno-cytochemical (ICC) staining was performed on cultured cells seeded at 3x104 
cells/well on poly-L-lysine coated 16 mm coverslips in 24-well plates,. Cells were washed 
three times in PBS warmed to 37°C, then fixed by the addition of formaldehyde to a final 
concentration 4% and incubated for 20 minutes at RT. The cells were then washed with 
PBS three times; at this point, cells were either left un-permeabilized or subjected to 
permeabilization by 20 minutes of treatment with 0.2% Triton X-100 in PBS. To prevent 
non-specific binding of antibodies, cells were incubated for 1 hour with either 10% goat 
or donkey serum diluted in PBS. Primary antibodies were applied in the same solution 
and left overnight at 4ºC; after extensive washing, fluorophore-conjugated secondary 
antibodies were added for 1 hour at room temperature. The cells were subjected to a final 
series of washings in PBS, prior to rinsing in deionized H2O and mounting onto 
microscope slides with VECTASHIELD Hardset Mounting medium.  
Immuno-fluorescent micrographs were taken with an inverted fluorescence microscope 
(Olympus IX71) equipped with a CCD camera or an inverted Zeiss confocal microscope 
(LSM 710) and analysed using Image-Pro Plus 5.1 or Zen Pro 2008, respectively. The 
omission of primary antibody gave the background of secondary antibody binding; the 
signal intensity above this was taken as positive reactivity. 
Live cultured cells were imaged with the inverted fluorescence microscope (Olympus 
IX71), following pre-incubation for 15 minutes at 37°C with Hoescht nuclear stain diluted 
into the culture medium to a final concentration of 1 µg/ml; images were processed and 
analysed using Image-Pro Plus 5.1 software. 
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2.8 Functional characterization of TRPV1 transiently-expressed in 
HEK-293 cells 
2.8.1 Electrophysiological recordings of cation influx in response to TRPV1 
activation 
HEK-293 cells, either untransfected or transiently-transfected with pIRES2-EGFP-
TRPV1, were seeded onto poly-L-lysine coated 33mm coverslips at 5x103 cells/coverslip 
and subjected to patch clamp recordings, using defined extracellular and recording 
solutions (Bohlen et al., 2010). Transfected HEK-293 cells exhibiting GFP fluorescence 
were assumed to be TRPV1-positive and selected for patching; subsequent perfusion of 
capsaicin to a final concentration of 1 µM confirmed a functional response elicited by 
TRPV1. The resultant influx Na+ was recorded by whole-cell recording, using a patch 
clamp system [EPC1 amplifier and controlled by HEKA pulse (HEKA Elektronik, 
Lambrecht, Germany)]. Cells presenting a strong inward current were washed to remove 
capsaicin and the extracellular solution was perfused with chimeric fusion proteins 
containing DkTx, as indicated in the figure legends. The experiment was then repeated 
with untransfected HEK-293 cells as a negative control. The described 
electrophysiological recordings were performed in collaboration with Dr. Ahmed Alsabi, 
DCU. 
2.8.2 Intracellular Ca2+ imaging following activation of TRPV1: acquisition of 
confocal images and data analysis 
HEK-293 cells transiently-transfected with pcDNA3.1-TRPV1 were plated onto 35 mm 
dishes coated with poly-L-Lysine at a density of 3x105 and loaded with 5 µM Fluo-4 AM 
in DMEM for 30 minutes at RT. Cells were then washed three times in HBSS, and placed 
on an inverted Zeiss confocal microscope (LSM 710) and regions of interest selected 
which contained a high-proportion of cells exhibiting a healthy morphology. An argon 
laser was used to excite the fluorophore at 488 nm, and the baseline fluorescence was 
recorded for ~20s, following which the cells were exposed to either capsaicin or DkTx 
fusion proteins diluted in HBSS to a final concentration of 1 µM and 5 µM, respectively. 
A timed series of images were taken over 120s, with images of fluorescent signals 
grabbed every ~2 s. The intensity of fluorescence emission at 505–530 nm was analysed 
offline on a cell-by-cell basis using Zeiss software (Zen Pro 2008). 
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2.9 Investigation of the biological activities of recombinant growth-
factor fusions 
2.9.1 Dose-dependent survival of serum-starved PC-12 cells in response to 
recombinant NGF fusions 
The assay was designed based on a published protocol (Gazzano-Santoro et al., 1999); 
briefly, PC-12 cells were seeded at 4x104 per well in a 24-well plate in serum-free 
medium, and incubated for 48 hours at 37°C, 5% CO2 with either 2.5S NGF or purified 
rFc-ßNGF-(His)6 as indicated in the figure legend. AlamarBLUE™, a cell-permeable 
compound which produces fluorescent metabolites, was added to each well and incubated 
for a further 24 hours. Fluorescence was measured using a Tecan Safire II plate reader 
(excitation 570 nm, emission 585 nm). 
2.9.2 Phosphorylation of extracellular signal regulated kinases 1/2 in cells exposed 
to recombinant growth-factor fusions  
This assay was performed as described (Lu et al., 2014); briefly, either PC-12 or SH-
SY5Y cells were seeded 4x104 per well in a 24-well plate and cultured in serum-free 
medium overnight. Recombinant growth factors were diluted, as indicated in the figure 
legends, into serum-free DMEM and added to the cultured cells for up to 1 hour, prior to 
preparation of cell lysates. Western-blotting was subsequently performed to detect 
phosphorylation of extracellular signal regulated kinases 1/2 (ERK 1/2). 
2.10 Conjugation of BoNT/A-based core-therapeutics to targeting 
ligands 
2.10.1 SNARE-mediated protein stapling 
Protein stapling reactions were performed as previously published (Ferrari et al., 2012). 
Briefly, recombinant proteins containing C-terminal fusions of either full-length SNAP-
25 or VAMP 2(25-84) were combined with TAMRA-labelled synthetic peptide based on 
syntaxin(201-245), in a respective molar ratio of 5:7:7 in stapling buffer” (100 mM NaCl, 20 
mM HEPES, 0.8% n-octyl-β-D-glucopyranoside, pH 7.4) for one hour at RT. The 
efficiency of protein conjugation was determined by densitometric analysis of the 
observed size-shift on Coomassie stained SDS-PAGE. 
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A variation of protein stapling using the pull-down format was performed by 
immobilization of GST tagged protein fusions containing either SNAP-25 or VAMP 2(25-
84) on glutathione agarose, subsequently incubated with their corresponding stapling 
partners for 1 hour at RT in stapling buffer. The agarose was then washed extensively 
with the same buffer and the presence of both SNAP-25 and VAMP 2 confirmed by SDS-
PAGE followed with either Coomassie staining or Western-blotting. 
2.10.2 Conjugation of SpA-B containing fusions to either rabbit immunoglobulin G 
antibodies or rFc-ßNGF-(His)6   
The chimeric protein fusion encoded by construct number 11 of Table 2.2 was 
recombinantly expressed and immobilized on glutathione agarose, as described in section 
2.3.4. Typically, 10 µg of protein was immobilized on 10 µl of agarose and incubated for 
1 hour at 4°C with either 1 ml of rabbit serum, 3-fold molar excess of rabbit 
immunoglobulin G (IgG) antibodies diluted in 200 µl PBS (137 mM NaCl, 10 mM 
phosphate, 2.7 mM KCl, pH 8.3) or 200 µl of purified rFc-ßNGF-(His)6  in protein storage 
buffer. The agarose was washed extensively with PBS to remove excess unbound protein, 
and the coupled complexes were then released from agarose by incubation with 1 U 
thrombin for 40 minutes at RT; separation of the agarose and eluate was achieved by 
centrifugation with SigmaPrep™ filtration spin columns. 
The binding of proteins to SpA-B containing fusion proteins was investigated by SDS-
PAGE followed either by Coomassie staining or Western-blotting, with the antibodies 
indicated in the figure legends. Dot-blotting analysis was also performed by applying 2 
µl of 10-fold dilutions of the conjugated proteins directly to nitrocellulose membrane, 
blocking in TBS containing 5% (w/v) BSA and then probing the membrane with an anti-
rabbit IgG antibody conjugated to HRP for 1 hour at RT. Following additional wash steps, 
the membrane was exposed to ECL, and a digitised image of the fluorescent signals were 
recorded using G: BOX Chemi-16 gel documentation system (Syngene). 
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2.11 Treatment of cultured cells with recombinant BoNT/A derivatives 
and monitoring of SNAP-25 cleavage 
2.11.1 Toxin incubation, cell lysis, SDS-PAGE and immunoblotting 
Cultured rat TGNs were prepared as outlined in section 2.6.4. The mammalian cell lines 
listed in Table. 2.3 and cultured as described in 2.6.1, were typically seeded at 2x106 
cells/well in a 24-well plate and allowed to attach. Cells, were untreated or treated with 
either targeted or untargeted purified BoNT/A derivatives, diluted directly into the culture 
medium at the concentrations specified in figure legends. The cells were incubated at 
37°C, 5% CO2 for 42-48 hours, after which the medium was removed and the cells were 
washed with 2 x 1 of ml chilled PBS. Cell lysates were prepared by the addition of 100 
µl of SDS sample buffer directly to the cell monolayer, vigorous mixing and subsequent 
harvesting by aspiration. The lysates were then subjected to SDS-PAGE, followed by 
Western-blotting using antibodies which detect cleaved SNAP-25. 
2.11.2 Quantification of SNAP-25 cleavage 
After development with ECL, digital images of chemiluminescent signals were obtained 
using the G BOX Chemi-16 gel documentation system, and intensities of each lane 
quantified with ImageJ software. For determination of the fraction of SNAP-25 cleaved, 
the ratios were calculated against a requisite internal standard (i.e. a cytoskeleton protein) 
to normalize any variation in loading between wells. Treated samples were expressed 
relative to those for non-toxin treated controls. Data were processed using Excel and 
graphs generated using GraphPad Prism 6.0 software; each point represents the mean ± 
S.E.M, from several independent experiments. 
2.11.3 Binding of an anti-TrkA IgG conjugated-BoNT/A derivative to PC-12 lysate 
 
PC-12 lysate (2 µg in 2 µl) was applied directly to nitrocellulose membrane and incubated 
for 5 minutes at RT; further binding to the membrane was then prevented by blocking in 
TBS containing 5% (w/v) BSA for 30 minutes at RT. A BoNT/A derivative (5 ng) either 
conjugated to anti-TrkA IgG (see 2.10.2) or an unconjugated control, was applied directly 
to the lysate and incubated for 10 minutes at RT. The membrane was then washed 
extensively with TBS to remove unbound protein, and probed with an anti-LC/A antibody 
for 1 hour at RT. The membrane was subjected to additional washing prior to incubation 
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with an anti-species IgG antibody conjugated to HRP for 1 hour at RT. Following a final 
set of wash steps, the membrane was exposed to ECL, and digitised images of the 
fluorescent signals were recorded using G: BOX Chemi-16 gel documentation system 
(Syngene). 
 
2.12 Radio-iodination of BoNT/A derivatives and their binding to rat 
cultured cerebellum granule neurons 
2.12.1 Radio-labelling of BoNTs with 125I-iodine 
Recombinant wild-type BoNT/A or its mutated derivatives as indicated in the results 
section, were labelled with sodium 125I-iodine (125I) by a previously-described 
chloramine-T method  (Williams et al., 1983). Briefly, each BoNT (40 µg in 40 µl) was 
added to 1 mCi (10 µl) of carrier free 125I and derivatisation initiated by adding 
chloramine-T (5 µl of 2 mM, yielding a final concentration of 0.22 mM). The reaction 
was quenched after 40s by addition of an excess of L-tyrosine (25 µl of 1 mg/ml in 0.1 M 
sodium phosphate buffer pH 7.4 containing 150 mM NaCl). Free 125I and tyrosine were 
separated from the 125I-labelled toxin by gel filtration, using a PD-10 column equilibrated 
with the latter buffer, with an aliquot subsequently taken to determine the specific 
radioactivity. This was calculated by counting γ-emission with a γ-counter (LKB, 1275, 
minigamma counter), the counts per minute (CPM) were then converted to disintegrations 
per minute (DPM) based on a pre-determined counter efficiency of 58%. The DPM in the 
aliquot was then extrapolated to determine total amount of isotope (Ci) associated with 
toxin (mmol). Radio-labelled toxins were stored at 4°C in the presence of gelatin to a 
final concentration of 0.25% (w/v). 
2.12.2 Saturatable binding of 125I-BoNTs to rat cerebellum granule neurons and 
quantification of γ-emission  
Rat cultured cerebellum granule neurons (CGNs) prepared as previously described (Meng 
et al., 2007) by Dr. Jiafu Wang and cultured for a minimum of 10 days in vitro, were 
suspended in PBS and the total cell protein content was determined by BCA protein assay. 
Aliquots (50-150 µg) were supplemented with BSA to a final concentration of 1 mg/ml 
and incubated with increasing concentrations of each 125I-labelled toxin for 1 hour at 4°C, 
or together with its unlabelled counterpart at ≤100-fold molar excess over the highest 
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concentration of 125I-toxin used. Binding was terminated by centrifugation (9,000 x g for 
2 min) and resuspension in ice-cold PBS, after which pellets were washed two further 
times as described prior to γ-counting (LKB, 1275, minigamma counter). A scatchard plot 
was constructed by calculating the ratio of bound toxin to unbound toxin at each 
concentration, with the equilibrium disassociation constant (KD) subsequently determined 
by calculating the negative reciprocal of the resultant slope. The capacity of increasing 
concentrations of unlabelled BoNT/A (0-1 µM) to compete with 1 nM 125I-BoNT/A for 
CGN binding sites was performed as above. Data were processed using Excel and graphs 
generated using GraphPad Prism 6.0 software; each point represents the mean ± S.E.M, 
from several independent experiments. 
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Chapter 3. Chimeric fusion of a TRPV1-activating spider-venom 
peptide with a binding domain-deficient BoNT/A core-therapeutic: a 
novel retargeting strategy 
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3.1 Overview 
As presented in the General Introduction, TRPV1 is a polymodal integrator of noxious 
stimuli, highly selective for peptidergic nociceptors which exhibit SNARE-dependent 
release of pain-eliciting neuropeptides and inflammatory mediators (Wang and Woolf, 
2005). In response to agonist binding, TRPV1 undergoes ligand-induced endocytosis into 
vesicles which undergo acidification (Sanz-Salvador et al., 2012). This is a requisite for 
toxin internalization and the subsequent cytosolic delivery of its LC/A protease. TRPV1, 
thus, serves as a model candidate for the generation of novel retargeted BoNT/A-based 
anti-nociceptives.  
With TRPV1 established as an initial receptor candidate, the next consideration was 
designing a means by which to target it. Preliminary ideas included the chemical 
conjugation of BoNT/A to a commercially-available TRPV1 antibody, or generation of 
BoNT/A fused to a single-chain variable fragment (ScFv) antibody targeting TRPV1; the 
latter approach had already achieved some targeting of BoNT/A to another protein, P2X3 
(Ma et al., 2014). However, chemical linkage of BoNT/A has been reported as inefficient, 
and implicated in a reduction in activity (Band et al., 2010). Furthermore, as an antibody-
mediated approach only offered limited success, it was deemed imperative to adopt a 
more innovative and ambitious targeting strategy. 
 
My literature research for target candidates and their ligands had unearthed a remarkable 
TRPV1 agonist, Double-Knot Toxin (DkTx) isolated from the venom of the Malaysian 
Earth Tiger tarantula (Bohlen et al., 2010). This was recognised as a significant 
opportunity, the potential of which could be further exploited through development of an 
original targeting approach: generation of a BoNT/A-spider venom chimera. 
Consequently, a novel BoNT/A based fusion protein was generated, in which the HCC/A 
binding domain was deleted and replaced with DkTx to yield LC.HN.HCN/A-DkTx. The 
HCN sub-domain was retained, in contrast to the majority of other BoNT-retargeting 
strategies (see section 1.3), as it was hypothesised that greater fidelity to both native toxin 
structure and membrane interactions (Muraro et al., 2009) could potentially increase 
neuronal delivery of LC.HN.HCN/A-DkTx. 
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DkTx is a ‘short’ peptide of 79 residues, arranged in two tandemly repeated structural 
motifs termed inhibitory cystine knot (ICK), each characterized by 3 stabilizing 
disulphide bonds; the first 2 are involved in the creation of a loop, which is then threaded 
by a third disulphide creating the ‘knot’(Craik et al., 2001). This conformation confers 
incredible stability, serving as a model platform, exploited ubiquitously in nature and in 
an enormously diverse range of bioactive peptides (Herzig and King, 2015). DkTx is 
however, unique, as its 2 tandemly repeated ICK units are structurally and functionally 
autonomous, but act synergistically as a single polypeptide (Bohlen et al., 2010). 
DkTx is an irreversible agonist of TRPV1 which binds to the pore region locking this 
channel in an open conformation. The two independent knots of DkTx confer an 
antibody-like bivalency, enabling the toxin to bind two sites simultaneously within a 
single TRPV1 channel (Fig. 3.1 A and B). This bivalency is the basis of the irreversible 
nature of DkTx, as the disassociation constant is such that by the time one knot has 
disassociated, the other has reattached, and vice a versa. Recombinantly expressed DkTx 
possesses a half maximal effective concentration (EC50) of 144 nM (Bohlen et al., 2010) 
which, when combined with its well defined selectivity for TRPV1, provided a promising 
means for retargeting BoNT/A to TRPV1 expressing neurons. The specificity and high-
avidity of the binding of DkTx to TRPV1 was recently underscored by its utilization in 
two separate publications in a single issue of Nature (Erhu et al., 2013, Maofu et al., 
2013), with DkTx playing an integral role in revealing the full crystal structure of TRPV1; 
which hitherto had been unachievable (Moiseenkova-Bell and Wensel, 2009). 
The expression of soluble and functional ICK toxins is notoriously difficult (Kurokawa 
et al., 2001, Schmoldt et al., 2005, Sermadiras et al., 2013), considerably more so for a 
toxin such as DkTx which has two ICK motifs (Klint et al., 2013). DkTx contains 6 
separate disulfide bonds, which could afford the theoretical formation of ~280,000 
different disulfide bond isomers (Klint et al., 2013). Additionally, the generation of 
chimeric fusion proteins can have unpredictable effects on the functionality of the 
constituent protein domains. In anticipation of this, and supplementary to the generation 
of the LC.HN.HCN/A-DkTx chimera, it was deemed pertinent to additionally express 
recombinant DkTx without fusion to BoNT/A domains. This would expedite optimization 
of parameters for recombinant expression and purification of functional DkTx and, 
subsequently, enable evaluation of the consequence of additional polypeptide cargo on 
the biological activity of DkTx.  
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Figure 3. 1 DkTx structure and its interaction with TRPV1 
(A) Representation of the structure of DkTx, showing the tandemly-repeated ICK motif (knot 1 and knot 
2), separated by a linker (Julius, 2013). (B) Schematic showing the interaction of DkTx with the pore region 
of TRPV1; each knot is capable of binding a separate region within the channel. (C) Sequence alignment 
of the two knots of DkTx; yellow depicts cystine residues highly conserved in all ICKs while red shows 
residues which appear in both knots. Adapted from (Bohlen et al., 2010). 
To ascertain the contribution of DkTx to the targeting of LC.HN.HCN/A-DkTx, an 
untargeted control protein was generated (LC.HN.HCN/A) and investigated in parallel. The 
presence of the HCN/A sub-domain afforded an opportunity to investigate its contribution 
to neuronal binding. In light of interesting findings in this regards, a series of radio-ligand 
binding assays were performed with 125I labelled native BoNT/A, BoNT/AΔHCN in which 
the HCN was deleted, and BoNT/AW985L, containing a single point mutation in the HCN sub-
domain. The binding of these labelled BoNT/A derivatives to CGNs provided insight into 
the involvement of the HCN sub-domain in both toxin binding and, significantly, 
internalization. 
3.2 Results 
3.2.1 Design and cloning of expression constructs encoding the first generation of 
chimeric fusion proteins 
The inherent difficulty frequently encountered in the recombinant expression of 
functional disulfide bond containing proteins as mentioned above, emphasized that the 
initial cloning strategy was paramount for the successful expression of DkTx fusion 
proteins. To this end, the pET32b expression vector was selected, as insertion of 
recombinant genes into its multiple cloning site (MCS) produces in-frame fusion with 
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thioredoxin (Trx) tag. The Trx-tag is a 12 k cytoplasmic E. coli protein, widely utilized 
as a solubility enhancer when co-expressed as a fusion to recombinant proteins, especially 
with short peptides (Yasukawa et al., 1995). Trx tag also possesses intrinsic oxido-
reductase activity which can promote the formation of disulfide bonds through thio-
disulfide exchange (Young et al., 2012). As the Trx-tag does not exhibit any inherent 
affinity properties, the pET32b vector also confers fusion to both (His)6 and S-Tag, 
enabling purification by immobilized metal affinity chromatography (IMAC) or antibody 
affinity chromatography, respectively.  
 
Figure 3. 2 Cloning of expression constructs encoding the first generation of fusion proteins 
(A) Restriction digest of the depicted vector (SacI enzyme) was resolved by agarose gel electrophoresis 
and visualized by trans-UV. Arrow indicates the predicted plasmid size, as detailed below the gel. B) DNA 
for DkTx was commercially synthesized and provided in the pMA-T vector, that was subsequently 
restriction digested (SacI and XhoI enzymes), resolved by agarose gel electrophoresis and visualized by 
trans-UV. Arrow indicates the excised DkTx gene. (C-D) Performed as described in (A). 
 
A construct containing a mutated version of BoNT/A, in which nucleotides encoding the 
acceptor binding sub-domain (HCC/A) had been deleted, was provided by my co-
supervisor Dr. Jiafu Wang. The resultant gene LC.HN.HCN/A was subcloned into the 
pET32b expression vector (Fig. 3.2 A), producing Trx-(His)6-S-Tag-LC.HN.HCN/A to act 
as an untargeted control. In the next instance, the DNA for DkTx was synthesised, codon 
 48 
 
optimised for bacterial expression and provided in the pMA-T vector (Fig. 3.2 B); such 
codon optimisation has been reported to support soluble and functional expression of non-
prokaryotic proteins in bacterial expression systems (Burgess-Brown et al., 2008). The 
DkTx gene was subsequently subcloned either as a 3’ fusion to LC.HN.HCN/A to encode 
Trx-(His)6-S-Tag-LC.HN.HCN/A-DkTx (Fig. 3.2 C) or directly into the MCS of pET32b 
to encode Trx-(His)6-S-Tag-DkTx (Fig. 3.2 D). 
3.2.2 Recombinant expression and IMAC purification of the first generation of 
fusion proteins 
In addition to the critical nature of the DkTx construct design, the selection of an 
appropriate bacterial expression system was of equivalent significance. The standard E. 
coli expression strains possess a reductive cytoplasm adversative to disulfide bond 
formation (Kong and Guo, 2014). The Origami B™ E. coli strain contains mutations in 
both the thioredoxin reductase (trxB) and glutathione reductase (gor) genes (Seras-
Franzoso et al., 2012), creating an oxidizing cytoplasmic environment more conducive to 
disulfide bond formation. Hence, this has been widely affirmed to enhance functional 
expression of disulfide bond containing proteins (Berkmen, 2012). The Origami B™ strain 
is known to be particularly successful in the expression of disulfide containing protein 
when used in conjunction with the pET32b expression vector (Stewart et al., 1998). Thus, 
the combination of both the pET32b vector and the Origami B™ expression strain 
increased the probability of obtaining soluble and functional DkTx fusion proteins.  
Trx-(His)6-S-Tag-LC.HN.HCN/A-DkTx and Trx-S-Tag-(His)6-DkTx were expressed in E. 
coli by auto-induction and purified from the resultant lysates by IMAC. Subsequent 
analysis of the respective purifications was performed by SDS-PAGE followed by 
Coomassie staining which visualized predominant bands at the predicted respective Mr 
of 145 k and 27 k (Fig. 3.3 A and B), as determined by a semi-log plot. The untargeted 
control protein, Trx-(His)6-S-Tag-LC.HN.HCN/A, was expressed and purified 
independently by Dr. Matthew King. 
The design of the first generation fusion proteins was such that successive cleavage with 
thrombin and enterokinase proteases was expected to remove the Trx-(His)6 and S-Tags, 
respectively. The enterokinase cleavage of Trx-(His)6-S-Tag-LC.HN.HCN/A-DkTx 
proved ineffective, failing to produce the expected size shift on SDS-PAGE, and resulted 
in the degradation of the protein, evident by the appearance of multiple protein bands at 
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higher concentrations of enterokinase (Fig. 3.3 C, left panel). Thrombin cleavage proved 
efficient in removing the N-terminal Trx tag (Fig. 3.3 C, right panel), and simultaneously 
cleaved the protease site between LC/A and HN/A, converting the single-chain purified 
protein to disulfide bond linked di-chain (Fig. 3.3 D). Although the S-Tag was retained 
in the purified proteins due to the inefficiency of the requisite enterokinase cleavage, as 
it was not utilized for any further purpose and to simplify descriptions, the tag is omitted 
from future protein names. 
 
Figure 3. 3 Recombinant expression and IMAC purification of the first generation of fusion 
proteins 
(A) SDS-PAGE followed by Coomassie staining confirmed the expression and IMAC purification of Trx-
(His)6-S-Tag-LC.HN.HCN/A-DkTx at the predicted Mr of 145 k. (B) SDS-PAGE followed by Coomassie 
staining, demonstrated the expression and IMAC purification of Trx-(His)6-S-Tag-DkTx at the predicted 
Mr of 27 k. (C) Coomassie stained SDS-PAGE of Trx-(His)6-S-Tag-LC.HN.HCN/A-DkT treated with either 
enterokinase (EK) or thrombin (Thr) proteases. Treatment with enterokinase resulted in degradation of the 
protein (left panel), while thrombin cleavage produced a 20 k size shift corresponding to Trx-(His)6 removal 
(right panel). (D) Thrombin treated S-Tag-LC.HN.HCN/A-DkTx was resolved on SDS-PAGE in non-
reducing and reducing conditions (+2.5% ßME) and subjected to Coomassie staining. 
 
3.2.3 SNARE protease activities of both LC.HN.HCN/A-DkTx and the untargeted 
control were comparable to that of wild-type BoNT/A  
The protease activity of both LC.HN.HCN/A and LC.HN.HCN/A-DkTx was assessed by an 
established in vitro protease cleavage assay (Wang et al., 2012), confirming the successful 
conversion of both proteins to di-chain following thrombin cleavage. The protease 
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activities of the respective proteins were shown to be comparable, and corresponded to 
the cleavage efficiency of native BoNT/A (Fig. 3.4). This provided confirmation that 
neither the genetic manipulation of the BoNT/A domains, retention of the S-Tag nor the 
inclusion of a DkTx fusion impacted upon the LC/A protease. 
 
Figure 3. 4 In vitro cleavage of a recombinant SNAP-25 fragment substrate by LC.HN.HCN/A-DkTx, 
the untargeted control or recombinant wild-type BoNT/A 
(A). In-vitro SNAP-25 cleavage assay was performed with 0.1 – 100 nM LC.HN.HCN/A or LC.HN.HCN/A-
DkTx, and 0.1 – 10 nM BoNT/A. Cleavage of the SNAP-25 fragment substrate was visualized by 
Coomassie staining of SDS-PAGE. (B) Densitometric analysis of data from (A) performed with ImageJ 
software to determine percentage of SNAP-25 cleaved at each respective concentration, Data plotted are 
means ± S.E.M; n=3. 
 
3.2.4 Endogenous and exogenous expression of TRPV1 and SNAP-25 in cultured cell 
lines 
Functional characterization of DkTx, and the subsequent assessment of its ability to 
mediate delivery of the LC protease into cells, required co-expression of both the TRPV1 
target and the SNAP-25 substrate. Rat TGN and dorsal root ganglion (DRG) primary 
neurons express TRPV1 and SNAP-25 (Winter, 2005, Meng et al., 2016). However, the 
valuable and finite supply of rats from which to harvest these neurons, coupled with 
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difficulties with both dissection and culturing encouraged the screening for TRPV1 and 
SNAP-25 expression in available HEK-293, F11 and SH-SY5Y cell lines (Fig. 3.5 A). 
The F11 cell line was of particular interest, as these are derived from DRG and reported 
to express TRPV1 (Goswami et al., 2010). However, following immuno-blotting of the 
cell lysates with antibodies against either TRPV1 or SNAP-25, no endogenous expression 
of TRPV1 could be detected, although SNAP-25 could be readily seen in both F11 and 
SH-SY5Y cell lysates (Fig. 3.5 A). As the initial focus was establishing the functionality 
of DkTx, and no cell line endogenously expressed TRPV1, mammalian expression 
vectors were constructed to facilitate its exogenous expression by transient transfection. 
To this end only HEK-293 cells were found to be capable of expressing TRPV1 following 
transfection; TRPV1 could not be detected in the other cell lines (Fig. 3.5 A). HEK-293 
cells were found to produce functional TRPV1 channels, sufficient to facilitate 
assessment of the biological activity of the DkTx fusion (see 3.2.5).  
However, TRPV1 expression in HEK-293 cells corresponded with morphological 
changes, reduced cell proliferation and an overall reduction in cell viability when 
compared to untransfected controls; this prevented the development of a cell line stably 
expressing TRPV1. The cytotoxicity of TRPV1 expression was hypothesised to be due 
to increased entry of Ca2+ into cells, in keeping with previous observations (Thomas et 
al., 2007). The subcloning of TRPV1 into pIRES2-GFP and pIRES2-dsRED expression 
vectors, in addition to conferring the respective co-expression of either green-fluorescent 
protein (GFP) or red-fluorescent protein (RFP) reporters to aid selection of TRPV1 
positive cells, reduced the overall level of TRPV1 expression (Fig. 3.5B). Consequently, 
this appeared to increase the tolerance of HEK-293 cells to TRPV1 expression; however, 
attempts at developing a stable cell line still proved unsuccessful, as no cells survived the 
selection process. The cell-surface localization of TRPV1 in HEK-293 cells transfected 
with pIRES2-GFP-TRPV1 was confirmed by ICC staining of non-permeabilized cells; 
imaged by Z-stack confocal microscopy (Fig. 3.5 C). 
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Figure 3. 5 Analysis of endogenous and exogenous TRPV1 expression in cultured cell lines 
(A) HEK-293, F11 or SH-SY5Y cells were either untreated, or transfected with pcDNA3.1_TRPV1 and 
subjected to Western-blotting with antibodies against TRPV1 and SNAP-25, with α-Tubulin serving as a 
loading control. (B) HEK-293 cells were transiently transfected with one of the three indicated expression 
vectors, lysed and subjected to Western-blotting with antibodies against TRPV1 or α-Tubulin. Fluorescence 
microscopy was performed prior to lysis to visualize GFP and RFP reporters, with Hoechst stain used to 
produce nuclear staining. (C) HEK-293 cells were transfected with pIRES2-GFP-TRPV1 and subjected to 
ICC using an anti-TRPV1 antibody, followed by a second antibody conjugated Alexa Fluor® 590 
fluorescent probe, subsequently imaged by Z-stack confocal microscopy. 
 
3.2.5 Recombinantly-expressed Trx-(His)6-DkTx is biologically active 
The retargeting of LC.HN.HCN/A-DkTx to TRPV1 expressing cells could only be 
achieved if DkTx is functionally active. In order to establish if the pET32b 
vector/Origami B™ E. coli combination was capable of producing biologically active 
DkTx, a series of functional assays were performed using Trx-(His)6-DkTx. This protein 
was selected over LC.HN.HCN/A-DkTx as its smaller mass facilitated production of 
greater protein yields, more conducive to the micro molar concentrations required for 
DkTx functional assays (Bohlen et al., 2010). The Trx and (His)6 tags were not removed 
due to problems with the protease cleavage as previously detailed (Fig. 3.3 C). Moreover, 
the preservation of the protein tags on DkTx was hypothesised to be advantageous, as it 
would demonstrate that the protein was capable of interacting with TRPV1 despite an 
encumbered N-terminus and would, thus, be representative of the LC.HN.HCN/A-DkTx 
fusion. 
The retention of the (His)6 tag also presented further opportunity, as in the absence of an 
antibody specific for DkTx, an anti-(His)6 antibody could be used for detection of Trx-
(His)6-DkTx. The binding of the latter to either wild-type HEK-293 cells or those 
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transiently-expressing TRPV1 was evaluated by ICC staining using antibodies against 
either TRPV1 or (His)6. The co-localization of (His)6 and TRPV1 specific signals 
confirmed successful and selective association of Trx-(His)6-DkTx with TRPV1 
expressing cells (Fig. 3.6 A).  
With the binding of DkTx to TRPV1-positive cells established, the next step was to 
determine if it was capable of activating the channel. To this end, voltage-clamp 
recordings were performed on HEK-293 transfected with pIRES2-GFP-TRPV1 (Fig. 3.6 
B). The presence of a functional TRPV1 channel in GFP-positive cells was confirmed by 
exposure to 1 µM capsaicin as previously published (Neelands et al., 2005); following 
washout of capsaicin, the current amplitude was returned to baseline. The cells were 
subsequently exposed to 1.3 µM of Trx-(His)6-DkTx; this produced an inward current 
comparable to that of capsaicin but which was still present after washing, demonstrating 
the irreversible binding of DkTx to the channel (Bohlen et al., 2010).  
TRPV1 is a non-selective cation channel but has a high propensity for Ca2+. Hence, the 
detection of an increase in intracellular Ca2+ levels is a well-established functional assay 
for its activation (Tóth et al., 2004, Meng et al., 2016). HEK-293 cells expressing TRPV1 
were loaded with Fluo-4-AM, a Ca2+ specific green fluorescent indicator, and baseline 
fluorescence was established. Following exposure to 1 µM capsaicin but not to the wash 
buffer, the fluorescence level was increased in a proportion of cells, surmised to be 
TRPV1 positive. Once the controls had been established, the experiment was repeated 
with 5 µM Trx-(His)6-DkTx, using fresh cells, which responded with a comparable 
increase in fluorescence as that elicited by capsaicin (Fig. 3.6 C). A secondary effect was 
observed following treatment with either capsaicin or Trx-(His)6-DkTx; the responsive 
cells underwent morphological changes and ultimately detached from the culture dish, 
corroborating previous observations that rapid TRPV1-mediated Ca2+ influx can induce 
cell death (Puntambekar et al., 2004, Thomas et al., 2007). The experiment was 
subsequently repeated with wild-type HEK-293 cells, with no cells responding to either 
capsaicin or Trx-(His)6-DkTx (Fig. 3.6 D); confirming that the increase in intracellular 
Ca2+ levels was a specific response to TRPV1 activation. 
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Figure 3. 6 Trx-(His)6-DkTx binds and activates TRPV1 exogenously-expressed in HEK-293 cells 
(A) HEK-293 cells either wild-type, or transfected with pcDNA3.1-TRPV1 were treated with 1 µM Trx-
(His)6-DkTx diluted directly into the culture medium, incubated for 5 minutes at 37°C, washed extensively 
and fixed by treatment with 4% formaldehyde solution. ICC staining was subsequently performed using 
antibodies specific for either (His)6 or TRPV1 followed by secondary antibodies conjugated to either Alexa-
Fluor® 488 or Alexa-Fluor® 590 fluorescent probes, nuclear staining by DAPI is shown in blue. Image 
chosen is representative (n=10). (B) HEK-293 cells transfected with pIRES2-GFP-TRPV1 were seeded 
onto coverslips, GFP positive cells presumed to be TRPV1-expressing were selected and patched. The 
perfusion of 1 µM capsaicin diluted in the extracellular solution induced an inward current, confirming the 
presence of functional TRPV1 channels, with currents returning to baseline following washout. Trx-(His)6-
DkTx was subsequently applied by perfusion to a final concentration of 1.3 µM and elicited an inward 
current, which persisted after washing. The current amplitude from responsive cells treated with either 1 
µM capsaicin or 1.3µM Trx-(His)6-DkTx (each N=4) was subjected to statistical analysis and compared by 
un-paired student t-test; P < 0.01. (C) HEK-293 cells transfected with pcDNA3.1-TRPV1 were loaded with 
Fluo-4-AM Ca2+ indicator and fluorescent signal measured following laser excitation at 488 nm was taken 
as baseline fluorescence (f0). Subsequent washing with HBSS failed to provoke an increase in fluorescent 
signal, whereas application of either 1 µM capsaicin (blue line) or 5 µM Trx-(His)6-DkTx (red line) diluted 
in the latter buffer produced rapid increases in intracellular fluorescence (f). Inset images are fluorescence 
signals prior to and after the application of Trx-(His)6-DkTx. Values are the mean ± S.D.; n=8 from 
individual cells, normalized against baseline fluorescence. (D) Performed as in (C) using untransfected 
wild-type HEK-293 cells. 
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3.2.6 TRPV1 and SNAP-25 can be co-expressed in HEK-293 cells following transient 
co-transfection 
The combination of pET32b and Origami B™ E. coli shown to competently produce 
functional DkTx sustained the supposition that DkTx might be adept at targeting 
LC.HN.HCN/A to TRPV1 expressing cells. However, assessment of LC.HN.HCN/A-DkTx 
retargeting required cellular co-expression of TRPV1 as the target of DkTx, and SNAP-
25 as the substrate of LC/A to give a detectable readout. The lack of endogenous TRPV1 
expression in available cell lines which expressed SNAP-25 presented a difficulty, further 
compounded by the inability to over-express TRPV1 in these same cells (Fig. 3.5 A). 
Significantly, the exogenous expression of SNAP-25 in HEK-293 cells had been 
previously employed as a means of evaluating delivery of biotinylated BoNT/A, targeted 
to avidin-conjugated low-density lipoprotein receptor (Yeh et al., 2011). 
 
Figure 3. 7 Exogenous co-expression of both TRPV1 and SNAP-25 in HEK-293 cells following 
transient transfection 
(A) HEK-293 cells transiently co-transfected with 1 µg of pcDNA3.1_TRPV1 and 0.25 µg of pIRES2-
GFP-SNAP-25 combined in the same transfection reagent complex, were incubated for 48 hours. Cell 
lysates were prepared and subjected to Western-blotting with antibodies against TRPV1, α-Tubulin or 
SNAP-25. (B) HEK-293 cells were co-transfected as described in (A). ICC staining was performed using 
an anti-TRPV1 antibody with a secondary antibody conjugated to an Alexa-Fluor® 590 fluorescent probe 
used to detect binding, with subsequent image acquisition performed by fluorescence microscopy. GFP 
fluorescence was conferred by pIRES2-GFP-SNAP-25. Image chosen is representative (n=10). 
This prompted the development of a novel system for the initial appraisal of 
LC.HN.HCN/A-DkTx targeting, in which both TRPV1 and SNAP-25 were co-expressed 
in HEK-293 cells by co-transfection with pcDNA3.1-TRPV1 and pIRES2-GFP-SNAP-
25. Co-transfection of plasmids has been demonstrated to produce high efficiency co-
expression in positively transfected cells, with low incidence of separate expression (Xie 
et al., 2011). The presence of both TRPV1 and SNAP-25 in HEK-293 cells was 
subsequently confirmed by Western-blotting (Fig. 3.7 A), and the co-expression of these 
proteins in positively-transfected cells was determined by a combination of ICC staining 
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and fluorescence microscopy (Fig. 3.7 B), with less than 10% of transfected cells 
demonstrating singular expression. 
3.2.7 HEK-293 cells co-expressing TRPV1 and SNAP-25 are an ineffective system 
for the evaluation of DkTx-mediated delivery of the SNARE protease 
HEK-293 cells co-expressing TRPV1 and SNAP-25 (see 3.2.6), were treated with 1-25 
nM of either LC.HN.HCN/A-DkTx or untargeted control for 48 hours prior to lysis, with 
subsequent Western-blotting performed with anti-TRPV1 or anti-SNAP-25 antibodies. 
This analysis established that both TRPV1 and SNAP-25 are expressed, and confirmed 
the presence of SNAP-25 cleavage (Fig. 3.8 A). The levels of cleaved SNAP-25 were, 
however, comparable between both toxins at each concentration (Fig. 3.8 B). 
The previously described compromise of HEK-293 cell viability being associated with 
TRPV1 expression was hypothesised to have rendered the cells more permeable to toxin, 
resulting in non-specific entry of both LC.HN.HCN/A and LC.HN.HCN/A-DkTx. In 
addition, the relative levels of both TRPV1 and SNAP-25 expression in individual cells 
could not be ascertained, with an inevitable differential existing between each cell (Xie 
et al., 2011). Further to this, as expression of both TRPV1 and SNAP-25 in HEK-293 
cells is artificial, the cellular dynamics cannot be anticipated. The culmination of these 
deficiencies rendered the initial targeting results inconclusive. 
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Figure 3. 8 SNAP-25 cleavage in HEK-293 cells co-expressing TRPV1 and SNAP-25 treated with 
LC.HN.HCN/A-DkTx or untargeted control 
(A) HEK-293 cells, co-transfected with pcDNA3.1-TRPV1 and pIRES2-GFP-SNAP-25 were treated with 
LC.HN.HCN/A-DkTx or LC.HN.HCN/A for 48 hours prior to lysis. The lysates were then subjected to SDS-
PAGE followed by Western-blotting with antibodies against TRPV1, α-Tubulin or SNAP-25. (B) Cleaved 
SNAP-25 as a percentage of total SNAP-25 was determined by densitometric analysis using ImageJ 
software. Data plotted are means ± S.E.M; n =3. 
3.2.8 LC.HN.HCN/A binds and intoxicates TGNs comparable to LC.HN.HCN/A-DkTx 
but less efficiently than native BoNT/A 
The inadequacy of HEK-293 cells co-expressing TRPV1 and SNAP-25, as a system for 
preliminary evaluation of LC.HN.HCN/A-DkTx targeting, compelled the immediate use of 
cultured neurons. TGNs were selected due to their expression of both TRPV1 and SNAP-
25 (Meng et al., 2016). In addition, they represent an established model for sensory 
neurons with a well-defined physiological role in pain sensation (Durham et al., 2004), 
which have previously been employed for the development of BoNT/A-based anti-
hyperalgesics (Meng et al., 2007, Meng et al., 2009). 
TGNs were harvested from neonatal rats and cultured as previously described (Malin et 
al., 2007) and subsequently treated with LC.HN.HCN/A-DkTx or LC.HN.HCN/A as 
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indicated, or 1 nM of wild-type BoNT/A (Fig. 3.9 A). The relative association of 
LC.HN.HCN/A-DkTx or LC.HN.HCN/A with TGNs was determined by Western-blotting 
using an anti-LC/A antibody, capable of detecting LC/A of both toxins at comparable 
levels at least at higher doses (300 and 100 nM). Additionally, there was no significant 
difference in SNAP-25 cleavage observed between either toxins at any concentration 
(Fig. 3.9 B), with ~20% cleavage observed in cells treated with 300 nM of either 
LC.HN.HCN/A-DkTx or LC.HN.HCN/A. 
 
Figure 3. 9 SNAP-25 cleavage levels in TGNs following treatment with LC.HN.HCN/A-DkTx, 
untargeted control or wild-type BoNT/A 
(A) TGNs treated with 300 – 3 nM of LC.HN.HCN/A-DkTx or LC.HN.HCN/A, or 1 nM of BoNT/A were 
incubated for 24 hours, prior to washing and preparation of cell lysates, which were subjected to Western-
blotting using antibodies against LC/A or SNAP-25. (B) Cleaved SNAP-25 as a percentage of total was 
determined by densitometric analysis, using ImageJ software. Data plotted are means ± S.E.M; n=3 from 
independent experiments. Statistical analysis performed by unpaired student t-test; n.s. = not significant, 
p>0.05. 
 
Treatment of TGNs with 1 nM of full-length BoNT/A, containing an intact receptor 
binding domain, produced ~50% cleavage of SNAP-25. This emphasised that neither 
LC.HN.HCN/A-DkTx nor LC.HN.HCN/A was capable of mediating efficient delivery of the 
protease relative to native BoNT/A. Interestingly, the ability of higher concentrations of 
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LC.HN.HCN/A to bind to TGNs and cleave SNAP-25, led to the supposition that the HCN/A 
domain was potentially mediating low-affinity binding to the cell membrane, in keeping 
with previous observations (Muraro et al., 2009). This proposed interaction was 
postulated to be promoting pervasion of the untargeted control into cells and, thus, 
masking any low-efficiency targeting being conferred by DkTx.  
3.2.9 Comparison of the binding of 125I-labelled BoNT/A or BoNT/AΔHCN to 
cerebellar granular neurons 
To ascertain the contribution of HCN/A to the cellular interaction and intoxication of 
LC.HN.HCN/A, the nucleotides encoding the HCN (residues I874-Q1091) were deleted 
from a previously described BoNT/A gene construct (Wang et al., 2011). The subsequent 
protein (rAΔHCN), along with full-length BoNT/A (rA), were recombinantly expressed 
and purified by Dr. Jiafu Wang, who additionally performed the genetic deletion. 
The rA and rAΔHCN proteins were radiolabelled with 125I to high-specific activity (~920 
and ~840 Ci/mmol, respectively) by an established protocol, based on the chloramine-T 
method (Williams et al., 1983). The saturatable binding of 125I-rA to rat cultured CGNs 
was investigated (Fig. 3.10 A) by incubation of cells with increasing concentrations, in 
both the presence and absence of 1 µM of an unlabelled single-chain mutant of protease-
inactive BoNT/A (Wang et al., 2011). Scatchard analysis of the binding data confirmed 
that 125I-rA binds to CGNs with high-affinity (KD = 0.46 ± 0.03 nM) (Fig. 3.10 B). 
Additionally, unlabelled BoNT/A dose-dependently competed the binding of 125I-rA with 
an IC50 ~ 9 nM. (Fig. 3.10 C). Significantly, measurement of the interaction of 
125I-
rAΔHCN with CGNs (Fig. 3.10 D), revealed no saturatable high-affinity binding. Thus, it 
can be deduced that the HCN sub-domain contributes to the neuronal binding of BoNT/A. 
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Figure 3. 10 Binding of 125I-labelled BoNT/A or BoNT/AΔHCN to CGNs 
(A) CGNs were incubated with increasing concentrations of 125I-rA alone (○) or in the presence of 1 µM 
unlabelled BoNT/A (□) for 1h at 4°C before three washes.  The radioactive content of the pellet was 
measured using a γ counter. Subtracting non-saturatable binding (□) from the total binding (○) yielded the 
saturatable binding (Δ). Data are mean ± S.E.M from two independent experiments performed in duplicates. 
(B) Scatchard plot showing the saturatable binding of 125I-rA to CGNs, KD = 0.46 nM. (C) Binding of 1 
nM 125I-BoNT/A to CGNs in the presence of increasing concentrations of unlabelled BoNT/A was 
performed as in (A). (D) Binding of rAΔHCN performed as in (A); deletion of HCN from BoNT/A greatly 
reduced its binding to CGNs. Data plotted are means ± S.E.M from two independent experiments performed 
in duplicates. Statistical analysis carried out by unpaired student t-test, ***P < 0.001. 
 
3.2.10 Tryptophan 985 in the HCN of BoNT/A contributes to the delivery of the 
SNARE protease into cultured CGNs without influencing the initial binding 
As a direct contribution of the HCN to neuronal binding of BoNT/A was now established, 
it was pertinent to examine residues potentially involved. The crystal structure of a BoNT 
mosaic serotype C/D in complex with tetraethylene glycol (PG4) has been solved (Zhang 
et al., 2013). PG4 is a moiety typical of the hydrophobic fatty acid tails of phospholipids 
and, as such, has been taken to mimic the cell membrane. The aforementioned crystal 
structure enabled the identification of several residues of the HCN which seemingly 
interact with PG4. 
To investigate their functional role, 8 of the putative PG4 binding residues in HCN/A were 
individually altered by site-directed mutagenesis, and the 8 resultant proteins 
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recombinantly expressed and purified. Their subsequent functional characterization 
identified one mutation (W985L), as having a direct role in neuronal intoxication, as the 
consequent protein (rAW985L) exhibited a 10-fold decrease in intra-neuronal SNAP-25 
cleavage compared to wild-type BoNT/A (Fig 3.11 A), without loss of LC protease 
activity (Fig. 3.11 B). This work was performed Dr. Jiafu Wang. In order to ascertain if 
rAW985L exhibited reduced binding to neuronal cells, the protein was labelled with 
125I to 
a specific activity of ~740 Ci/mmol, and binding to CGNs performed as previously 
described. Significantly, 125I- rAW985L exhibited high-affinity (KD = 0.47 ± 0.01 nM) 
saturatable binding (Fig. 3.11 C and D), nearly identical to that of native 125I-rA (Fig. 3.10 
B). Hence, the HCN/A sub-domain is involved not only in initial binding, but also 
contributes to the productive internalization of BoNT/A. 
 
Figure 3. 11 Mutation of W985L in BoNT/A HCN decreases cleavage of SNAP-25 in cultured CGNs 
without a reduction in initial cell binding 
(A) CGNs treated with increasing concentrations of either rA or rAW985L were cultured for 24 hours at 37°C 
prior to washing and preparation of cell lysates. These were subjected to SDS-PAGE followed by Western-
blotting with an anti-SNAP-25 antibody. The arrow and arrowhead indicate intact and cleaved SNAP-25, 
respectively. Data plotted are mean ± S.E.M, n=3. (B) A representative Coomassie stained SDS-PAGE gel 
showing BoNT/A WT and W985L mutant have similar protease activities in cleaving GST-SNAP-25C73-
(His)6 substrate. The arrow and arrowhead indicate intact and cleaved substrate, respectively. Experiments 
in (A) and (B) were carried out by Dr. Jiafu Wang. (C) Binding of 125I-BoNT/A(W985L) to CGNs was 
performed as in Fig. 3.10 (A). Subtracting non-saturatable binding in the presence of 1 µM unlabelled 
rA(W985L) SC (○) from the total binding (□) yielded the saturatable binding (Δ). Data are mean ± S.E.M 
from two independent experiments performed in duplicates. (D) Scatchard plot showing the saturatable 
binding of 125I-rAW985L to CGNs, giving a KD = 0.47 nM.  
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3.2.11 Cloning, bacterial expression and abortive purification of second generation 
fusion proteins 
This confirmation that HCN/A sub-domain directly contributes to both toxin binding and 
productive internalization, although a significant finding, was not of direct benefit to the 
targeting of LC.HN.HCN/A-DkTx to TRPV1. In an attempt to reduce the HCN-mediated 
binding of the untargeted control, whilst simultaneously increasing the targeting capacity 
of DkTx and preserving HCN-mediated internalization, an innovative approach was 
adopted. This involved development of a second generation of fusion constructs (Fig. 
3.12 A). These constructs encoded the C-terminal receptor binding sub-domain of 
BoNT/B (HCC/B), attached to the C-terminus of HCN/A. The residues (K1192E, Q1200K)  
responsible for binding to the BoNT/B synaptotagmin II acceptor (Rummel et al., 2007),  
were mutated to generate a binding deficient-mutant domain (HCC/Bmut). The receptor 
binding domain of BoNT/B was chosen on account of the critical residues for 
synaptotagmin II binding being published, with the comparable residues for BoNT/A SV2 
binding not becoming available (Benoit et al., 2014, Strotmeier et al., 2014) till after this 
work. The cloning of these constructs is detailed in Fig. 3.12 B. 
The rationale behind this approach was two-fold: firstly, the new untargeted control 
(LC.HN.HCN/A-HCC/Bmut) would no longer have the HCN/A domain free on the C-terminus 
which could, conceivably, have been promoting interaction with the cell membrane. 
Secondly, the HCC/Bmut sub-domain should not be able to bind the synaptotagmin II 
protein receptor, but would still confer binding to GD1a and GT1b  gangliosides (Atassi 
et al., 2014). It was hypothesised that this would enable the DkTx targeted toxin 
(LC.HN.HCN/A-HCC/Bmut-DkTx) to more closely mirror the dual receptor binding strategy 
of native toxin (Berntsson et al., 2013) which, in tandem with the HCN, could potentially 
increase the delivery of protease into TRPV1-expressing cells. The presence of HCC/Bmut 
sub-domain would also confer ganglioside binding to the untargeted control, perceived 
as an opportunity to investigate the contribution of dual receptor binding to BoNT 
neuronal delivery when targeting to an exogenous protein receptor. 
In addition, the cloning strategy was improved and simplified, with the constructs 
encoding the second generation fusion proteins redesigned to allow simultaneous single 
step removal of all protein tags, and concurrent di-chain formation following treatment 
with thrombin protease. The second fusions were expressed in Origami B E. coli, however 
 63 
 
neither LC.HN.HCN/A-HCC/Bmut-DkTx nor LC.HN.HCN/A-HCC/Bmut could be purified 
from the resultant bacterial lysates (Fig. 3.12 C), despite several attempts at optimization.  
 
Figure 3. 12 Design, cloning of expression constructs and attempted purification of the second 
generation of fusion proteins 
(A) Graphic depiction of the constructs designed for bacterial expression of a second generation of fusion 
proteins. (B) DNA sequences encoding either LC.HN.HCN/A-HCC/Bmut or LC.HN.HCN/A-HCC/Bmut-DkTx 
were amplified by PCR with appropriate 5’ and 3’ restriction sites to allow insertion into pET32b expression 
vector (left panel). The resultant pET32b vectors containing either of the inserted genes (right panel) were 
subjected to restriction enzyme digest (XhoI enzyme), resolved by agarose gel electrophoresis and 
visualized by trans-UV. Arrows indicate the predicted sizes as detailed below the gels. (C) Coomassie 
stained SDS-PAGE confirmed that neither LC.HN.HCN/A-HCC/Bmut-(His)6 nor LC.HN.HCN/A-HCC/Bmut-
DkTx-(His)6 could be purified by IMAC following recombinant expression. E1, E2 and E3 correspond to 
IMAC eluted fractions; arrow indicates the approximate predicted molecular masses of the two proteins. 
 
3.3 Discussion 
The previously adopted methods for retargeting of BoNTs primarily involved chemical 
conjugation of pertinent targeting ligands to BoNT/A (Chaddock et al., 2000a, Chaddock 
et al., 2000b, Mustafa et al., 2013), a process which can be difficult to control and often 
produces heterogeneous products (Foster et al., 2006). The use of a fusion approach, as 
outlined in this Chapter, is fairly unique; the only previously published accounts of such 
a strategy involved targeting of BoNT/C (Foster et al., 2006) or BoNT/A (Fonfria et al., 
2016) via fusion of epidermal-growth factor (EGF). The EGF protein however, unlike 
DkTx, is amenable to bacterial expression even as a fusion protein (Ishikawa et al., 2001, 
Abdull Razis et al., 2008). 
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This Chapter describes the first instance in which the soluble and functional bacterial 
cytoplasmic expression of DkTx has been achieved, with previous recombinant 
expression of DkTx entailing secretion to the E. coli periplasm (Klint et al., 2013) or 
resorting to oxidative refolding from inclusion bodies (Bohlen et al., 2010, Bae et al., 
2012). Furthermore, this is the first successful functional expression of DkTx as a 
constituent of a fusion protein. The combination of pET32b vector in conjunction with 
the Origami B™ E. coli expression strain has, therefore, been validated as a system for 
generation of functionally-active disulfide bond stabilized targeting ligands. The 
successful expression and purification of soluble Trx-(His)6-LC.HN.HCN/A-DkTx can 
also be achieved with this vector/expression strain combination. 
The exogenous expression of TRPV1 in HEK-293 cells resulted in the surface expression 
of functional capsaicin-responsive channels, in accord with previous work (Erhu et al., 
2013, Julius, 2013, Maofu et al., 2013). Although this system facilitated confirmation of 
Trx-(His)6-DkTx biological activity, the co-expression of SNAP-25 in these same cells 
was ultimately inadequate as a means of assessing (His)6-LC.HN.HCN/A-DkTx 
retargeting. This emphasised that evaluation of forthcoming retargeting strategies would 
have to be restricted to validated and established model systems. The subsequent finding 
that both LC.HN.HCN/A-DkTx and LC.HN.HCN/A produced comparable binding and 
equivalent SNAP-25 cleavage in cultured TGNs, implied that the HCN/A of the untargeted 
control was capable of binding to the neuronal membrane. This was an obvious 
disadvantage in terms of DkTx-mediated retargeting but was, paradoxically, also 
fortuitous as it prompted further investigation of the contribution of the HCN sub-domain 
to BoNT/A neuronal intoxication. The subsequent comparison of the binding of both rA 
and rAΔHCN to CGNs, following their labelling with 125I, confirmed that the HCN performs 
an integral role in the initial binding of BoNT/A to neuronal cells. Furthermore, 
identification of W985 in HCN being an important contributor to productive internalization 
represents a significant advance towards deciphering the membrane interactions which 
support neuronal delivery of BoNT/A. 
The established contribution of the HCN/A to neuronal binding was theorized to have 
promoted the binding of the untargeted control and, thus, to have negated detection of 
any DkTx-mediated targeting. Unfortunately, the subsequent attempt at mitigating 
binding of LC.HN.HCN/A to cells, by the innovative approach of creating a novel full-
length LC.HN.HCN/A-HCC/Bmut chimera, proved unsuccessful. The difficulty in purifying 
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the latter has previously been experienced in the expression of other BoNT chimeras 
(Wang et al., 2011, Wang et al., 2012), highlighting that despite their modular nature and 
general tolerance of genetic manipulation, certain combinations are destabilizing to the 
overall protein structure. 
A significant limitation in the interpretation of DkTx-mediated targeting was the inability 
to confirm the biological activity of DkTx when expressed as a fusion to LC.HN.HCN/A, 
due to the µM concentrations required for the established DkTx functional assays (Bohlen 
et al., 2010). Significantly, this highlighted that despite the specificity and high-avidity 
binding of DkTx to TRPV1, its reported EC50 of 144 nM (Bohlen et al., 2010) was a 
concentration at which the untargeted control was shown to bind cells, and induce SNAP-
25 cleavage. The aforementioned publications on BoNT/A retargeting had utilized 
targeting ligands of far higher affinity, exemplified by EGF possessing an EC50 of 2 nM 
(Neelam et al., 1998). The recognition and appreciation of the need for not only a specific 
but, also, a high-affinity targeting ligand underscored that DkTx was potentially 
inadequate for retargeting of BoNT/A.  
The culmination of concerns and complications with the initial fusion strategy, 
fortuitously coincided with the publication of an innovative protein coupling technology, 
termed protein stapling (Ferrari et al., 2012). Protein stapling had proven successful in 
the coupling of a BoNT/A-based therapeutic to a diverse range of recombinant targeting 
peptides; these displayed limited abilities to deliver the LC/A protease into neuronal cell 
lines (Arsenault et al., 2013). This technology provided not only a potential solution to 
encountered difficulties, but also presented an opportunity to concurrently evaluate a 
published BoNT/A conjugation/retargeting strategy. This gainful combination prompted 
the immediate adoption of the approach, the implementation and successful application 
of which, is described in Chapter 4.  
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Chapter 4. Evaluation of a protein stapling strategy and its 
applicability to DkTx-mediated targeting of the BoNT/A core-
therapeutic 
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4.1 Overview 
The difficulty in assessing the adequate delivery of LC.HN.HCN/A-DkTx fusion into 
TGNs was postulated to be multi-faceted. An initial consideration was that the DkTx 
ligand was non-functional when fused to the BoNT/A domains, exasperated by the 
inability to confirm interaction of the fusion with TRPV1 due to the µM concentrations 
of DkTx required for functional analysis. Additionally, the established contribution of 
HCN/A to neuronal binding and internalization was suggested to promote interaction of 
the untargeted LC.HN.HCN/A control with the TGN membrane which could mask any 
targeting being conferred by the DkTx targeted molecule. Consequently, the initial fusion 
strategy was considered ineffectual as a means of conjugating DkTx to BoNT/A, 
necessitating a new approach. 
The use of an innovative conjugation technology termed ‘protein stapling’, based on the 
assembly of the neuronal SNARE complex, had proven successful as a means of coupling 
LC.HN/A to a selection of neuropeptide and growth-factor targeting ligands and 
delivering the LC/A protease into neuroblastoma cell-lines, albeit to a limited extent 
(Arsenault et al., 2013). Protein stapling exploits the high-efficiency formation of SNARE 
complex, and involves the tagging of protein components with respective fragments of 
the SNARE complex constituents (SNAP-25, VAMP 2 and syntaxin); when combined, 
these assemble as a conjugated complex of extraordinary chemical and thermal stability. 
Application of ‘stapling’ to BoNT/A retargeting entailed the bacterial expression of 
LC.HN/A fused to full-length SNAP-25 and pertinent ligands fused to VAMP 2(25-84), with 
a peptide based on syntaxin(201-245) synthesised commercially (Fig. 4.1). The combination 
of these components in a molar ratio of 5:7:7, for 60 minutes at room temperature 
incorporated <90% of LC.HN/A-SNAP-25 into a stapled SDS-resistant supra-molecular 
entity, which could only be disassociated following exposure to temperatures exceeding 
95°C (Darios et al., 2010). 
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Figure 4. 1 Illustration of the protein stapling strategy 
(A) LC.HN/A genetically fused on its C terminus to full-length SNAP-25. (B) Synthetic peptide based upon 
syntaxin residues 201-245. (C) A targeting ligand genetically fused on either its N or C terminus to VAMP 
2 fragment (residues 25-84). (D) Combining the three components produces a highly stable complex. Figure 
adapted from (Darios et al., 2010). 
 
The conjugation of DkTx to LC.HN/A by this strategy was perceived as affording multiple 
advantages. In the first instance, the independent expression of LC.HN/A-SNAP-25 and 
VAMP 2-DkTx would enable the functional optimization and characterization of the two 
proteins prior to stapling. Significantly, the singular expression of VAMP 2-DkTx should 
enable the production of sufficient protein yields to facilitate confirmation of its 
interaction with TRPV1, prior to coupling to LC.HN/A-SNAP-25. Furthermore, 
LC.HN/A-SNAP-25 lacking any stapled ligand was considered an ideal untargeted 
control, particularly as the membrane binding HCN/A sub-domain was omitted. Although 
the requirement of the HCN/A for efficient neuronal delivery of native BoNT/A was 
confirmed (see Chapter 3), its inclusion in retargeted BoNT/A variants could potentially 
be a disadvantage, for reasons described above. On the other hand, the previous success 
of BoNT retargeting approaches which employed only the LC and HN, implied that the 
entire HC was dispensable when targeting via exogenous ligands. 
 
The protein stapling strategy had been utilized for the successful conjugation of the core-
therapeutic to a panel of 9 targeting ligands (Arsenault et al., 2013), in addition to the 
 69 
 
reassembly of full-length BoNT/A from two SNARE-tagged components (Darios et al., 
2010). This approach, therefore, permitted a more expeditious screening of ligands than 
would be achievable by protein fusion. Furthermore, the fusion strategy is hindered by 
the uni-directional nature of protein translation, obliging putative ligands to a constrained 
N-terminus, due to the requisite fusion to the C-terminus of HN/A. The protein stapling 
technology however, affords flexibility, permitting either N terminal or C terminal 
tagging with VAMP 2 (Arsenault et al., 2013). A necessity to examine more ligands than 
DkTx was apparent, due to the latent risk of investing in a solitary targeting moiety. 
In order to comprehensively evaluate protein stapling-mediated targeting, a proven 
ligand, VAMP 2-EGF, was generated in parallel with VAMP 2-DkTx. Treatment of 
neuroblastoma cells with 10 nM LC.HN/A-stapled-EGF had been shown to produce a 
significant increase in SNAP-25 cleavage over that of the untargeted LC.HN/A-SNAP-25 
control (Arsenault et al., 2013). VAMP 2-EGF would, thus, serve as a positive control for 
both the stapling conjugation reaction and the subsequent cellular targeting. This should 
aid the accurate interpretation of VAMP 2-DkTx targeting results, while permitting a 
concurrent appraisal of the published findings.  
 
4.2 Results 
4.2.1 Cloning, expression and purification of Trx-(His)6 tagged LC.HN/A-SNAP-25 
and VAMP 2-DkTx 
The original publications (Darios et al., 2010, Ferrari et al., 2012, Arsenault et al., 2013, 
Ferrari et al., 2013) employed the pGEX-KG expression vector for all stapling constructs, 
with subsequent affinity purification of the recombinantly expressed components via the 
vector encoded GST. Due to my previous success attained with the pET32b vector, in 
particular the functional expression of a DkTx fusion, and in order to expedite construct 
generation by making use of available reagents, the stapling constructs were cloned into 
pET32b as detailed in Fig. 4.2 A. The cloning strategy was designed in conjunction with 
Dr. Matthew King, who additionally generated the pET32b-LC.HN/A-SNAP-25 
construct.  
VAMP 2-DkTx DNA was generated by PCR amplification of the ligated genes encoding 
human VAMP 2(25-84) and DkTx, with an intervening sequence encoding 27 alternating 
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glycine-serine residues. The linker length was adopted on the hypothesis that a relatively 
long intervening sequence between VAMP 2 and DkTx would confer greater flexibility, 
supporting the ability of both “knots” of DkTx to interact with TRPV1. Insertion of the 
resultant DNA followed by a (His)6 purification tag into the pET32b vector created a 5’ 
in-frame fusion with the advantageous Trx tag (detailed in Chapter 3) generating pET32b-
Trx-(His)6-VAMP 2-DkTx (Fig. 4.2 B).  
 
Figure 4. 2 Cloning, expression and purification of the first generation of stapling components 
(A) Illustration of the first generation stapling constructs. (B) VAMP 2-DkTx gene was amplified by PCR 
to incorporate appropriate restriction enzyme sites for insertion into the pET32b vector. The resultant 
pET32b_VAMP 2-DkTx vector subjected to restriction digest (XhoI), resolved by agarose gel 
electrophoresis and visualized by trans-UV. Arrows indicates the predicted DNA sizes. (C) SDS-PAGE 
followed by Coomassie staining confirmed expression and IMAC purification of Trx-(His)6-VAMP 2-
DkTx at the predicted Mr of 35 k. Abbreviations: IMAC flow-through (FT); IMAC wash (W1). (D) SDS-
PAGE followed by Coomassie staining revealed expression of (His)6-LC.HN/A_SNAP-25 at the expected 
Mr of 125 k, but the resultant protein could not be purified by IMAC.  
 
Recombinant expression of both Trx-(His)6-VAMP 2-DkTx and LC.HN/A-SNAP-25-
(His)6 was performed in Origami B™ E. coli by auto-induction. IMAC purification of 
Trx-(His)6-VAMP 2-DkTx gave yields of ~3 mg/L, as determined by BCA protein assay. 
The Coomassie staining of IMAC fractions subjected to SDS-PAGE detected a 
predominant protein band at the predicted Mr of 27k, as determined by semi-log plot (Fig. 
4.2 C). In contrast, the IMAC purification of LC.HN/A-SNAP-25-(His)6 proved 
ineffectual, although Coomassie staining of SDS-PAGE gels detected a strong protein 
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band in the bacterial lysate, corresponding to the predicted Mr of 125 k (Fig. 4.2 D); the 
resultant protein being almost entirely insoluble, with the tiny soluble proportion failing 
to bind the IMAC resin.  
4.2.2 GST-fusion tag increases the solubility of LC.HN/A-SNAP-25 and facilitates its 
purification by affinity chromatography  
The inability to express and purify soluble LC.HN/A-SNAP-25-(His)6 was jarringly 
analogous to issues formerly encountered with LC.HN.HCN/A.HCC/Bmut. However, as 
soluble expression of LC.HN/A-SNAP-25 had been achieved when fused with a GST 
purification tag (Ferrari et al., 2012), it was evident that the latter was functioning as an 
enhancer of solubility, in keeping with previous observations (Costa et al., 2014). This 
compelled an overhaul of the cloning strategy, with reversion to the established approach 
(Ferrari et al., 2013). LC.HN/A-SNAP-25 DNA was amplified by PCR with appropriate 
restriction sites to permit insertion into the pGEX-KG expression vector. The induction 
of recombinant genes into the MCS of pGEX-KG generated an in-frame 5’ fusion 
nucleotides encoding a 25 k GST purification tag, with an intervening thrombin protease 
cleavage site (Fig 4.3 A). The location of this protease site is particularly advantageous, 
as it facilitates thrombin-mediated release of recombinant proteins from GST following 
affinity purification, with the GST tag remaining immobilized on the glutathione affinity 
agarose. 
The resultant protein, GST-LC.HN/A-SNAP-25, was recombinantly expressed in BL21 
(DE3) E. coli by IPTG induction, following which the clarified bacterial lysate was 
incubated with affinity resin. Analysis by Coomassie staining of SDS-PAGE gels 
indicated significant binding of GST-LC.HN/A-SNAP-25 to the resin, validating the 
contribution of GST to increased solubility (Fig. 4.3 B). The subsequent incubation with 
thrombin protease released LC.HN/A-SNAP-25 from the agarose associated GST tag, 
resulting in the predicted 25 k decrease in molecular mass (Fig. 4.3 B). In addition, 
treatment with thrombin simultaneously cleaved at the internal protease site between the 
LC/A and HN/A, converting the protein from single-chain into di-chain isoform (Fig. 4.3 
B), with a protein yield of ~1 mg/L determined by BCA protein assay. Utilization of the 
pGEX-KG expression vector for expression of LC.HN/A-SNAP-25 was, therefore, a 
significant advancement on the previously employed strategy, enhancing the soluble 
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expression and providing a single-step approach to liberate the protein from the associated 
purification tag, as well as to convert it to the di-chain form. 
 
Figure 4. 3 Design, cloning and purification of second generation of LC.HN/A-SNAP-25 
(A) LC.HN/A-SNAP-25 gene was generated by PCR amplification with appropriate restriction enzyme sites 
for insertion into pGEX-KG vector (left panel). The resultant pGEX-KG-LC.HN/A-SNAP-25 vector (right 
panel) was subjected to restriction enzyme single digest with XhoI (SD) or double digest with XmaI and 
XhoI (DD), resolved by agarose gel electrophoresis and visualized by trans-UV. Arrows indicated the 
predicted DNA sizes, as detailed below the gels. (B) SDS-PAGE followed by Coomassie staining, 
confirmed expression and affinity purification of GST-LC.HN/A-SNAP-25; subsequent treatment with 
thrombin protease released di-chain LC.HN/A-SNAP-25. The addition of ßME (2.5%) to a purified sample 
disassociated the disulfide linked LC and HC fragments. 
4.2.3 SNARE-protease efficiency of LC.HN/A-SNAP-25 is comparable to that of 
wild-type recombinant BoNT/A 
The protease activity of LC.HN/A-SNAP-25 was assessed by a standard in vitro protease 
cleavage assay (Wang et al., 2012) and shown to correspond to the level of cleavage 
efficiency by wild-type BoNT/A (Fig. 4.4 A and B). This established that neither the 
presence of GST adjacent to LC/A prior to removal by thrombin cleavage nor the 
retention of the C-terminal fusion of SNAP-25 impeded the folding or activity of LC/A. 
Furthermore, the thrombin mediated conversion of LC.HN/A-SNAP-25 to active di-chain 
was confirmed. 
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Figure 4. 4 In vitro cleavage of recombinant SNAP-25 fragment substrate by LC.HN/A-SNAP-25 or 
full-length BoNT/A 
(A) GFP-SNAP-25(134-206) incubated with the indicated concentration of LC.HN/A-SNAP-25 or BoNT/A, 
was subjected to SDS-PAGE followed by Coomassie staining. (B) Densitometric analysis data from (A) 
performed with ImageJ software to determine % cleavage at each concentration. Data plotted are means ± 
S.E.M; n=3. 
 
4.2.4 Trx-(His)6-VAMP 2-DkTx undergoes rapid degradation at room temperature 
IMAC purification of Trx-(His)6-VAMP 2-DkTx, although producing a high yield, was 
deemed of inadequate purity for any downstream stapling reaction, as a significant 
number of co-purified unidentified protein bands were detected (Fig. 4.2 C). A devised 
solution of performing ion-exchange chromatography to increase the purity of the sample 
could not be undertaken, as it materialized that following purification Trx-(His)6-VAMP 
2-DkTx was highly unstable at room temperature, with the protein rapidly degrading (Fig. 
4.5 A). 
A review of the literature implicated the adopted 27 residue linker as the instigator of Trx-
(His)6-VAMP 2-DkTx degradation, as overly-long linker sequences have been previously 
demonstrated to induce protein instability (Prescott et al., 1999). To address this the linker 
sequence was shortened to 10 residues, with the resultant protein expressed and purified 
as previously described. This significantly increased the temperature tolerance and 
stability of Trx-(His)6-VAMP 2-DkTx but, ultimately, failed to entirely stabilize the 
protein (Fig. 4.5 A and B). 
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Figure 4. 5 Analysis of the temperature stability of Trx-(His)6-VAMP 2-DkTx 
(A) Trx-(His)6-VAMP 2-DkTx samples containing a 27 or 10 residue linker were incubated for up to 1 hour 
at 22°C prior to being subjected to SDS-PAGE followed by coomassie staining. (B) Densitometric analysis 
of the data from (A). Data plotted are means ± S.E.M; n=3. 
 
4.2.5 Fusion of GST to VAMP 2-DkTx significantly improves the purity and stability 
of the purified protein 
The instability of VAMP 2-DkTx was irreconcilable with both stapling to LC.HN/A-
SNAP-25 or any preceding functional assays, thereby, rendering the protein ineffectual. 
As the former issues with expression and purification of soluble LC.HN/A-SNAP-25 had 
been overcome through utilization of the pGEX-KG vector and its associated GST 
purification tag, this encouraged the immediate adoption of this cloning strategy for both 
VAMP 2-DkTx and VAMP 2-EGF. 
The pGEX-KG constructs were designed and cloned as depicted in Fig. 4.6 A and B. 
Recombinant expression of both GST-VAMP 2-DkTx and GST-VAMP 2-EGF was 
performed in BL21 (DE3) E. coli, the expression strain previously employed in the 
generation of protein stapling ligands (Arsenault et al., 2013), thus, ensuring rigorous 
adherence to the established protocols. As with the purification of LC.HN/A-SNAP-25 
following GST affinity purification, treatment with thrombin released VAMP 2-DkTx 
from the affinity resin by orchestrating cleavage of the associated 25 k GST tag. The 
resultant purified protein was visualized by Coomassie staining of SDS-PAGE gels at the 
predicted Mr of 16 k (Fig. 4.6 C), with a protein yield of ~3 mg/L, as determined by BCA 
protein assay. Employment of GST purification for VAMP 2-DkTx, rectified the previous 
concern regarding protein purity and, most significantly, the purified VAMP 2-DkTx 
remained stable (Fig. 4.6 D). On account of the comparable sizes of both the genes and 
resultant DkTx and EGF proteins, the data for cloning and expression of both VAMP 2-
DkTx and VAMP 2-EGF were almost identical; thus, only the data relating to VAMP 2-
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DkTx are presented, but fully representative of the corresponding findings for VAMP 2-
EGF. 
 
Figure 4. 6 Design, cloning, expression, affinity purification and stability analysis of the second 
generation of VAMP 2-DkTx 
(A) Illustration of the second generation VAMP 2-DkTx and VAMP 2-EGF constructs. (B) PCR 
amplification was used to generate the VAMP 2-DkTx with appropriate restriction enzyme sites to enable 
insertion into pGEX-KG vector (left panel).  The resultant pGEX-KG_VAMP 2-DkTx vector (right panel) 
was subjected to restriction digest (XhoI), agarose gel-electrophoresis and visualized by trans-UV. Arrows 
indicated the predicted DNA sizes, as detailed below the gels. The gels presented are representative of the 
parallel cloning of pGEX-KG_VAMP 2-EGF. (C) Coomassie staining of SDS-PAGE gels confirmed 
expression and affinity purification of GST-VAMP 2-DkTx. Cleavage with thrombin protease released 
VAMP 2-DkTx from the 25 k GST tag, which remained associated with the glutathione agarose. The gel 
is representative of the parallel expression and purification of GST-VAMP 2-EGF. (D) VAMP 2-DkTx 
incubated at 22°C for up to 1 hour was resolved on SDS-PAGE, Coomassie stained and subjected to 
densitometric analysis. Data plotted are means ± S.E.M; n=3. 
 
 
4.2.6 Initial combination of the stapling components did not produce the predicted 
SDS-resistant conjugated complex 
The protein stapling reaction, as previously outlined, is based upon the formation of the 
highly stable SNARE complex and, thus, involves combining full-length SNAP-25 with 
the minimal contributing domains of both VAMP 2(25-84) and syntaxin (202-247), in a 
respective molar ratio of 5:7:7 for 1 hour at room temperature. The predicted result is 
high efficiency formation of an exceptionally stable SDS-resistant complex (Arsenault et 
al., 2013). With the aforementioned purification and stability issues relating to the 
recombinant LC.HN/A-SNAP-25 and the VAMP 2 tagged ligands successfully resolved, 
it was possible to progress to protein conjugation. The 45 residue syntaxin peptide, with 
 76 
 
an N-terminal TAMRA flurophore as published (Arsenault et al., 2013), was synthesised 
commercially by Biomatik to 90% purity, indicated in the companies quality control data-
sheet. The initial stapling reaction was performed with the VAMP 2-EGF control, the 
resultant formation of LC.HN/A-staple-EGF was anticipated to produce protein bands on 
Coomassie stained SDS-PAGE at Mr of ~145 k in non-reducing conditions (Fig. 4.7 A), 
and at ~95 k following reductant-induced dissociation of the LC/A (Fig. 4.7 B). In 
addition, the incorporation of the TAMRA-labelled syntaxin into the complex was 
expected to result in a fluorescent signal at the above molecular masses following 
exposure of the gel to Trans-UV. These expected observations could not be detected with 
either VAMP 2-EGF or VAMP 2-DkTx, despite multiple attempts at optimization. This 
indicated that either coupling was not occurring, or that the coupled complex was being 
formed but was stable when run on SDS-PAGE, in contradiction of the published work 
(Arsenault et al., 2013). These findings highlighted that additional issues prevailed with 
either the conjugation protocol or the proteins stapling components. 
 
Figure 4. 7 Initial stapling of VAMP 2-EGF and LC.HN/A-SNAP-25 proved unsuccessful  
(A) LC.HN/A-SNAP-25, VAMP 2-EGF and synthetic syntaxin peptide were combined at a respective 5:5:7 
molar ratio and incubated for 1 hour at room temperature. The samples were then subjected to SDS-PAGE 
followed by Coomassie staining and subsequently exposed to Trans-UV to visualize TAMRA labelled 
syntaxin. (B) Samples from (A) were combined with ßME (2.5%) and subjected to SDS-PAGE, followed 
by Coomassie staining. Note, VAMP 2-EGF exhibits stronger protein staining in the presence of reductant.  
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4.2.7 LC.HN/A-SNAP-25 and VAMP 2-EGF bind with low efficiency in the absence 
of syntaxin 
As both LC.HN/A-SNAP-25 and VAMP 2-EGF/VAMP 2-DkTx were now cloned, 
expressed and purified exactly as published, it stood to reason that they should be capable 
of interacting and, thus, implicated the commercially-synthesised syntaxin peptide as the 
“weak link”. In order to confirm the competency of VAMP 2 and SNAP-25, a set of 
experiments were performed based on the established pull-down of SNARE complex 
components by immobilized cognate constituents (Söllner et al., 1993, Shen et al., 2007). 
To this end, either GST-VAMP 2-EGF or GST-LC.HN/A-SNAP-25 was immobilized on 
glutathione agarose, and ability to pull-down their respective purified stapling partner 
from solution was assessed (Fig. 4.8 A and B, respectively). The pull down of LC.HN/A-
SNAP-25 by agarose immobilized GST-VAMP 2-EGF was detected by Western-blotting, 
using an anti-SNAP-25 antibody (Fig. 4.8 A), confirming that the SNAP-25 and VAMP 
2 constituents of the respective proteins were capable of interacting. This was further 
validated by the converse pull-down, in which agarose immobilized GST-LC.HN/A-
SNAP-25 successfully pulled down VAMP 2-EGF, on this occasion detectable by 
Coomassie staining and further confirmed by Western-blotting using an antibody which 
detects VAMP 2. Significantly, the inclusion of the syntaxin peptide in the reaction did 
not increase the pull-down efficiency of VAMP 2-EGF (Fig. 4.8 B). The pull-down 
experiments validated that the recombinant stapling proteins were capable of interacting, 
and that their binding was independent of syntaxin, with inclusion of the latter failing to 
increase the pull-down efficiency or confer SDS resistance to the resultant complex.  
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Figure 4. 8 Pull-down of stapling components by their immobilized counterparts 
(A) Western-blotting using an anti-SNAP-25 antibody confirmed agarose immobilized GST-VAMP 2-EGF 
binds to purified LC.HN/A-SNAP-25 following 60-minute incubation. (B) Coomassie staining of SDS-
PAGE verified the binding of agarose immobilized GST-LC.HN/A-SNAP-25 to purified VAMP 2-EGF, 
further confirmed by Western-blotting using an anti-VAMP 2 antibody. 
4.2.8 The oxidation of the commercial syntaxin peptide rendered it ineffectual for 
SNARE complex formation/stabilization 
To identify and resolve the prevailing issue with either the protein stapling components 
or protocol, training was arranged at the laboratory of Prof. Davletov in the University of 
Sheffield. This involved the interchange of reagents from the ICNT and from Prof. 
Davletovs lab, and detailed instruction on all aspects of the protocol. The critical 
sequences of the protein components were confirmed as identical, and the stapling 
reaction protocols when compared and contrasted were found to be synonymous, 
indicating that a lack of complex formation was due to one of the three stapling 
constituents. 
The sequential interchange of the latter determined that both LC.HN/A-SNAP-25 and 
VAMP 2-EGF were capable of forming an SDS resistant stable complex with their 
respective counterparts provided by Prof. Davletov (Fig. 4.9 A and B), corroborating the 
results from the pull-down experiments. When an aliquot of syntaxin provided by Prof. 
Davletov was employed in the stapling reaction, it resulted in the high-efficiency 
formation of an SDS resistant ‘stapled’ complex, producing both the expected size shift 
on Coomassie staining SDS-PAGE, and corresponding fluorescence from incorporation 
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of the TAMRA flurophore into the complex (Fig 4.9 A and B). In contrast, the 
commercial syntaxin peptide purchased from Biomatik was unable to support complex 
formation. The datasheet for the syntaxin peptide synthesized for Prof. Davletov was 
acquired, and an identical order placed using the same company (Peptide Synthetics UK). 
 
Figure 4. 9 Inter-exchange of stapling components from ICNT and the University of Sheffield 
(A) LC.HN/A-SNAP-25 either from the ICNT or from the lab of Prof. Davletov, University of Sheffield 
was combined with VAMP 2 fused to the receptor binding domain of BoNT/A (VAMP 2-HC/A) and a 
syntaxin peptide (Sheffield) at a respective molar ratio of 5:7:7 for 1 hour at room temperature. Heating of 
the sample to ~95°C was used to disassociate the SDS resistant complex prior to resolution by SDS-PAGE 
followed by Coomassie staining. The fluorescence conferred by the TAMRA labelled syntaxin was 
visualized by trans-UV. (B) Performed as in (A) using LC.HN/A-SNAP-25 from the ICNT, and VAMP 2-
EGF samples either from ICNT or Sheffield. (C) Performed as in (A) using syntaxin peptides as indicated. 
(D) The three samples of commercial syntaxin were subjected to SDS-PAGE and exposed to trans-UV to 
visualize the TAMRA flurophore. Note, the levels of sequence oxidation altered the migration rate of the 
peptide. 
The replacement syntaxin peptide was supplied by Peptide Synthetics UK in two forms 
of purity, 48% and 90%, dependent on the synthesis protocol employed, with the degree 
of purity corresponding to the level of sequence oxidation. The company reported that the 
latter was exacerbated by the presence of the TAMRA flurophore, which contains a 
conjugative phenyl character, promoting oxidation of syntaxin methionine residues. The 
differential between the 48% and 90% purity syntaxin peptides did not impede complex 
formation, with both producing comparable levels of SDS-resistant stapled product.  In 
contrast, no complex formation was detected with the original syntaxin peptide supplied 
by Biomatik, denoted as 0% purity (Fig. 4.9 C). When the syntaxin peptides were 
analyzed by SDS-PAGE, the level of peptide oxidation was shown to produce a 
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differential migration pattern, with the oxidized form migrating slower than the non-
oxidized form (Fig. 4.9 D). The syntaxin peptide originally supplied by Biomatik was 
determined to be fully oxidized (0% purity), when compared with the 48% and 90% purity 
samples supplied by Peptide Synthetics UK.  
4.2.9 Use of high-purity syntaxin produced SDS-resistant conjugation of VAMP 2-
EGF or VAMP 2-DkTx to LC.HN/A-SNAP-25 
The ability to effectively recapitulate the protein stapling technology finally allowed 
progression to retargeting assessment. Stapling of both VAMP 2-DkTx (Fig. 4.10 A) and 
VAMP 2-EGF (Fig. 4.10 B), was performed as previously described. In both cases SDS-
resistant complex formation was affirmed, and could be detected by both Coomassie 
staining of SDS-PAGE gels and through visualization of the incorporated TAMRA-
labelled syntaxin. Efficiency of the stapling reaction was found to vary between VAMP 
2-EGF and VAMP 2-DkTx, determined by densitometric analysis, to be ~80% and ~30%, 
respectively (Fig. 4.10 C). Furthermore, it was observed that stapling of VAMP 2-DkTx 
resulted in the production of aggregates which failed to enter the gel (Fig. 4.10 B). 
Precipitation of LC.HN/A-staple-DkTx was not observed in the complex solution 
following centrifugation, with the aggregation only detected when samples were run on 
SDS-PAGE. 
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Figure 4. 10 Conjugation of either VAMP 2-EGF or VAMP 2-DkTx to LC.HN/A-SNAP-25 
(A) Complex formation following combination of LC.HN/A-SNAP-25, VAMP 2-EGF and syntaxin in a 
respective 5:7:7 molar ration, was visualized by Coomassie staining of SDS-PAGE and Trans-UV. Heating 
of the samples to 95°C for 5 minutes was used to disassociate the SDS-resistant complexes. (B) Stapling 
reaction performed as in (A), except substituting VAMP 2-DkTx in the place of VAMP 2-EGF. (C) % 
complex formation was determined by densitometric analysis of the Coomassie stained SDS-PAGE gels. 
Data plotted are means ± S.E.M; n=3. 
4.2.10 Treatment of serum-starved SH-SY5Y cells with VAMP 2-EGF induces ERK 
1/2 phosphorylation 
The ability to confirm the functional activity of uncoupled VAMP 2-tagged ligands was 
considered one of the principle advantages of the protein stapling. Thus, prior to 
assessment of LC.HN/A-staple-EGF targeting of SH-SY5Y neuroblastoma cells, it was 
pertinent to first confirm that VAMP 2-EGF was capable of interacting with the EGF 
receptor (EGFR). Expression of EGFR in SH-SY5Y cells has been established (Lu et al., 
 82 
 
2014), and binding of EGF induces intracellular signalling events which include the 
phosphorylation of extracellular receptor kinase 1 and 2 (ERK 1/2) (Lu et al., 2014). 
Functionality of VAMP 2-EGF was consequently assessed by a qualitative but sensitive 
phosphorylation assay which involved serum-starving SH-SY5Y overnight to reduce 
background phosphorylation; this was followed by a 5 minute exposure to increasing 
concentrations of VAMP 2-EGF prior to preparation of cell lysates. Western-blotting 
using antibodies against either the phosphorylated or non-phosphorylated isoforms of 
ERK 1/2, demonstrated that VAMP 2-EGF treatment induced ERK 1/2 phosphorylation, 
with no response detected in the untreated control (Fig. 4.11 A). The increase in signal 
for p-ERK 1/2 corresponded to a dose-dependent reduction in signal for the 
unphosphorylated species, with blotting using an anti-SNAP-25 antibody confirming 
comparable loading between all conditions. 
In a further attempt to confirm VAMP 2-EGF activity, SH-SY5Y cells were treated with 
up to 300 nM VAMP 2-EGF for 42 hours in an attempt to induce cell differentiation. 
Disappointingly, there were no morphological changes detectable when compared to the 
untreated control (Fig. 4.11 B), corroborating previous observations that it is challenging 
to induce SH-SY5Y differentiation via EGFR (Tyson et al., 2003).  
 
Figure 4. 11 Functional interaction between VAMP 2-EGF and SH-SY5Y cells 
(A) SH-SY5Y cells, serum-starved overnight prior to 5 minute treatment with increasing concentrations of 
VAMP 2-EGF were lysed and subjected to Western-blotting using antibodies against ERK1/2, -p-ERK 1/2 
and SNAP-25. Increase in p-ERK 1/2 signal correlates with a decrease in the detection of the non-
phosphorylated isoform. (B) SH-SY5Y cells either untreated, or treated with VAMP 2-EGF diluted into 
the culture medium to a final concentration of 300 nM, were incubated for 42 hours at 37°C, 5% CO2. Cells 
were incubated with Hoechst nuclear stain prior to image acquisition. 
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4.2.11 LC.HN/A-staple-EGF increases cleavage of SNAP-25 in SH-SY5Y cells 
relative to the untargeted control, but the increment is lost at concentrations which 
exceed 10 nM 
To ascertain if the stapling technology represented a viable strategy for adapting to both 
DkTx and potential future targeting ligands, it was deemed appropriate to first recapitulate 
the targeting of LC.HN/A-staple-EGF reported by others (Arsenault et al., 2013). 
LC.HN/A-staple-EGF complex was prepared as previously described (Fig. 4.10 A), 
producing a coupling efficiency of ~80% (Fig. 4.10 C). The original publication on 
LC.HN/A-staple-EGF targeting employed a fixed toxin concentration of 10 nM (Arsenault 
et al., 2013). To investigate if targeting of LC.HN/A-staple-EGF could be detected at a 
lower concentration, and conversely to determine if there was any significant uptake of 
untargeted control at higher doses, SH-SY5Y cells were treated with 1, 10 and 100 nM 
of either LC.HN/A-staple-EGF or LC.HN/A-SNAP-25 untargeted control for 42 hours 
prior to lysis. Western-blotting of the resultant cell lysates with an antibody which detects 
both cleaved and uncleaved SNAP-25 confirmed truncation of SNAP-25 in cells treated 
with 10 nM of LC.HN/A-stapled-EGF, but not with 10 nM of untargeted LC.HN/A-SNAP-
25 (Fig. 4.12 A). This successful recapitulation of the published result (Arsenault et al., 
2013), confirmed that protein stapling could be utilized for ligand-mediated delivery of 
LC/A into pertinent cells. There was, however, comparable SNAP-25 cleavage detected 
for both the EGF targeted and untargeted LC.HN/A-SNAP-25 control at 100 nM treatment 
concentration and, thus, highlighted a significant limitation of the strategy. The 
subsequent reprobing of the blot with an antibody against LC/A cleaved SNAP-25 
(SNAP-25/A), which is far more sensitive in the detection of the cleaved isoform, 
confirmed increased truncation of SNAP-25 in cells treated with both 1 nM and 10 nM 
of LC.HN/A-stapled-EGF, but again could not discern any difference at the higher 
treatment dose of 100 nM. Furthermore, this sensitive antibody was able to detect a 
minute level cleavage of SNAP-25 in cells treated with 10 nM untargeted LC.HN/A-
SNAP-25 (Fig. 4.12 B). 
The succeeding treatment of SH-SY5Y cells with a narrower dose range of either 
LC.HN/A-staple-EGF or LC.HN/A-SNAP-25 (Fig. 4.12 C), and subsequent Western-
blotting performed with the sensitive anti-SNAP-25/A antibody, confirmed the presence 
of cleaved SNAP-25 in cells treated with untargeted LC.HN/A-SNAP-25 at 
concentrations as low as 2.5 nM. It was evident following densitometric analysis that 
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LC.HN/A-stapled-EGF produced greater levels of truncated SNAP-25 (Fig. 4.12 D), 
confirming that LC/A was being retargeted, albeit to limited extent, into SH-SY5Y cells 
through the EGF targeting peptide. However, the delivery of the “untargeted” LC.HN/A-
SNAP-25 into SH-SY5Y cells was a grave concern, as it demonstrated that the protein 
stapling retargeting strategy was not as refined as anticipated. 
 
Figure 4. 12 SNAP-25 cleavage in SH-SY5Y cells following treatment with LC.HN/A-staple-EGF or 
untargeted control 
(A) SHSY-5Y cells treated with the indicated concentrations of either LC.HN/A-staple-EGF or LC.HN/A-
SNAP-25 were incubated for 42 hours, prior to washing and preparation of cells lysates; these were 
subjected to Western-blotting using an antibody which detects both cleaved (arrowhead) and uncleaved 
(arrow) isoforms of SNAP-25 or the only the cleaved isoform (SNAP-25/A). (B) Data from (A), normalized 
against levels of total SNAP-25 was subjected to densitometric analysis using ImageJ software. Data plotted 
are means ± S.E.M; n=3 from three independent experiments, statistical analysis carried out by unpaired 
student t-test, ** p < 0.01, **** p < 0.0001, n.s., p > 0.05. (C) SH-SY5Y cells were treated as described in 
(A), and subjected to Western-blotting using antibodies against either α-Tubulin or cleaved SNAP-25/A. A 
high exposure of the resultant blot was taken to permit detection of SNAP-25/A in LC.HN/A-SNAP-25 
treated samples. (D) Data from (C) was subjected to densitometric analysis. Data plotted are means ± 
S.E.M; n=3, normalized against the α-Tubulin loading control; statistical analysis was performed by 
unpaired student t-test, ** p < 0.01, *** p < 0.001. 
 
4.2.12 VAMP 2-DkTx is non-functional and does not interact with TRPV1 
In advance of the assessment of LC.HN/A-staple-DkTx retargeting, it was essential to first 
confirm the functional activity of the DkTx ligand. This was particularly pertinent in light 
of the findings that 100 nM untargeted LC.HN/A-SNAP-25 was capable of inducing 
significant SNAP-25 cleavage in SH-SY5Y cells, a concentration below the published 
144 nM EC50 of DkTx (Bohlen et al., 2010). An additional consideration was that the 
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previously attained DkTx functionality, described in the Chapter 3, had been achieved 
through use of the pET32b expression vector and the associated Trx fusion tag. This 
system was regrettably incompatible with the VAMP 2-DkTx protein as detailed in Fig. 
4.5, necessitating utilization of an expression strategy less conducive to the disulfide bond 
formation. The functional assessment of VAMP 2-DkTx was performed by both Ca2+ 
influx measurement (Fig 4.13 A) and electrophysiology recordings (Fig. 4.13 B and C) 
using HEK-293 cells transiently-expressing TRPV1. The presence of functional TRPV1 
channels on the HEK-293 cells was confirmed in both cases by exposure to the TRPV1 
agonist, capsaicin. Subsequent treatment with up to 5 µM VAMP 2-DkTx failed to illicit 
any functional response, signifying that VAMP 2-DkTx was inactive and incapable of 
interacting with TRPV1. 
 
Notwithstanding the inability to demonstrate functional activity of VAMP 2-DkTx, 
availability of LC.HN/A-staple-DkTx warranted assessment of its ability to target to 
TRPV1 expressing TGNs (Meng et al., 2016). Furthermore, this would ascertain if the 
observed penetration of untargeted LC.HN/A-SNAP-25 into SH-SY5Y cells would be 
reprised in cultured sensory neurons. An additional constraint on LC.HN/A-staple-DkTx, 
was the observation that following stapling, the resultant complex appeared to produce 
aggregates when run on SDS-PAGE (Fig. 4.10 A). Cultured TGNs were treated with 1, 
10 and 100 nM of either LC.HN/A-staple-DkTx or LC.HN/A-SNAP-25 for 42 hours prior 
to lysis. Subsequent Western-blotting of the resultant neuronal lysates using the anti-
SNAP-25/A antibody detected comparable SNAP-25 cleavage between both toxins at each 
respective concentration (Fig. 4.13 D), indicating the formation of LC.HN/A-staple-DkTx 
aggregates did not effect its delivery into neurons. The lack of targeting effect was of 
more pressing concern, as it confirmed the inactivity of the DkTx targeting ligand and, 
furthermore, highlighted that LC.HN/A-SNAP-25 was as adept at infiltrating cultured 
TGNs as it was SH-SY5Y cells.  
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Figure 4. 13 Functional assessment of VAMP 2-DkTx in HEK-293 cells transiently-expressing 
TRPV1: SNAP-25 cleavage by conjugate or control protein in cultured TGNs 
(A) HEK-293 cells transiently-expressing TRPV1 were loaded with Fluo-4-AM Ca2+ indicator and 
measurement of fluorescent signal following laser excitation at 488 nm was used to determine baseline 
fluorescence (f0). Washing with either HBSS or treatment with 5 µM VAMP 2-DkTx diluted in the latter 
buffer failed to provoke an increase in fluorescence, whereas exposure to 1 µM capsaicin diluted in HBSS 
produced an increase in intracellular fluorescence (f). Values are the mean ± S.D.; n=8 from individual 
cells, normalized against baseline fluorescence. Inset images are fluorescence signal prior to, and after the 
application of either capsaicin or VAMP 2-DkTx, as indicated. (B) HEK-293 cells transiently-transfected 
with pIRES2-GFP-TRPV1 were seeded onto coverslips, GFP-positive cells were presumed to be TRPV1 
expressing, selected and patched. The perfusion of VAMP 2-DkTx to a final concentration of 1 µM in the 
extracellular solution failed to induce an inward current. The cells were washed and capsaicin was 
subsequently perfused to a final concentration of 1 µM; this elicited an inward current, confirming the 
presence of functional TRPV1 channels. (C) Performed as in (B), but with the presence of functional 
TRPV1 channels confirmed prior to VAMP 2-DkTx application. (D) TGNs cells were treated as indicated 
for 42 hours, lysed, and subjected to Western-blotting using antibodies against SNAP-25/A or ß-Tubulin III. 
The subsequent densitometric analysis was performed with ImageJ software. Data plotted are means ± 
S.E.M, normalized against ß-Tubulin III as a loading control. Statistical analysis was performed by unpaired 
student t-test, n.s. = p > 0.05; n=3 from three independent experiments. 
 
4.2.13 Employment of SHuffle® E. coli expression strain, and co-expression of 
chaperone proteins is ineffective at increasing VAMP 2-DkTx functionality 
As the previous tactic of expressing functional DkTx through fusion to Trx could not be 
employed, with the recombinant approach seemingly restricted to the prescribed pGEX-
KG strategy, an additional methodology for maximizing disulfide bond formation was 
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required. A comprehensive review of the literature identified a novel E. coli expression 
strain based on BL21 (DE3) termed SHuffle®. This E. coli strain possesses all of the 
advantageous characteristics of the previously employed Origami B™ strain (Seras-
Franzoso et al., 2012), but in addition to the trxB and gor mutations which create a more 
oxidizing bacterial cytoplasm, the SHuffle® strains contains an additional mutation which 
results in the cytoplasmic expression of Disulfide bond C. The latter is a prokaryotic 
disulfide bond isomerase usually expressed in the E. coli periplasm (Lobstein et al., 2012), 
which has an integral role in orchestrating correct disulfide bond formation through 
isomerization of mis-oxidized proteins to their native states (Kurokawa et al., 2001). In 
addition, employment of the SHuffle® strain, in conjunction with the exogenous co-
expression of seventeen kilodalton protein (Skp) and trigger-factor (TF) chaperones had 
been shown to significantly enhance the functional cytoplasmic expression of complex 
disulfide bond stabilized proteins (Lamppa et al., 2013). The pACYC duet vector for co-
expression of Skp and TF was obtained from the original authors and subjected to 
restriction enzyme linearization to confirm the predicted molecular size (Fig. 4.14 A). 
SHuffle® E. coli were subsequently transformed with either pGEX-KG-VAMP 2-DkTx 
only, or co-transformed with both pACYC-Skp_TF and pGEX-KG-VAMP 2-DkTx.  The 
recombinant expression from the respective transformants was induced by IPTG 
overnight at 22°C, following which the bacterial lysates were subjected to SDS-PAGE 
followed by Coomassie staining, this confirmed the co-expression of both Skp and TF in 
the pertinent bacteria, which significantly enhance the solubility of VAMP 2-DkTx in 
SHuffle® (Fig. 4.14 B). Unfortunately, following GST affinity purification and 
subsequent removal of the GST tag by thrombin cleavage, VAMP 2-DkTx expressed in 
SHuffle® in the absence of Skp and TF became almost entirely insoluble (Fig. 4.14 C). 
Conversely, although the co-expression of TF and Skp enhanced the solubility of VAMP 
2-DkTx, the Skp chaperone remained associated with VAMP 2-DkTx and was co-
purified following release from the agarose immobilized GST tag (Fig. 4.14 C). 
Consequently, the SHuffle® E. coli strain, even with the co-expression of chaperone 
proteins, was deemed inadequate for functional expression of VAMP 2-DkTx 
 88 
 
 
Figure 4. 14 Expression of VAMP 2-DkTx in SHuffle™ E. coli with or without co-expressed 
chaperone proteins, and purification by affinity chromatography 
(A) pACYC_TF_Skp was subjected to restriction digest (XhoI enzyme), resolved by agarose gel-
electrophoresis and visualized by trans-UV. (B) SHuffle® E. coli, were transformed with either pGEX-KG-
VAMP 2-DkTx, or pGEX-KG-VAMP 2-DkTx and pACYC_TF_Skp (+ chaperones). The recombinant 
expression of the proteins was induced overnight at 22°C via IPTG. The total and soluble fractions of the 
resultant lysates were subjected to SDS-PAGE followed by Coomassie staining. (C) The soluble lysates 
from (B) were incubated with glutathione agarose, washed extensively and treated with thrombin protease 
to release VAMP 2-DkTx. The agarose prior to thrombin treatment, or the eluate following treatment, were 
subjected to SDS-PAGE followed by Coomassie staining. 
4.3 Discussion 
The ability to productively deliver the LC.HN/A-stapled-EGF into cultured SH-SY5Y 
cells, corroborates the published work, and validates protein stapling as an effective 
conjugation strategy, applicable to BoNT retargeting. The increased delivery of 
LC.HN/A-stapled-EGF into cultured cells was however marginal, with detection restricted 
to a narrow window of low nM concentrations (1-10 nM) and requiring a 42 hour 
incubation (Arsenault et al., 2013). This highlighted that the EGF targeting ligand was 
inefficient at mediating delivery of the SNARE protease. Furthermore, the detected 
SNAP-25 cleavage elicited by untargeted LC.HN/A-SNAP-25 was an obvious concern, 
suggesting that even when lacking the HC, the retained HN domain is capable of binding 
to the cell membrane. This observation is supported by recent findings that the isolated 
HN/A domain is capable of associating with the plasma membrane (Ayyar et al., 2015, 
Ayyar and Atassi, 2016).  
The capacity of untargeted LC.HN/A-SNAP-25 to intoxicate cells, coupled with the poor 
efficiency of EGF in delivering the stapled complex, explained the employment of a fixed 
toxin concentration of 10 nM by the original authors. This validated the supposition that 
DkTx, with an EC50 of 144 nM, was unlikely to mediate a detectable increase in protease 
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delivery over the untargeted control. In addition, the culmination of difficulties in 
expressing function VAMP 2-DkTx indicated that obtaining testable material in a 
reasonable time-frame was unlikely. 
The protein stapling strategy is an impressive conjugation technology, notwithstanding 
the extensive troubleshooting that was required for its successful implementation. 
Although capable of mediating a degree of cellular targeting it did not confer the 
envisaged ligand flexibility; this was highlighted by the challenge in obtaining stable and 
functional VAMP 2-DkTx. Identification and application of suitable targeting moieties is 
an appreciated constraint in developing retargeted BoNT molecules (Masuyer et al., 
2014); therefore, an innovative approach was required which would permit the screening 
of diverse, high-affinity ligands. To this end, a novel coupling strategy was designed and 
developed based on the binding of Staphylococcus aureus protein A (SpA) to 
immunoglobulin G (IgG) antibodies; the design and application of this progressive 
approach is detailed in Chapter 5. 
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Chapter 5. A conjugate of an IgG binding domain and BoNT/A core-
therapeutic targets TrkA-expressing cells following coupling to anti-
TrkA IgG or a Fc-ßNGF fusion 
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5.1 Introduction   
The retargeting of BoNT/A derivatives by previous strategies, including protein stapling, 
largely employed mammalian growth-factors (Chaddock et al., 2000a, Foster et al., 2006, 
Arsenault et al., 2013) which possess low nM or even pM affinity for their respective 
receptors. Hence, comparatively low-affinity ligands such as DkTx prove far more 
challenging. Although the stapling strategy afforded several advantages, and successfully 
targeted the core-therapeutic to SH-SY5Y cells following conjugation to VAMP 2-EGF, 
the detectable cleavage of SNAP-25 by the untargeted control revealed that more 
proficient ligands of even higher-affinity were required for effective targeting.  
TrkA, the high-affinity receptor for NGF (Wiesmann et al., 1999), consequently came to 
the fore as a favourable target substitute to TRPV1, particularly as TrkA is co-expressed 
with the latter in peptidergic C-fibre nociceptors (Averill et al., 1995). Homodimerized 
NGF (ßNGF) possesses an EC50 of 0.1 nM (Mehta et al., 2012), and upon binding to TrkA 
induces internalization of the complex into signalling endosome which undergo 
acidification (Grimes et al., 1996). Consequently, ßNGF would be expected to be 
significantly more efficacious at delivering BoNT/A core-therapeutic than DkTx. 
Furthermore, the chemical conjugation of ßNGF to a binding domain deficient BoNT/A 
had been previously demonstrated to productively target TrkA expressing cells  
(Chaddock et al., 2000a), affording an opportunity to evaluate an additional ligand for 
BoNT retargeting. It was, however, deemed imperative for progression of the project to 
also develop an additional parallel approach for the targeting of TrkA. Significantly, the 
binding site of βNGF has been localized to the IgG like domain of TrkA (HoldenPaul et 
al., 1997), and IgG antibodies which bind this region have been shown to induce receptor 
crosslinking, resulting in its internalization (Clary et al., 1994). Accordingly, the 
conjugation of the BoNT/A core-therapeutic to a pertinent antibody was a promising 
alternative means of targeting TrkA. 
Although the protein stapling presented ligand flexibility as an advantage, there was no 
provision for the conjugation to IgG. As demonstrated in Chapter 4, the approach was in 
fact quite restrictive, with any deviation from the prescribed protocol proving ineffective. 
Furthermore, the difficulty in achieving biologically-active VAMP 2-DkTx highlighted 
the inherent challenge in expressing complex eukaryotic targeting moieties in a bacterial 
system. Notwithstanding these deficiencies, the independent expression of the protein 
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stapling core-therapeutic and targeting ligands represented an advance on the initially 
employed fusion approach. In order to preserve this advantageous attribute, an innovative 
conjugation strategy was devised and developed based on the binding to IgG of 
Staphylococcus aureus virulence factor Protein A (SpA). 
SpA consists of 5 highly modular IgG binding domains (A-E) (Moks et al., 1986), which 
bind to both the fragment crystallisable (Fc) and fragment antigen-binding (Fab) regions 
of IgG, with an overall KD value of ~5x10
-9 M (Tsukamoto et al., 2014). Each IgG binding 
domain is thermodynamically autonomous (Deis et al., 2014), and capable of 
independently binding IgG with high efficiency and stability (Jansson et al., 1998). 
Accordingly, the incorporation of a SpA domain into a BoNT/A core-therapeutic was 
perceived as a new way to conjugate the latter to IgG. To this end, the IgG binding domain 
B of SpA (SpA-B), the best characterized (Deisenhofer, 1981) and most utilized of the 
domains (Lindborg et al., 2013), was selected and the residues responsible for the binding 
to IgG Fab (D36, 37), were mutated by site-directed mutagenesis (Fig. 5.1 A and B) (Kim 
et al., 2010). As the Fab region of IgG is responsible for recognition of the antibody 
epitope, precluding this interaction reduced the potential for hindrance of target binding 
by coupled IgG. The fusion of this SpA-Bmut domain onto the C-terminus of LC.HN/A 
generated a new core-therapeutic (LC.HN/A-SpA-Bmut) (Fig. 5.1 C and D). 
 
Figure 5. 1 Overview of LC.HN/A-SpA-Bmut core-therapeutic 
(A) Representation of the SpA protein, indicating the relative stability of 5 IgG binding domains, region X 
and the LPXTG sortase signal which are responsible for attachment to the bacterial cell wall. (B) Amino 
acid sequence of the SpA-B domain, residues involved in binding of Fc (Q9, 10) and IgG Fab (D36, 37) 
are highlighted in green and red, respectively. (C) Schematic of the novel LC.HN/A-SpA-Bmut DNA cloned 
into pGEX-KG expression vector, indicating the thrombin protease sites, and the inter-chain disulfide bond. 
(D) Hypothetical structure of the resultant purified protein. Adapted and combined from the crystal 
structure of BoNT (Masuyer et al., 2015) and SpA-B (Sato et al., 2004). 
LC.HN/A-SpA-Bmut was designed to enable selective monovalent coupling to IgG Fc 
without any requirement for chemical modification and, consequently, permit the direct 
use of unadulterated commercial IgG targeting TrkA. As it was also desirable to target 
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this receptor via conjugation of the core-therapeutic to ßNGF, an innovative approach of 
tagging the latter with a single-chain of the fragment crystallisable domain of rabbit IgG 
(rFc) was developed. The NGF protein is expressed as an immature monomeric precursor 
containing an N-terminal pre-pro peptide, which orchestrates extensive post-translational 
modifications of the nascent protein (Seidah et al., 1996). Accordingly, the recombinant 
expression of functional NGF is difficult to achieve in bacterial systems (Kurokawa et 
al., 2001). However, baculovirus mediated expression of NGF in Sf9 insect cells results 
in the correct intracellular processing of NGF, and the secretion of biologically-active 
homodimeric ßNGF into the cell supernatant (Buxser et al., 1991). To this end, a 
recombinant baculovirus for insect cell expression of rFC-ßNGF was generated, with an 
incorporated C-terminal (His)6 to facilitate subsequent IMAC purification (Fig. 5.2 A). 
The SpA-Bmut fusion strategy would, therefore, confer exceptional flexibility, providing 
a singular approach for the coupling of LC.HN/A-SpA-Bmut to either anti-TrkA IgG or 
rFC-ßNGF (Fig. 5.2 B) and, thus, an opportunity to directly compare the targeting 
efficiencies via these diverse moieties. 
 
Figure 5. 2 Schematic of SpA-Bmut coupling strategy 
(A) Illustration of the recombinant fusion protein rFc-NGF. Pre-ProNGF-rFc-(His)6, when expressed in Sf9 
insect cells undergoes intracellular processing, and enters the secretion pathway, removing the pre-pro 
signal and resulting in secretion of homo-dimerized rFc-ßNGF-(His)6 into the Sf9 supernatant. A C-
terminal (His)6 enables IMAC purification, which is removed by thrombin cleavage. The crystal structure 
of ßNGF is shown, without fusion to rFc; adapted from (Wiesmann et al., 1999). (B). The affinity of SpA-
Bmut for IgG Fc would facilitate coupling of LC.HN/A-SpA-Bmut to either anti-TrkA IgG or rFc-ßNGF-
(His)6 without any requirement for chemical modification or crosslinking. 
 
5.2 Results 
5.2.1 Site-directed mutagenesis of SpA-B Fab binding sites and recombinant 
expression of GST-SpA-Bmut 
The DNA encoding SpA-B in the pGEX-KG vector was provided by Prof. Joan 
Geoghegan (Trinity College Dublin) and the nucleotides encoding residues responsible 
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for IgG Fab interaction (D36, 37) were subsequently mutated to alanine by site-directed 
mutagenesis; this is an established substitution which abolishes binding to IgG Fab (Kim 
et al., 2010). The pGEX-KG vectors containing either SpA-BWT or SpA-Bmut were 
linearized by single-site restriction digest prior to being subjected to agarose gel 
electrophoresis, this gave the predicted molecular size for both vectors (Fig. 5.3 A), with 
subsequent DNA sequencing performed to confirm successful sequence mutagenesis. The 
pGEX-KG-SpA-Bmut vector was transformed into BL21 (DE3) E. coli, and recombinant 
expression performed by IPTG induction. The resultant bacterial lysate was subjected to 
SDS-PAGE followed by Coomassie staining (Fig. 5.3 B), which confirmed a significant 
yield of soluble protein at ~33k, the predicted molecular mass of GST-SpA-Bmut. The 
latter was immobilized on glutathione agarose, with SpA-Bmut being released from the 
agarose-associated GST tag following incubation with thrombin protease. A final yield 
of ~3 mg/L was determined by BCA protein assay. The results described are 
representative of the parallel expression and purification of SpA-BWT. 
 
Figure 5. 3 Mutagenesis of SpA-B IgG Fab binding sites, expression and purification of the 
resultant SpA-Bmut protein 
(A) pGEX-KG vectors containing genes encoding either SpA-BWT or SpA-Bmut were subjected restriction 
digest linearization (BamHI enzyme), resolved by agarose gel electrophoresis and visualized by Trans-UV. 
(B) The bacterial lysate containing recombinantly-expressed GST-SpA-Bmut and the subsequent samples 
from the affinity-chromatography were subjected to SDS-PAGE followed by Coomassie staining. Cleavage 
with thrombin protease released SpA-Bmut from GST-tag which remained associated with the glutathione 
agarose. 
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5.2.2 Abolishment of IgG Fab interaction does not impact upon the binding of SpA-
Bmut to IgG.  
In order to confirm that SpA-Bmut was capable of coupling to rabbit IgG, GST-SpA-Bmut 
immobilized on glutathione agarose was incubated with rabbit serum for 1 hour at 4°C, 
washed extensively, prior to being subjected to SDS-PAGE both in the presence and 
absence of reductant. The subsequent Coomassie staining (Fig. 5.4 A) demonstrated that 
GST-SpA-Bmut retained a significant amount of bound protein with a Mr of ~250 k. In the 
presence of reductant this protein disassociated into ~50 k and ~25 k components, 
corresponding to the predicted molecular masses of the IgG heavy and light-chains, 
respectively. The parallel incubation of serum with a glutathione agarose only control 
established that the binding to the serum protein was being conferred by SpA-Bmut. The 
identity of this 250 k protein was confirmed as rabbit IgG by subsequent Western-blotting 
using an anti-rabbit IgG antibody (Fig. 5.4 B). 
The consequence of limiting interaction to IgG Fc on the overall affinity for IgG was 
investigated by incubation of either agarose immobilized GST-SpA-BWT or GST-SpA-
Bmut with rabbit serum, with the relative levels of bound IgG assessed by dot-blot analysis 
using an anti-rabbit IgG antibody (Fig. 5.4 C). The comparable signal in the respective 
10-fold dilutions confirmed no significant difference in the amount of IgG bound by either 
wild-type or mutated SpA-B.  
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Figure 5. 4 Binding of SpA-B or SpA-Bmut to rabbit IgG 
(A) GST-SpA-Bmut immobilized on glutathione agarose was incubated with rabbit serum for 1 hour at 4°C, 
washed extensively and subjected to SDS-PAGE followed by Coomassie staining. (B) Samples from (A) 
were analysed by Western-blotting using an anti-rabbit IgG antibody. (C). Either GST-SpA-BWT or GST-
SpA-Bmut immobilized on glutathione agarose was incubated with rabbit serum for 1 hour at 4°C, washed 
extensively, and released from the agarose by thrombin cleavage. Samples were then subjected to a series 
of 10-fold dilutions before being applied directly to nitrocellulose membrane and subjected to dot-blotting 
with an anti-rabbit IgG antibody. 
 
5.2.3 Cloning, expression and purification of LC.HN/A-SpA-Bmut.  
The expression vector pGEX-KG-LC.HN/A-SNAP-25 detailed in the Chapter 4 was 
subjected to restriction enzyme double digest by XbaI and XhoI to excise the DNA 
encoding the C-terminal SNAP-25. The DNA encoding SpA-Bmut which had been 
amplified by PCR to incorporate consensus restriction sites, was digested in parallel. 
DNA ligation was subsequently performed to insert SpA-Bmut into the position previously 
occupied by SNAP-25, resulting in pGEX-KG-LC.HN/A- SpA-Bmut (Fig. 5.5 A). The 
vector was transformed into BL21 (DE3) E. coli and the protein was recombinantly 
expressed by IPTG induction. Analysis of the resultant bacterial lysate by Coomassie 
staining of SDS-PAGE, confirmed successful expression of an appreciable yield of 
soluble product at the predicted Mr of ~135 k, corresponding to single-chain GST-
LC.HN/A-SpA-Bmut  (Fig. 5.5 B). Subsequent affinity-chromatography purification on 
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glutathione agarose immobilized a significant quantity of the latter, although residual 
product could be detected in the flow-through and washes. Incubation with thrombin 
protease released LC.HN/A-SpA-Bmut from the agarose-associated GST tag, producing the 
predicted ~ 25 k decrease in molecular mass corresponding to the removal of GST. 
Analysis of the separated eluate containing LC.HN/A-SpA-Bmut, in both the absence and 
presence of reductant, confirmed that LC.HN/A-SpA-Bmut had been predominantly 
converted to disulfide linked di-chain (Fig. 5.5 B). A final yield of ~1mg/L of bacterial 
culture was determined by BCA protein assay. 
 
Figure 5. 5 Cloning, expression and purification of LC.HN/A-SpA-Bmut 
(A) PCR amplification of SpA-Bmut incorporated consensus restriction digest sites allowing its insertion 
into pGEX-KG-LC.HN/A in exchange for SNAP-25. DNA samples from the principle cloning steps were 
subjected to agarose gel electrophoresis prior to visualization by Trans-UV. Arrows indicate the predicted 
DNA sizes as detailed to the left of the gels. (B) The bacterial lysate containing recombinantly-expressed 
GST-LC.HN/A-SpA-Bmut and samples from the subsequent affinity-chromatography purification were 
subjected to SDS-PAGE (+/- ßME) followed by Coomassie staining. Cleavage with thrombin protease 
(Thr) released LC.HN/A -SpA-Bmut from GST-tag, and arbitrated the conversion to disulfide linked di-chain.  
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5.2.4 LC.HN/A-SpA-Bmut couples to rabbit IgG with high efficiency 
Immobilization of GST-LC.HN/A-SpA-Bmut on agarose before thrombin-mediated release 
proved convenient for the subsequent coupling to IgG. The latter could be incubated in 
molar excess to saturate the SpA-Bmut binding sites, prior to washing to remove both 
surplus unbound IgG and any contaminants present. As such, commercial rabbit IgG 
containing BSA stabilizer (included by the supplier) was incubated with agarose bound 
GST-LC.HN/A-SpA-Bmut at ~3-fold molar excess, prior to washes. Ensuing analysis of 
the washes and the agarose resin by SDS-PAGE followed by Coomassie staining 
demonstrated a substantial amount of IgG remained coupled to GST-LC.HN/A-SpA-Bmut 
(Fig. 5.6 A). Specificity of this interaction was unveiled by the contrasting presence of 
BSA only in the washes. Parallel analysis by Western-blotting using an anti-rabbit 
antibody substantiated the results from SDS-PAGE, and confirmed the identity of the 
rabbit IgG (Fig. 5.6 B). 
Subsequent thrombin cleavage released LC.HN/A-SpA-Bmut-IgG from the agarose-
associated GST tag, reflected by the SDS-PAGE of the eluate which identified Coomassie 
stained protein bands corresponding to both IgG and LC.HN/A-SpA-Bmut (Fig. 5.6 C). 
Analysis of the eluate was then performed by non-denaturing polyacrylamide gel 
electrophoresis (native-PAGE) to confirm the integrity of the coupled complex (Fig. 5.6 
D). 
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Figure 5. 6 Coupling of LC.HN/A-SpA-Bmut to IgG 
(A) Glutathione-agarose immobilized GST-LC.HN/A-SpA-Bmut was incubated with 3-fold molar excess of 
rabbit IgG, followed by extensive washing with PBS. Coupling of IgG was demonstrated by SDS-PAGE 
followed by Coomassie staining. (B) Samples from (A) were subjected to Western-blotting with anti-rabbit 
secondary antibodies. (C) LC.HN/A-SpA-Bmut coupled to rabbit IgG was released from agarose bound GST 
by cleavage with thrombin protease. Samples of either the agarose prior to thrombin treatment or the eluate 
following treatment were subjected to SDS-PAGE followed by Coomassie staining. (D) Native-PAGE 
followed by Coomassie staining demonstrated a shift in mobility of LC.HN/A -SpA-Bmut due to binding of 
IgG. 
 
5.2.5 IgG coupled to LC.HN/A-SpA-Bmut retains ability to bind its target antigen 
Prior to assessment of cellular targeting of LC.HN/A-SpA-Bmut following coupling to anti-
TrkA IgG, which was in limited supply, it was paramount to confirm that the associated 
IgG could bind its prescribed antigen. To this end, agarose-immobilized GST-LC.HN/A-
SpA-Bmut was coupled to a rabbit antibody which binds to goat IgG, and incubated with 
the latter conjugated to alkaline phosphatase (AP). The presence of goat IgG following 
washing was confirmed by Western-blotting with an anti-goat antibody (Fig. 5.7 A) or by 
an enzyme-linked immunosorbent assay following addition of AP substrate (Fig. 5.7 B). 
SpA domains exhibit a species-specific affinity for IgG, having negligible affinity for that 
raised in goat (Iangone, 1982). Consequently, the presence of goat IgG can be directly 
attributed to the binding of the coupled rabbit anti-goat antibody. Interestingly, the SpA-
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Bmut domain is capable of refolding sufficiently on the Western-blotting membrane to 
bind antibodies raised in rabbit during the second blotting incubation (Baum et al., 2009). 
Hence, GST-LC.HN/A-SpA-Bmut can be detected at its predicted Mr of ~135 k (Fig. 5.7 
A). 
 
Figure 5. 7 IgG coupled to LC.HN/A-SpA-Bmut can bind its target antigen 
(A) Agarose-immobilized GST-LC.HN/A-SpA-Bmut either uncoupled or coupled to an antibody which binds 
goat IgG was incubated with the latter for 1 hour at 4°C, washed extensively and subjected to Western-
blotting with anti-goat secondary. (B) Experiment was performed as in (A), using goat IgG conjugated to 
alkaline phosphatase; binding of the latter was confirmed by colorimetric change (measured by absorbance 
at 650 nm) following addition of enzyme substrate. Data plotted are means ± S.E.M; n=3, statistical analysis 
performed by unpaired student t-test; *** p < 0.001. 
 
5.2.6 LC.HN/A-SpA-Bmut retains full protease activity following coupling to IgG  
SNAP-25 protease activity of LC.HN/A-SpA-Bmut (+/- coupled IgG), following release 
from glutathione agarose, was investigated by an established in vitro cleavage assay using 
a recombinant SNAP-25 fragment substrate (Wang et al., 2012) (Fig. 5.8 A and B). This 
established that LC.HN/A-SpA-Bmut retained protease activity comparable to that of wild-
type BoNT/A (Wang et al., 2012), which was not impeded by subsequent coupling to 
IgG. 
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Figure 5. 8 In vitro cleavage of recombinant SNAP-25 fragment substrate by LC.HN/A-SpA-Bmut 
with or without coupled IgG 
(A) GFP-SNAP-25(134-206), incubated with 1.25 – 20 nM of LC.HN/A-SpA-Bmut either uncoupled or coupled 
to rabbit IgG, was subjected to SDS-PAGE followed by Coomassie staining. (B) Densitometric analysis 
data from (A) was performed with ImageJ software to determine % cleavage at each concentration. Data 
plotted are means ± S.E.M; n=3. 
 
5.2.7 Assessment of commercial IgG against TrkA 
Having established the protocol for conjugating IgG to LC.HN/A-SpA-Bmut, the next stage 
was to ascertain if coupling to an appropriate IgG raised against TrkA could deliver the 
SNARE protease into TrkA-expressing cells. Consequently, a commercial IgG against 
TrkA was selected based on its epitope (residues 342-356), coinciding with an IgG 
binding region previously shown to induce receptor internalization (Clary et al., 1994). 
To establish that the chosen IgG was capable of binding to TrkA and subsequently 
targeting LC.HN/A-SpA-Bmut, an appropriate cell system was required. To this end, PC-
12 cells, a clonal rat cell-line which express both TrkA and SNAP-25 (Tischler and 
Greene, 1975, Shone and Melling, 1992) were selected and cultured. PC-12 cells were 
chosen over cultured neurons, as the latter must be maintained in the presence of high 
concentrations of NGF to sustain viability (Malin et al., 2007) which, in theory, could 
compete with anti-TrkA targeted LC.HN/A-SpA-Bmut. Significantly, PC-12 cells can be 
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grown in the absence of NGF, but following its addition to the culture medium, they adopt 
a neuronal phenotype, characterized by an outgrowth of neurites (Zhou et al., 1995) and 
an upregulation in TrkA expression (McKelvey et al., 2013). 
An initial assessment of the IgG anti-TrkA IgG was performed by Western-blotting of 
PC-12 cell lysates from either undifferentiated or differentiated cells, with HEK-293 cell 
lysate functioning as a negative control (Fig. 5.9 A). The immunoblot confirmed binding 
to a protein at ~150 k in PC-12 lysate, the predicted molecular mass for glycosylated 
TrkA (Ehlers et al., 1995). In addition, the levels of TrkA were shown to increase 
following exposure to 2.5S NGF. The parallel Western-blotting with an anti-SNAP-25 
antibody reaffirmed the presence of SNAP-25, endorsing PC-12 cells as an appropriate 
system in which to evaluate TrkA targeting of LC.HN/A-SpA-Bmut. To confirm the ability 
of the IgG to bind to intact PC-12 cells, the latter were cultured and differentiated by 
treatment with 2.5S NGF, confirming functionality of the TrkA receptor present on the 
cell surface. The binding of the anti-TrkA IgG to both differentiated and undifferentiated 
PC-12 cells was demonstrated by ICC staining (Fig. 5.9 B). 
 
Figure 5. 9 Confirmation that IgG raised against TrkA binds to PC-12 lysate and intact cells 
(A) HEK-293 or PC-12 cells lysates from either undifferentiated or differentiated cells were subjected to 
Western-blotting with antibodies against TrkA, α-Tubulin or SNAP-25. (B) PC-12 cells undifferentiated, 
or differentiated by 96 hours pre-treatment with 100 ng/ml 2.5S NGF, were subjected to ICC staining using 
the anti-TrkA antibody; a second antibody conjugated to Alexa-Fluor® 488 was used to detect binding. 
Image acquisition was performed by both fluorescence and bright-field microscopy; images chosen are 
representative (n=10 for each condition). 
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5.2.8 Coupling of anti-TrkA IgG to LC.HN/A-SpA-Bmut increases binding to PC-12 
cells and improves intracellular delivery of protease relative to the untargeted 
control 
Coupling of anti-TrkA IgG to LC.HN/A-SpA-Bmut significantly increased its binding to 
PC-12 lysate relative to uncoupled control, as determined by dot-blotting using an anti-
LC/A antibody (Fig. 5.10 A). To investigate if this elevated binding correlated with the 
efficient delivery of the SNARE protease into cultured PC-12 cells, the latter were treated 
with 0.1-10 nM of untargeted control, or LC.HN/A-SpA-Bmut coupled to anti-TrkA IgG. 
Western-blotting of the resultant cell lysates revealed increased SNAP-25 cleavage for 
the TrkA targeted toxin at 0.1 – 1 nM. However, equivalent SNAP-25 cleavage was 
detected for the untargeted control at 10 nM concentration (Fig. 5.10 B and C). 
This initial dose-range finding indicated that anti-TrkA IgG was capable of mediating 
increased delivery of the SNARE protease at low nM concentrations, but with higher 
amounts the untargeted control bound non-specifically and was internalized into the PC-
12 cells, such that the targeting effect of the IgG could no longer be discerned. To 
distinguish effective targeting, PC-12 cells were subsequently treated with lower 
concentrations of the toxins (1.2 – 0.15 nM) and the relative levels of SNAP-25 cleavage 
were determined by Western-blotting. The analysis confirmed anti-TrkA targeted toxin 
cleaved SNAP-25 at as low as 0.15 nM (Fig. 5.10 D and E), while negligible cleavage 
was detected for the untargeted control at any of the concentrations. 
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Figure 5. 10 Coupling of TrkA targeting IgG to LC.HN/A-SpA-Bmut increases binding and protease 
delivery into PC-12 cells 
(A) PC-12 cell lysate (2 µg) was dot blotted onto nitrocellulose membrane, blocked with 5% BSA and 
incubated with 5 ng of LC.HN/A-SpA-Bmut (+/- coupled anti-TrkA IgG) for one hour. The membrane was 
washed extensively and the relative levels of binding were determined by dot-blotting using an anti-LC/A 
antibody. Densitometric analysis was performed with ImageJ software. Data plotted are means ± S.E.M, 
n=3, from independent experiments, normalized against the binding of anti-TrkA IgG. Statistical analysis 
performed by unpaired t-test: *** p < 0.001.  (B) PC-12 cells were seeded at 4x105 per well in a 24-well 
plate, and treated with indicated concentrations of LC.HN/A-SpA-Bmut (+/- coupled anti-TrkA IgG) for 48 
hours prior to preparation of cell lysates; these were subjected to SDS-PAGE followed by Western-blotting 
with antibodies against α-Tubulin and SNAP-25/A. (C) Densitometric analysis of data from (B). Data 
plotted are means ± S.E.M, normalized against the α-Tubulin loading control, statistical analysis performed 
by unpaired t-test: n.s. p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, n=3 from independent experiments. 
(D-E) Performed as for (B) and (C). 
 
5.2.9 Design and cloning of recombinant baculovirus for expression of rFc-ßNGF-
(His)6 or ßNGF-(His)6  
To develop the additional approach of targeting LC.HN/A-SpA-Bmut via coupling to 
ßNGF, a recombinant baculovirus construct encoding Pre-proNGF-rFc-(His)6 was 
generated for the subsequent expression of rFc-ßNGF-(His)6 in Sf9 insect cells. 
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Additionally, a second baculovirus encoding Pre-proNGF-(His)6 was generated as a 
positive control for baculovirus mediated Sf9 expression of functional homodimeric 
ßNGF-(His)6 (Buxser et al., 1991). 
The baculovirus constructs were generated using the Baculodirect™ system, in which the 
initial cloning is performed in a bacterial gateway vector (pENTER/D-TOPO), containing 
two recombination sites (attL1 and attL2) between which a gene of interest is inserted. 
Linearized Baculodirect™ DNA contains the corresponding recombination sites (attR1 
and attR2), and site-specific recombination is catalysed by LR clonase™ II enzyme. This 
results in the insertion of the gene of interest into the baculovirus DNA backbone, in 
exchange for a gene which encodes herpes simplex virus type 1 thymidine kinase (TK). 
The DNA encoding Pre-proNGF-rFc-(His)6 was designed and synthesised with codon 
optimization for insect cell expression, with subsequent PCR reactions performed to 
amplify the Pre-proNGF-rFc-(His)6 or Pre-proNGF-(His)6 genes (Fig. 5.11 A), with an 
additional 3’ nucleotide sequence (CACC). The respective purified PCR reactions were 
subsequently incubated individually with linearized pENTER/D-TOPO vector 
conjugated to Topoisomerase I enzyme. The latter cleaves the PCR product producing an 
overhang of the inserted 3’ sequence, and mediates its ligation with complementary bases 
in pENTER/D-TOPO. The pENTER/D-TOPO vectors containing Pre-proNGF-rFc-
(His)6 or Pre-proNGF-(His)6 genes were then propagated in transformed E. coli, purified, 
linearized by single-site restriction digest; agarose gel electrophoresis followed by Trans-
UV exposure  (Fig. 5.11 B) confirmed that both vectors correspond to their respective 
predicted molecular sizes. 
The gateway vectors were subsequently incubated, independently, with linearized 
Baculodirect™ DNA in the presence of LR clonase™ II. A sample from each reaction 
was subjected to PCR analysis, using primers with complement sequences in the 
Baculodirect™ DNA backbone. The ensuing agarose gel electrophoresis (Fig. 5.11 C) 
confirmed the presence of PCR products corresponding to the predicted sizes of the Pre-
proNGF-rFc-(His)6 or Pre-proNGF-(His)6 genes in the respective PCR reactions. The 
heterogeneity of either sample reflects the poor purity of the respective baculovirus 
constructs following initial generation. 
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Figure 5. 11 Cloning of recombinant baculovirus constructs for expression of rFc-ßNGF-(His)6 or 
ßNGF-(His)6 
(A) PCR reactions to amplify DNA encoding Pre-ProNGF-rFc-(His)6 or Pre-ProNGF-(His)6 with a 3’ 
CACC nucleotide sequence, were subjected to agarose gel electrophoresis followed by Trans-UV imaging. 
Arrows indicate the predicted product sizes. (B) pENTER/D-TOPO vectors containing Pre-ProNGF-rFc-
(His)6 or Pre-ProNGF-(His)6 were linearized with XhoI restriction enzyme, resolved by agarose gel 
electrophoresis and imaged by Trans-UV. Arrows indicate the predicted plasmid sizes. (C) The baculovirus 
recombination reactions for Pre-ProNGF-rFc-(His)6 or Pre-ProNGF-(His)6 were subjected to PCR using 
primers designed against consensus sequences within the Baculovirus backbone. The PCR products were 
subjected to agarose gel electrophoresis and imaged by Trans-UV. Arrows indicate the predicted product 
sizes. 
 
5.2.10 Baculovirus generation and pilot expression of rFc-ßNGF-(His)6 or ßNGF-
(His)6  
The recombinant baculovirus encoding Pre-proNGF-rFc-(His)6 or Pre-proNGF-(His)6 
were selected and amplified through successive rounds of Sf9 cell infection (Fig. 5.12 A). 
Initially, Sf9 insect cells cultured in a 6-well plate were transfected with either of the 
aforementioned constructs in the presence of 100 nM ganciclovir. The latter is a cell 
permeable nucleoside analogue, which upon phosphorylation by cytoplasmic TK, 
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incorporates into the genome of Sf9 cells and inhibits DNA replication (Rubsam et al., 
1999). Consequently, Sf9 cells transfected with non-recombined baculovirus are 
negatively selected (Godeau et al., 1992), ensuring only cells transfected with a 
baculovirus in which TK has been excised following successful recombination of Pre-
proNGF-rFc-(His)6 or Pre-proNGF-(His)6 were propagated (Fig. 5.11C). The respective 
cells were cultured until displaying morphology phenotypical of baculovirus infection 
(Fig. 5.12 B) (van Oers et al., 2015), at which point the supernatants were harvested, 
denoted as passage 1 (P1), and used to directly infect Sf9 cells in a higher volume flask 
format (P2). The recombinant baculovirus constructs were subjected to 3 such cycles of 
selection/amplification, following which the purity of the respective virus stocks was 
determined by PCR analysis as previously described (Fig. 5.12 C). Subsequent agarose 
gel electrophoresis of the PCR reactions confirmed the presence of homogenous DNA 
products corresponding to the predicted molecular size of either Pre-pro-ßNGF-rFc-
(His)6 or Pre-pro-ßNGF-(His)6. The viral titre of each respective baculovirus was then 
determined by a series of plaque assays, which established that both baculovirus had been 
amplified successfully, with corresponding viral titres of ~2 × 109 pfu/ml. 
To determine if the baculovirus constructs were capable of mediating recombinant 
expression of either ßNGF-(His)6 or rFC-ßNGF-(His)6, a pilot expression was performed. 
Sf9 insect cells were infected with either baculovirus at a multiplicity of infection (MOI) 
of 0.05 and cultured for 72 hours, following which the cell supernatants were harvested 
and subjected to Western-blotting using an anti-(His)6 antibody (Fig. 5.12 D). The 
subsequent analysis confirmed the presence of (His)6 containing proteins at the predicted 
molecular masses of ~28 k and ~80 k, corresponding to homodimeric ßNGF-(His)6 or 
rFC-ßNGF-(His)6, respectively; with no (His)6  signal detected in the supernatant of the 
infected control. 
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Figure 5. 12 Selection and amplification of baculovirus constructs, and pilot expression of ßNGF-
(His)6 or rFc-ßNGF-(His)6 
(A) 1. The recombinant baculovirus generated was transfected into Sf9 insect cells cultured in 6-well plates. 
2. The cells were cultured until exhibiting morphology phenotypical of baculovirus infection (P1 virus). 3. 
The supernatant from infected cells was harvested, and used to directly infect Sf9 cells in a higher volume 
flask format (P2). The virus could be further amplified by successive cycles of infection to generate higher 
viral titre (P3+). 4. Once a high titre baculovirus was produced, parameters for optimal recombinant 
expression of target protein were established. (B) Sf9 cells seeded at 2x106/well in a 6-well plate were 
transfected with recombinant baculovirus encoding pre-proNGF-(His)6 and cultured for 72 hours prior to 
image acquisition. (C) DNA present in the supernatant of Sf9 cells following 72 hours infection with either 
Pre-ProNGF-rFc-(His)6 or Pre-ProNGF-(His)6 baculovirus, was precipitated and subjected to PCR 
amplification using primers designed against consensus sequences within the Baculovirus backbone. The 
resultant PCR products were subsequently resolved by agarose gel electrophoresis and imaged by Trans-
UV. Arrow indicates the predicted product sizes. (D) The supernatants from uninfected Sf9 cells, or those 
infected with either Pre-ProNGF-rFc-(His)6 or Pre-ProNGF-(His)6 baculovirus for 72 hours, were subjected 
SDS-PAGE followed by Western-blotting with an anti-(His)6 antibody. 
5.2.11 Optimization of conditions for expressing and purifying rFc-ßNGF-(His)6 
The detection of ßNGF-(His)6 in the supernatant of Sf9 cells following infection with Pre-
proNGF-(His)6 encoding baculovirus was a successful recapitulation of previous work 
(Buxser et al., 1991), validating Sf9 insect cells as a system for the secretion of processed 
ßNGF. Moreover, the detection of the novel rFC-ßNGF-(His)6 protein from a parallel 
infection confirmed Sf9 cells remained capable of processing and secreting 
homodimerized ßNGF following its fusion to rFc. In order to maximise the recombinant 
yields of rFC-ßNGF-(His)6 a series of expression parameters were assessed. The most 
commonly employed baculovirus expression protocols involve harvesting 72 hours post 
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infection, a sufficient time-frame for ample recombinant expression, while minimizing 
the risk of product degradation, exacerbated by protease release from lytic cells in late-
stage (72+ hours) of infection (Gómez-Sebastián et al., 2014). To investigate the optimal 
duration of infection for expression of rFC-ßNGF-(His)6, Sf9 cells were seeded at 2x10
6 
cells/ml, infected with an MOI of 0.05, and samples were taken of the supernatants at 
time of infection, and up to 96 hours post infection. Subsequent analysis by Western-
blotting using an anti-(His)6 antibody, detected a strong rFC-ßNGF-(His)6 signal 72 hours 
post-infection, with increased signal detected following 96 hours infection (Fig. 5.13 A). 
Consequently, 96 hours post-infection was selected as the optimal infection time for 
expression of rFC-ßNGF-(His)6. 
The next parameter considered was MOI, the previous work on ßNGF expression in Sf9 
cells utilized a MOI of 0.05 (Nguyen et al., 1993), comparatively low to the value of 10 
used in the expression of other recombinant proteins (de Pinheiro et al., 2016). Low MOI 
infection affords the practical advantage of requiring less virus stock but, more 
significantly, high MOI infection can overload the production machinery of the cells 
resulting in poor recombinant yields. Furthermore, high MOI infection can induce over-
emphasis on viral replication resulting in an accumulation of inhibitory defective 
interfering viral particles (Kool et al., 1991), a phenomenon known as the passage effect. 
Sf9 cells at 2x106 cells/ml were infected with an MOI ranging from 0.05 -100, and 
supernatants harvested 96 hours post infection, prior to being subjected to SDS-PAGE 
followed either by Coomassie staining or Western-blotting as above (Fig. 5.13 B). 
Subsequent analysis confirmed an inverse relationship between MOI and rFC-ßNGF-
(His)6 expression/secretion. Furthermore, Coomassie staining revealed an MOI-
dependent increase in the expression of a protein at the predicted molecular mass for 
glycoprotein 64 (Gp64), an endogenous baculovirus envelope protein and, thus, 
confirmed a shift to viral replication at higher MOIs.  
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Figure 5. 13 Optimization of parameters for expression and purification of rFC-ßNGF-(His)6 
(A) Sf9 cells seeded at 2x106 cells/well in a 6-well plate were infected with Pre-ProNGF-rFc-(His)6 
baculovirus at an MOI of 0.05 and cultured for 96 hours at 27.5°C. Samples of the supernatant were 
collected every 24 hours and subjected to Western-blotting using an anti-(His)6 antibody. (B) Sf9 cells 
seeded as above were infected with Pre-ProNGF-rFc-(His)6 rBaculovirus with an MOI 0.05 – 100, cultured 
for 96 hours at 27.5°C, prior to harvesting of the supernatants. Samples of which were subjected to SDS-
PAGE followed by either Coomassie staining or Western-blotting with an anti-(His)6 antibody. (C) Sf9 
cells seeded at 2x106 cells/well in a 6-well plate were either uninfected or infected with Pre-ProNGF-rFc-
(His)6 baculovirus at an MOI of 0.05. The cells were incubated for 96 hours, prior to harvesting of the 
supernatant, followed by preparation of cell lysates. Western-blotting of samples was performed with an 
anti-(His)6 antibody. (D) Sf9 cells infected as in (C), were lysed with I-PER® insect cell protein extraction 
reagent 96 hours post-infection. The lysate was fractionated by centrifugation and samples were subjected 
to SDS-PAGE followed by Western-blotting with an anti-(His)6 antibody. Arrow indicates the predicted 
size for rFc-ßNGF-(His)6. (E) Sf9 cells seeded at 2x106/ml in a total volume of 500 ml were infected at an 
MOI of 0.05 and cultured for 96 hours, following which the cell supernatant was subjected to IMAC 
purification. Western-blotting of IMAC samples was performed with an anti-(His)6 antibody. Arrow 
indicates the predicted size for rFc-ßNGF-(His)6. 
 
Although rFC-ßNGF-(His)6 could be detected in the Sf9 supernatant following 
expression, the yields were lower than anticipated, particularly as baculovirus infection 
of Sf9 cells was shown to be capable of producing significant quantities of Gp64. To 
investigate if the deficiency was in the expression or the secretion of rFC-ßNGF-(His)6, 
Sf9 cells were infected for 96 hours at an MOI of 0.05, following which the supernatant 
was harvested and the cells were lysed; both samples were subjected to Western-blotting 
with an anti-(His)6 antibody (Fig. 5.13 C). Comparison of the signal corresponding to 
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rFC-ßNGF-(His)6 between both the Sf9 lysate and supernatant, indicated that only a 
minute proportion of the protein was being secreted, with the majority remaining 
intracellular. To determine if intracellular rFC-ßNGF-(His)6  could be released from Sf9 
cells following lysis, the expression was repeated and cells were lysed using  I-PER® 
insect cell protein extraction reagent, a proprietary reagent optimized for extraction of 
soluble proteins from insect cells. The resultant lysate was subsequently fractionated by 
centrifugation, and subjected to SDS-PAGE followed by either Coomassie staining or 
Western-blotting (Fig. 5.13 D); this determined that although I-PER® solubilized the 
majority of Sf9 proteins, intracellular rFC-ßNGF-(His)6 was predominantly insoluble. 
As the soluble and, thus, purifiable portion of rFC-ßNGF-(His)6 was constrained to that 
which was secreted into the Sf9 supernatant, the expression scale was increased. Sf9 cells 
were seeded in 500 ml suspension culture at 2.5x106 cells/ml, infected with an MOI of 
0.05 and harvested 96 hours post-infection. The resultant supernatant was subjected to 
IMAC purification, with subsequent analysis of the IMAC samples performed by 
Western-blotting (Fig. 5.13 E); this confirmed that the majority of secreted rFc-ßNGF-
(His)6 could be purified and concentrated, although remaining detectable only by 
immuno-blotting. 
 
5.2.12 Purified rFc-ßNGF-(His)6 retains significant biological activity 
Binding of ßNGF to TrkA induces intracellular transphosphorylation, with ERK 1/2 being 
major downstream effectors (Mitchell et al., 2012). Although the protein yield could not 
be determined, to ascertain whether the purified rFc-ßNGF-(His)6 was functional and 
capable of activating TrkA, a qualitative but sensitive phosphorylation assay was 
performed (Fig. 5.14 A). PC-12 cells which had been serum-starved overnight to reduce 
background phosphorylation were treated for up to 1 hour with purified rFc-ßNGF-(His)6, 
or a 2.5S NGF as a positive control. Lysates from untreated cells (0 minutes) and those 
treated for 15, 30 and 60 minutes were harvested and subjected to Western-blotting with 
antibodies against phosphorylated-ERK 1/2, unphosphorylated ERK 1/2 and SNAP-25 
which functioned as a loading control. Analysis of the resultant blot confirmed that rFc-
ßNGF-(His)6 treatment induced phosphorylation of ERK 1/2, corresponding to a 
reduction in signal for the unphosphorylated isoform. The phosphorylated ERK 1/2 signal 
was found to decrease over time, corroborating the transient nature of ERK 1/2 
phosphorylation (Adachi et al., 2002). 
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With a degree of rFc-ßNGF-(His)6 functionality established, a more qualitative appraisal 
of its activity was performed using an established PC-12 survival assay (Gazzano-Santoro 
et al., 1999). In prolonged serum withdrawal PC-12 cells perish, but the presence of ßNGF 
dose-dependently promotes their survival. Treatment of serum-starved PC-12 cells with 
either increasing volumes of purified rFc-ßNGF-(His)6, or concentrations of commercial 
2.5S NGF, revealed that 10 µl rFc-ßNGF-(His)6 retained functional activity equivalent to 
10 ng/ml of commercial 2.5S NGF (Fig. 5.14 B). The potency of rFc-ßNGF-(His)6 was 
further reflected by the degree of PC-12 neurite outgrowth induced by 1:100 dilution of 
purified sample being comparable to that induced by 50 ng/ml 2.5S NGF (Fig. 5.14 C). 
Together these results indicated that despite its low protein concentration, purified rFc-
ßNGF-(His)6 possessed significant biological activity. 
 
Figure 5. 14 Functional characterization of purified rFc-ßNGF-(His)6 
(A) PC-12 cells seeded at 4x104 cells per well in a 12-well plate were cultured overnight at 37°C, 5% C02 
in serum-free medium prior to treatment with 100 ng/ml 2.5S NGF or 100 µl of rFc-ßNGF-(His)6. Cells 
were incubated for up to 60 minutes, washed once with ice-cold PBS, lysed and subjected to Western-
blotting using antibodies against p-ERK1/2, ERK1/2 and SNAP-25. (B) PC-12 cells, seeded at 4x104 per 
well in a 24-well plate in serum-free medium, were incubated with indicated dilution of either 2.5S NGF 
or purified rFc-ßNGF-(His)6 in a final volume of 500 µl for 48 hours at 37°C, 5% C02. AlamarBLUE™ (50 
µl) was added to each well and incubated for a further 24 hours prior to measurement of fluorescence 
(excitation 570 nm, emission 585 nm). Data plotted are means ± S.E.M, n=3. (C) PC-12 cells seeded at 
1x104 per well in a 12-well plate, were treated with 10 µl of purified rFc-ßNGF-(His)6 or 50 ng/ml 2.5S 
NGF diluted directly into 1 ml of culture medium. Cells were incubated for 96 hours at 37°C, 5% C02, prior 
to image acquisition. Images chosen are representative (n=10 for each condition). 
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5.2.13 Coupling of LC.HN/A-SpA-Bmut to rFc-ßNGF increases delivery of the 
SNARE protease into PC-12 cells 
Purified rFc-ßNGF-(His)6 efficiently coupled to agarose immobilized GST-LC.HN/A-
SpA-Bmut, as detected by Western-blotting using an anti-ßNGF antibody (Fig. 5.15 A). 
The resultant complex (LC.HN/A-SpA-Bmut-rFc-ßNGF) was released from the agarose 
associated GST by thrombin cleavage, which also arbitrated removal of the (His)6 tag. 
PC-12 cells treated with LC.HN/A-SpA-Bmut-rFc-ßNGF or untargeted control were lysed 
and subjected to Western-blotting with antibodies against either α-Tubulin or SNAP-25/A 
(Fig. 5.15 B and C). Subsequent analysis confirmed that coupled rFc-ßNGF was able to 
productively target LC.HN/A-SpA-Bmut despite the low incidence of complex, and 
produced a significant increase in SNAP-25 cleavage over that of the untargeted control.  
 
Figure 5. 15 LC.HN/A-SpA-Bmut couples to rFc-ßNGF, which targets the SNARE protease into PC-
12 cells 
(A) Glutathione-agarose immobilized GST-LC.HN/A-SpA-Bmut was incubated with 200 µl of purified rFc-
ßNGF-(His)6 for 2 hours at 4°C, followed by washing with PBS. LC.HN/A-SpA-Bmut coupled to rFc-ßNGF 
was released from agarose-bound GST by cleavage with thrombin protease, which also removed the (His)6 
purification tag. Samples of the agarose before and after rFc-ßNGF-(His)6 incubation, and the eluate 
following thrombin treatment, were subjected to SDS-PAGE followed by Western-blotting with an anti-
ßNGF antibody. (B) PC-12 cells were seeded at 4x105 per well in a 24-well plate, and treated with indicated 
concentration of LC.HN/A-SpA-Bmut (+/- coupled rFc-βNGF) for 48 hours prior to preparation of cell 
lysates; these were subjected to Western-blotting with antibodies against α-Tubulin and SNAP-25/A. (C) 
Densitometric analysis of data from (B). Data plotted are means ± S.E.M, normalized against α-Tubulin as 
a loading control; n=3 from independent experiments. Statistical analysis was carried out by unpaired t-
test: * p < 0.05, ** p < 0.01, *** p < 0.001. 
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5.2.14 rFc-ßNGF and anti-TrkA IgG mediate comparable delivery of protease into 
PC-12 cells  
To assess the relative abilities of rFc-ßNGF or anti-TrkA IgG to mediate protease delivery 
into PC-12 cells, the respective proteins were coupled to LC.HN/A-SpA-Bmut as 
previously described, and PC-12 cells were treated in parallel with the resultant 
conjugates. Subsequent Western-blotting of the cell lysates revealed comparable levels 
of cleaved SNAP-25 for both targeting moieties (Fig. 5.16 A and B). When consideration 
is made for the proportion of IgG coupled to LC.HN/A-SpA-Bmut relative to that coupled 
to rFc-ßNGF, it can be surmised that rFc-ßNGF mediated targeting is significantly more 
efficient than its IgG counterpart. 
 
Figure 5. 16 rFc-ßNGF and anti-TrkA IgG mediate delivery of comparable levels of SNARE 
protease into PC-12 cells 
(A) PC-12 cells seeded at 4x105 per well in a 24-well plate were treated with the indicated concentrations 
of LC.HN/A-SpA-Bmut coupled to either rFc-βNGF or anti-TrkA IgG. Cells were incubated for 48 hours 
prior to the preparation of cell lysates and Western-blotting subsequently performed with antibodies against 
α-Tubulin and SNAP-25/A. (C) Densitometric analysis of data from (B). Data plotted are means ± S.E.M, 
normalized against α-Tubulin as a loading control; n=3 from independent experiments. Statistical analysis 
was carried out by unpaired t-test: * p < 0.05, ** p < 0.01, *** p < 0.001. (B) Densitometric analysis of 
data from (A). Data plotted are means ± S.E.M, normalized against α-Tubulin as a loading control; n=3 
from independent experiments. n.s. p > 0.05. 
 
5.3 Discussion  
The SpA-Bmut strategy was conceived, and designed, to address the experienced short-
comings of both the protein fusion and stapling conjugation methods. The delivery of the 
LC.HN/A-SpA-Bmut into TrkA-expressing PC-12 cells, following coupling to either rFc-
ßNGF or anti-TrkA IgG, demonstrates the success of the approach. Moreover, it 
highlights the versatility of the strategy, enabling rapid conjugation of the BoNT core-
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therapeutic to diverse targeting ligands; this represents a major innovation as no other 
published protein conjugation strategy is applicable to the coupling of both IgG and 
recombinant ligands.  
Significantly, rFc-ßNGF delivered LC.HN/A-SpA-Bmut into PC-12 cells with efficiency 
comparable to considerably higher concentrations of coupled anti-TrkA IgG. As targeted 
therapeutics exhibit different internalization pathways, dependent upon their targeting 
ligand (Madshus et al., 1991, Fonfria et al., 2016), it can be concluded that the substantial 
biological activity of rFc-ßNGF negates the low occurrence of coupled complex. 
Although the concentration of rFc-ßNGF could not be determined, PC-12 cells were 
treated with a maximum of 1.2 nM of LC.HN/A-SpA-Bmut, and of this only a proportion, 
likely corresponding to very low pM concentrations, was coupled to rFc-ßNGF. The 
considerable SNAP-25 cleavage achieved in spite of this demonstrates the significant 
targeting by rFc-ßNGF.  
The pervasion of uncoupled LC.HN/A-SpA-Bmut into cells at higher concentrations is 
consistent with the ability of both the fusion and stapling untargeted controls to intoxicate 
cells. This, consequently, suggests an inherent constraint in the development of retargeted 
BoNT/A-based therapeutics in the absence of sufficient yields of high-affinity agonistic 
ligands. Unfortunately, the difficulty encountered in purifying larger quantities of rFc-
ßNGF-(His)6, despite extensive optimization, prohibited higher-efficiency coupling to 
LC.HN/A-SpA-Bmut. The low yields of soluble rFc-ßNGF-(His)6 are likely a consequence 
of either the rFc fusion impairing post-translational modifications which the nascent 
protein undergoes intracellularly in Sf9 cells, or due to a subsequent over-burdening of 
the Sf9 secretory pathway. It can, however, be predicted that if higher yields were 
obtained, the delivery of the ßNGF-targeted therapeutic would have been increased 
considerably. 
As exemplified by the multiple BoNT/A derivatives generated in this project, the 
development of targeted toxins is often constrained by both the availability and suitability 
of relevant targeting moieties and, thus, the identification, expression, purification and 
conjugation of the latter is often a rate-limiting step (Masuyer et al., 2014). The SpA-Bmut 
strategy was envisaged as a way in which to overcome this through expedient coupling 
to commercial IgG, vastly increasing the repertoire of readily available and validated 
targeting moieties. The feasibility of the approach is demonstrated by the increased 
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SNAP-25 cleavage detected in PC-12 cells following treatment with anti-TrkA coupled 
LC.HN/A-SpA-Bmut. Consequently, in addition to its application in the targeting of 
BoNT/A to cells which express nociceptive transducers, the LC.HN/A-SpA-Bmut core-
therapeutic could, potentially, serve as a novel approach for evaluating the ability of 
targeting antibody candidates to mediate toxin internalization. Preceding techniques for 
such antibody assessment have involved microscopy (Rappoport, 2008), radiolabelling 
(Sun et al., 1996), thymidine incorporation (Kuo et al., 2009) or cell viability assays 
(Mazor et al., 2007). Use of LC.HN/A-SpA-Bmut provides a simplified platform in which 
IgG can be coupled without requirement for chemical conjugation or cross-linking, and 
affords assessment of IgG-mediated internalization into an extensive range of target 
neurons or neuronal cell lines (Oyler et al., 1992, Némoz-Gaillard et al., 1998, Loranger 
and Linder, 2002) by Western-blotting detection of SNAP-25 cleavage product. This 
represents a major advance over prior techniques in terms of simplicity and 
reproducibility of IgG coupling, no compromise of cell-viability and a straightforward 
detection method. 
As the ability of the untargeted LC.HN/A-SpA-Bmut core-therapeutic to intoxicate cells at 
concentrations which exceed 10 nM is an obvious limitation, it is pertinent that the SpA-
Bmut conjugation strategy also has potential in the development of targeted toxins 
supplementary to BoNT/A. The avidity of bacterial proteins for IgG has previously 
demonstrated potential in the conjugation of both diphtheria toxin and Pseudomonas 
exotoxin to antibodies (Mazor et al., 2007, Kuo et al., 2009). However, these earlier 
approaches were restricted to coupling to IgG, and either failed to obtain high-efficiency 
conjugation, or required chemical crosslinking to stabilize the resultant complex. 
Furthermore, former approaches made no provision to address binding to IgG Fab, and 
employed multiple IgG binding domains, which could induce potential for steric 
hindrance between coupled partners.  
The comparable intoxication of PC-12 cells by LC.HN/A-SpA-Bmut coupled to either rFc-
ßNGF or anti-TrkA IgG highlights that for the development of targeted therapeutics the 
activity of the targeting ligand can in fact be more decisive than the proficiency of 
coupling; particular high-affinity recombinant ligands may serve as more efficient 
delivery agents than their IgG counterparts. Consequently, in addition to the coupling to 
IgG, it is significant that the SpA-Bmut is also applicable to the conjugation of recombinant 
ligands. The generation of such ligands is, however, a time-consuming and challenging 
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exercise, due both to the many steps involved in their generation and the frequent 
difficulty in retaining their biological activity. In most cases, as with DkTx, the original 
selection of a ligand is based on a supposition, influenced by information in the literature, 
that a particular cell-surface receptor represents a viable therapeutic target. The SpA-Bmut 
strategy affords a unique advantage, whereby, the initial utilization of appropriate IgG 
against a candidate receptor can be used to rapidly investigate its feasibility as a 
therapeutic target. This preliminary target evaluation can provide solid justification for 
embarking on recombinant ligand generation, potentially averting months of infertile 
investment. 
The rFC fragment outlined incorporates the IgG hinge region, serving as an adept linker 
sequence between the targeting ligand and SpA-Bmut binding sites, previously exploited 
in the expression of complex mammalian protein fusions (Park et al., 1998). Furthermore, 
the expression of Fc-containing fusion proteins has been achieved in bacterial (Ying et 
al., 2012), mammalian (Czajkowsky et al., 2012), yeast (Higel et al., 2016) and insect 
cells as described in this Chapter. Moreover, fusion to IgG Fc has been shown to increase 
yields and solubility of difficult to express proteins in mammalian expression systems 
(Jue et al., 2010). However, as the binding of SpA to IgG Fc does not require Fc 
glycosylation (Jefferis et al., 1998), bacterial expression of Fc fusions with targeting 
ligands, which are more amenable to functional expression than ßNGF, is an attractive 
consideration.  
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Chapter 6. General discussion and recommendations for future work 
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6.1 SpA-Bmut strategy represents an advance on preceding approaches for the 
conjugation of BoNT/A to targeting ligands 
Exploitation of BoNTs highly specific, potent and long-lasting inhibition of 
neurotransmitter release has demonstrated profound therapeutic success in the treatment 
of an ever-increasing number of pathological conditions (Münchau and Bhatia, 2000, 
Mahajan and Brubaker, 2007, Luvisetto et al., 2015). The same pharmacological 
properties which make BoNTs so efficacious, however, also make them the most potent 
acute lethal toxins known (Lebeda et al., 2008). Consequently, the development of 
retargeted BoNT-derived therapeutics (commonly termed targeted-secretion inhibitors) 
which seek to expand the toxins clinical utility while simultaneously reducing the 
prospect for motor-deficits, is the focus of intense academic and commercial investigation 
[reviewed by (Foster and Chaddock, 2010, Masuyer et al., 2014)]. Development of such 
retargeted BoNT/A-based therapeutics is, nevertheless, a complex and challenging 
endeavour, initially constrained by the identification of suitable cell-surface target 
receptors and appropriate targeting ligands. Following which, the functional expression, 
characterization and conjugating of the latter to a BoNT based core-therapeutic serves as 
a significant rate-limiting step. 
The initial strategy of generating a core-therapeutic fusion with a spider-venom peptide 
(DkTx), was a novel approach which sought to exploit the bivalent and specific binding 
of the latter to the TRPV1 channel. A fusion approach was perceived as the most efficient 
means of ligand conjugation, particularly because the chemical coupling of ligands to 
BoNT domains has been previously demonstrated to reduce toxin activity (Band et al., 
2010), or produce conjugation efficiency of only 12-16% (Chaddock et al., 2000a, 
Duggan et al., 2002). However, the difficulty in purifying and functionally characterizing 
the LC.HN.HCN/A-DkTx protein exemplifies the innate challenge in producing high-
yields of soluble and biologically active chimeric fusion proteins, particularly those 
containing ICK motifs (Klint et al., 2013). Furthermore, the process of cloning, 
expressing, purifying and characterizing each fusion proved laborious and time-
consuming and, thus, constrained the number of targeting ligands which could be 
generated and assessed. This limitation is highlighted by the previously published BoNT 
targeted fusions, based either on BoNT/C (Foster et al., 2006) or BoNT/A (Fonfria et al., 
2016), both employing only EGF as a ligand. 
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The protein stapling was envisaged as a means to expedite the generation and assessment 
of targeting ligands, supported by its prior application in the conjugation of LC.HN/A-
SNAP-25 to a panel of 9 targeting ligands (Arsenault et al., 2013). The anticipated 
advantages of this coupling method were, notwithstanding the experienced issues with 
the synthetic syntaxin peptide, undermined by the problematic expression, purification 
and stability of the recombinant components. The supposed flexibility of the approach 
was further negated by an inability to obtain biologically-active VAMP 2-DkTx, with 
extensive trouble-shooting required to produce a protein which was ultimately non-
functional. Conversely, in the absence of VAMP 2, DkTx expressed with a Trx tag was 
purified to an appreciable yield and purity, with confirmed biological activity. As the 
generation of chimeric protein fusions is so unpredictable, optimizing conditions for the 
production of even a single protein can represent a significant challenge. The protein 
fusion and protein stapling strategies were, consequently, both deemed inadequate for the 
development of a retargeted BoNT/A therapeutic, due to the innate difficulty in obtaining 
soluble, functional and high-proficiency targeting ligands through bacterial expression 
systems. 
The SpA-Bmut conjugation strategy addressed this short-coming by its ability to mediate 
the rapid and high-efficiency coupling of the BoNT/A core-therapeutic to commercially 
available IgG antibodies, thereby, providing a repertoire of readily available and validated 
moieties with which to target. Significantly, although the strategy supports the coupling 
of recombinant ligands tagged with rFc, it does not compel the approach and, thus, confers 
unique and unrivalled flexibility. The therapeutic potential of targeting antibody-toxin 
molecules (termed immunotoxins) to pertinent cellular targets is widely investigated as a 
potential strategy for therapeutic intervention in cancer and other disorders (Antignani 
and FitzGerald, 2013). There has, however, been only one published example of such a 
strategy being employed for BoNT retargeting: conjugation of a BoNT/A-based core-
therapeutic to an ScFv targeting P2X3 (Ma et al., 2014). This previous approach, although 
somewhat successful at mediating toxin targeting to P2X3 expressing DRGs, employed a 
single antibody chain and, thus, only a single epitope binding domain. A significant 
advantage of immunotoxins which employ whole antibodies, in addition to their high-
specificity, is the bivalent nature of the targeting antibodies. The binding of an antibody 
to either dual epitopes on a distinct cell-surface receptor, or to adjacent receptors, can 
induce their crosslinking, which normally results in internalization of the antibody-toxin 
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complex (Schmidt et al., 2008). As the SpA-Bmut strategy enables coupling to whole IgG, 
it can exploit this advantageous attribute which, potentially, could facilitate the proficient 
targeting of BoNT/A to diverse membrane targets, including those for which there is no-
known ligand. Although further comprehensive assessment of such targeting is required, 
the demonstrated coupling of LC.HN/A-SpA-Bmut to commercial IgG, followed by the 
increased binding and detectable delivery of the TrkA-targeted toxin into PC-12 cells, 
establishes the proof of principle for this innovative and versatile approach.  
6.2 Intoxication of cells by each of the untargeted BoNT/A core-therapeutics 
highlights an inherent flaw in their current design 
The contribution of the HCN sub-domain to neuronal binding, as outlined in Chapter 3, 
was initially perceived as a disadvantage for BoNT retargeting, promoting the association 
of the untargeted fusion control with cultured TGNs. However, as detailed in Chapters 4 
and 5, the subsequent untargeted controls, containing only the LC.HN/A domains, were 
also capable of intoxicating TGNs, SH-SY5Y and PC-12 cells. The significant finding 
that full-length BoNT/A containing a single mutation of W985L in the HCN sub-domain 
retains high-affinity saturatable binding to cultured CGNs, but demonstrates reduced 
toxin internalization, suggests that this sub-domain is indispensable for the efficient 
delivery of the SNARE protease. Evidently, replacing the whole HC domain of BoNT/A 
with exogenous binding moieties produces deficiencies in subsequent steps essential for 
cytosolic delivery of the LC protease. This necessitates higher concentrations of targeted 
toxins and longer cell treatments which, consequently, affords the untargeted controls 
increased opportunity to intoxicate cells. Future focus in the development of retargeted 
BoNT/A therapeutics should, therefore, be in maximising the efficiency of targeted 
delivery, and not in attempts to minimise the delivery of the untargeted control. 
This implies that the LC.HN domains utilized in all retargeted BoNTs published to-date 
are inadequate, and that future BoNT-based core-therapeutics must also incorporate the 
HCN. Further to this, as the BoNT/A residues involved in binding to SV2 have been 
published (Benoit et al., 2014, Strotmeier et al., 2014), prospective BoNT/A therapeutics 
may prove even more effective if the core-therapeutic contains full-length toxin but with 
mutated SV2 binding sites. This progressive approach would afford the full advantage of 
the adeptly-evolved BoNT/A internalization and translocation mechanics, preserving 
native interactions between toxin domains and the neuronal membrane, without risk of 
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high-affinity binding to neuronal acceptors. The specificity of binding could then be 
conferred by the employed targeting ligand which, in tandem with HCC ganglioside 
binding, the established contribution of the HCN to binding/internalization and its 
suggested involvement to LC translocation (Muraro et al., 2009) could, potentially, prove 
a far more proficient means of delivering the SNARE protease into target cells.  
A version of the described strategy was attempted in Chapter 3, in which a construct 
encoding a chimeric fusion of LC.HN.HCN/A and HCC/Bmut was generated. The inability 
to purify the resultant protein following recombinant expression, or the cognate protein 
which additionally contained DkTx, reaffirms the inherent challenge in producing novel 
protein fusions. It is conceivable however, considering the expression and purification of 
LC.HN/A-SNAP-25, that LC.HN.HCN/A-HCC/Bmut may have been more amenable to 
recombinant expression if the pGEX-KG vector and associated GST tag had been 
employed. 
Although LC.HN/A-SpA-Bmut coupled to anti-TrkA IgG demonstrated a significant 
increase in binding to PC-12 cells relative to the untargeted control, this did not correlate 
with the proficient intracellular delivery of the SNARE protease. It can be surmised, 
therefore, that the comparatively low degree of SNAP-25 cleavage detected is due either 
to a deficit in the subsequent internalization of the complex, or inefficient cytoplasmic 
translocation of the LC. To this end, the generation of a novel full-length SV2 binding 
deficient core-therapeutic (BoNT/Amut-SpA-Bmut) could, conceivably, rectify this 
significant limitation; this, in combination with the efficacy of IgG coupling, could 
establish the SpA-Bmut strategy as the preeminent method for developing future retargeted 
BoNT/A therapeutics. 
6.3 ßNGF-mediated targeting of TrkA represents a viable potential strategy for 
delivery of retargeted BoNT/A-based pain therapeutics 
The applicability of the SpA-Bmut approach to not only IgG coupling, but also to the 
conjugation of the core-therapeutic to recombinant ligands, is a significant advance on 
preceding techniques. This approach is, nonetheless, still constrained by the need to 
recombinantly express fusion proteins. Employment of baculovirus-mediated expression 
of rFc-ßNGF-(His)6 in insect cells was envisaged as a way to circumvent the limitations 
of the bacterial expression systems. Significantly, despite the low protein yields, Sf9 cells 
were capable of producing biologically-active rFc-ßNGF-(His)6, which could be coupled 
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to LC.HN/A-SpA-Bmut. Although the conjugation of rFc-ßNGF to the core-therapeutic 
was only detectable by immuno-blotting, the considerable functional activity of ßNGF 
was sufficient to negate the low occurrence of coupled complex, delivering the SNARE 
protease into PC-12 cells equivalent to significantly higher concentrations of anti-TrkA 
IgG. This confirms that for retargeted BoNT core-therapeutics which employ the isolated 
LC.HN domains, it is essential to employ a ligand that is not only specific and has high-
affinity, but one which is also adept at inducing the internalization of its receptor. 
The suggestion that a novel BoNT/Amut-SpA-Bmut core-therapeutic may improve the IgG 
targeted delivery of the SNARE protease into cells is, at this stage, hypothetical. 
Accordingly, it is still necessary to consider utilization of other targeting ligands. The 
high-efficiency with which rFC-ßNGF was shown to deliver the SNARE protease into 
PC-12 cells establishes its suitability as an effective ligand for the targeting of LC.HN/A-
SpA-Bmut to TrkA-expressing cells. The NGF mediated delivery of SNAP-25 protease 
into PC-12 cells has also been achieved following its coupling to a BoNT/A derivative 
lacking the HC (Chaddock et al., 2000a). In this instance, however, the removal of the HC 
was achieved not by recombinant means as with LC.HN/A-SpA-Bmut,  but by trypsin 
protease digestion; which can produce a heterogeneous LC.HN/A fragment (Shone et al., 
1985). Furthermore, NGF was purchased commercially and subsequently conjugated via 
chemical cross-linking using Traut’s reagent. This approach required an input of 2 mg of 
NGF to achieve ~250 µg of conjugated product, with higher efficiency linkage 
constrained by the susceptibility of LC to over derivatisation resulting in loss of 
enzymatic activity. Despite these limitations, chemical coupling of NGF targeted the 
SNAP-25 protease into PC-12 cells with an IC50 of 1.8 nM. This confirms, unequivocally, 
that for the development of targeted BoNT/A based therapeutics the affinity of the 
targeting ligand and the consequence of its receptor interaction, are absolutely paramount. 
Consequently, ßNGF-mediated targeting of TrkA represents a viable potential strategy 
for the future development of nociceptor retargeted BoNT/A-based pain therapeutics.  
While the increased levels of SNAP-25 cleavage achieved by LC.HN/A-SpA-Bmut-rFc-
ßNGF over the untargeted control is encouraging, this serves only as an initial proof of 
principle. A considerable challenge remains in generating sufficient quantities of material 
for a comprehensive assessment of the consequences of SNAP-25 truncation on 
exocytosis and channel surface localization in vitro and, potentially, of the anti-
nociceptive efficacy in vivo. 
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List of suppliers 
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Company Country Web address 
 
Alomone 
 
 
Israel 
 
www.alomone.com 
 
ATCC (Ordered through LGC 
standard) 
 
UK 
 
www.lgcstandards-atcc.org 
 
 
Bio-rad 
(Ordered through Fannin) 
 
 
Ireland 
 
www.fannin.eu 
 
Biomatik 
 
 
USA 
 
www.biomatik.com 
 
Eurofins Genomics 
 
 
Germany 
 
www.eurofinsgenomics.eu 
 
Jackson Immuno-research 
 
 
UK 
 
www.jireurope.com 
 
Envigo (formerly Harlan labs) 
 
 
UK 
 
www.envigo.com 
 
Life Technologies 
(Ordered through Biosciences) 
 
 
Ireland 
 
www.biosciences.ie 
 
Merck Millipore 
 
 
UK 
 
www.merckmillipore.com/IE 
 
Mirus Bio 
(Ordered through Medical 
Supply Company) 
 
 
Ireland 
 
www.medical-supply.ie 
 
New England Biolabs 
(Ordered through Brennan & 
Company) 
 
 
Ireland 
 
www.brennanco.ie 
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Perkin Elmer 
 
 
UK 
 
www.perkinelmer.com 
 
Peptide Synthetics 
 
 
UK 
 
www.peptidesynthetics.co.uk 
 
Qiagen 
 
 
UK 
 
www.qiagen.com 
 
Sarstedt 
 
 
Ireland 
 
www.sarstedt.com 
 
Sigma Aldrich 
(Additionally a supplier of GE 
Healthcare products) 
 
Ireland 
 
www.sigmaaldrich.com/ireland 
 
Vector Laboratories 
 
 
UK 
 
www.vectorlabs.com 
 
